_MEMBER_data_imp_1 - 94.0-96.0,_MEMBER_data_imp_1 - 96.0-98.0,_MEMBER_data_imp_1 - 98.0-100.0,_LogP_data_imp_1 - 94.0-96.0,_LogP_data_imp_1 - 96.0-98.0,_LogP_data_imp_1 - 98.0-100.0,GO,Description,_PATTERN_,_RANK_,GiniIndex
1,1,1,-3.5,-3,-2.4,GO:0006909,phagocytosis,M111,3,0
1,1,1,-3,-3.2,-3.1,hsa04620,Toll-like receptor signaling pathway,M111,3,0
1,1,1,-3.2,-3.7,-3.3,M17200,SA B CELL RECEPTOR COMPLEXES,M111,3,0
1,1,1,-4,-4.6,-3.9,R-HSA-8878159,Transcriptional regulation by RUNX3,M111,3,0
1,1,1,-2.3,-2.8,-2.1,M15,PID LYSOPHOSPHOLIPID PATHWAY,M111,3,0
1,1,1,-6.6,-4.7,-3,GO:0010001,glial cell differentiation,M111,3,0
1,1,1,-2.6,-2.4,-2.4,GO:2000737,negative regulation of stem cell differentiation,M111,3,0
1,1,1,-10,-9.4,-10,GO:0050778,positive regulation of immune response,M111,3,0
1,1,1,-3.4,-5,-2.3,R-HSA-8878166,Transcriptional regulation by RUNX2,M111,3,0
1,1,1,-3.9,-2.1,-2.2,GO:0097152,mesenchymal cell apoptotic process,M111,3,0
1,1,1,-7.7,-14,-6.8,GO:0050867,positive regulation of cell activation,M111,3,0
1,1,1,-13,-9.1,-6.8,GO:0009792,embryo development ending in birth or egg hatching,M111,3,0
1,1,1,-5.4,-3.7,-2.9,R-HSA-418594,G alpha (i) signalling events,M111,3,0
1,1,1,-5.3,-8,-4.2,GO:0046634,regulation of alpha-beta T cell activation,M111,3,0
1,1,1,-3.3,-3.5,-5.1,WP5373,Role of hypoxia angiogenesis and FGF pathway in OA chondrocyte hypertrophy,M111,3,0
1,1,1,-3.1,-3.5,-3.7,M235,PID TCR CALCIUM PATHWAY,M111,3,0
1,1,1,-4,-2.8,-3.3,GO:0007219,Notch signaling pathway,M111,3,0
1,1,1,-7.8,-6.1,-5.2,hsa05202,Transcriptional misregulation in cancer,M111,3,0
1,1,1,-5.2,-3.3,-3.7,GO:0003416,endochondral bone growth,M111,3,0
1,1,1,-4,-5.9,-6.1,GO:0042113,B cell activation,M111,3,0
1,1,1,-4.5,-3.3,-2.2,GO:0072163,mesonephric epithelium development,M111,3,0
1,1,1,-6.1,-3.4,-3.6,R-HSA-2454202,Fc epsilon receptor (FCERI) signaling,M111,3,0
1,1,1,-3.1,-4.5,-4,GO:0060760,positive regulation of response to cytokine stimulus,M111,3,0
1,1,1,-2.9,-2.2,-2.8,WP2884,NRF2 pathway,M111,3,0
1,1,1,-3.1,-2.1,-2.3,hsa04920,Adipocytokine signaling pathway,M111,3,0
1,1,1,-5.1,-5.2,-4.5,GO:0002460,adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains,M111,3,0
1,1,1,-13,-9.3,-6.8,GO:0043009,chordate embryonic development,M111,3,0
1,1,1,-2.9,-3,-2,R-HSA-181438,Toll Like Receptor 2 (TLR2) Cascade,M111,3,0
1,1,1,-4,-3.5,-3.7,GO:0060349,bone morphogenesis,M111,3,0
1,1,1,-10,-11,-5.2,GO:0071396,cellular response to lipid,M111,3,0
1,1,1,-11,-9.5,-8.6,GO:1903706,regulation of hemopoiesis,M111,3,0
1,1,1,-2.3,-4.1,-2.6,GO:0050871,positive regulation of B cell activation,M111,3,0
1,1,1,-7.8,-4.1,-5.3,GO:0050728,negative regulation of inflammatory response,M111,3,0
1,1,1,-5.4,-5.5,-2.8,GO:0002064,epithelial cell development,M111,3,0
1,1,1,-3.4,-3.5,-3.3,GO:0043405,regulation of MAP kinase activity,M111,3,0
1,1,1,-11,-9.2,-5.8,GO:0051960,regulation of nervous system development,M111,3,0
1,1,1,-2.6,-3.1,-4,M91,PID TCPTP PATHWAY,M111,3,0
1,1,1,-6,-5,-2.9,WP382,MAPK signaling pathway,M111,3,0
1,1,1,-5.2,-7.6,-8.8,R-HSA-112316,Neuronal System,M111,3,0
1,1,1,-5,-3.4,-3.4,GO:0003231,cardiac ventricle development,M111,3,0
1,1,1,-6.4,-5.8,-6.1,GO:0051090,regulation of DNA-binding transcription factor activity,M111,3,0
1,1,1,-5.1,-6.2,-4.8,GO:0048736,appendage development,M111,3,0
1,1,1,-4,-2.9,-2.4,GO:0099175,regulation of postsynapse organization,M111,3,0
1,1,1,-5.3,-5.5,-4.1,GO:0032680,regulation of tumor necrosis factor production,M111,3,0
1,1,1,-3.5,-4.5,-2.3,WP5053,Development of ureteric collection system,M111,3,0
1,1,1,-2.8,-4.8,-4.3,M195,PID CMYB PATHWAY,M111,3,0
1,1,1,-9.3,-14,-8.5,GO:1903037,regulation of leukocyte cell-cell adhesion,M111,3,0
1,1,1,-6.6,-6.4,-6.7,GO:0007169,transmembrane receptor protein tyrosine kinase signaling pathway,M111,3,0
1,1,1,-9.6,-7.6,-5.6,GO:0072001,renal system development,M111,3,0
1,1,1,-2.2,-4.5,-3.6,GO:2000106,regulation of leukocyte apoptotic process,M111,3,0
1,1,1,-4.3,-3.7,-4.7,M255,PID HIF1 TFPATHWAY,M111,3,0
1,1,1,-5.8,-7.1,-3.1,GO:0002819,regulation of adaptive immune response,M111,3,0
1,1,1,-2,-2.4,-2.2,GO:0034405,response to fluid shear stress,M111,3,0
1,1,1,-8.6,-10,-8.5,GO:0030217,T cell differentiation,M111,3,0
1,1,1,-3.1,-2.1,-2.1,M151,PID AR TF PATHWAY,M111,3,0
1,1,1,-11,-12,-11,GO:0008283,cell population proliferation,M111,3,0
1,1,1,-5.9,-5.3,-7.3,GO:0002757,immune response-activating signaling pathway,M111,3,0
1,1,1,-4.7,-2.5,-2.3,GO:0003281,ventricular septum development,M111,3,0
1,1,1,-4.3,-2.9,-4.1,GO:0001656,metanephros development,M111,3,0
1,1,1,-5.3,-6.2,-6.3,GO:0046631,alpha-beta T cell activation,M111,3,0
1,1,1,-2.6,-3.3,-4,GO:0030833,regulation of actin filament polymerization,M111,3,0
1,1,1,-4.3,-2.8,-3.3,GO:0098868,bone growth,M111,3,0
1,1,1,-4.7,-2.1,-4.4,R-HSA-1433557,Signaling by SCF-KIT,M111,3,0
1,1,1,-9.6,-6.8,-6.5,GO:0048880,sensory system development,M111,3,0
1,1,1,-2,-2.1,-4.5,GO:0060078,regulation of postsynaptic membrane potential,M111,3,0
1,1,1,-3.4,-4.1,-2.4,hsa04211,Longevity regulating pathway,M111,3,0
1,1,1,-4.1,-5.1,-4.2,GO:0007411,axon guidance,M111,3,0
1,1,1,-3.2,-3.8,-4.1,GO:0061440,kidney vasculature development,M111,3,0
1,1,1,-6.8,-4.8,-5,WP2882,Nuclear receptors meta pathway,M111,3,0
1,1,1,-4.7,-3.6,-5.3,GO:0045766,positive regulation of angiogenesis,M111,3,0
1,1,1,-5.4,-3.8,-3,M65,PID FRA PATHWAY,M111,3,0
1,1,1,-5.2,-5.8,-6.7,GO:0002062,chondrocyte differentiation,M111,3,0
1,1,1,-8.7,-8.4,-7.1,hsa04380,Osteoclast differentiation,M111,3,0
1,1,1,-4.5,-4.4,-2.6,GO:0010595,positive regulation of endothelial cell migration,M111,3,0
1,1,1,-11,-11,-11,GO:0071345,cellular response to cytokine stimulus,M111,3,0
1,1,1,-4.6,-4.8,-5.8,GO:0141091,transforming growth factor beta receptor superfamily signaling pathway,M111,3,0
1,1,1,-5.8,-5.2,-4.5,GO:0003206,cardiac chamber morphogenesis,M111,3,0
1,1,1,-7.8,-3.1,-4,R-HSA-2871809,FCERI mediated Ca+2 mobilization,M111,3,0
1,1,1,-7.8,-6.3,-3.7,GO:0010594,regulation of endothelial cell migration,M111,3,0
1,1,1,-11,-11,-11,GO:0007167,enzyme-linked receptor protein signaling pathway,M111,3,0
1,1,1,-5,-4.3,-3.7,hsa04022,cGMP-PKG signaling pathway,M111,3,0
1,1,1,-5.7,-3.6,-3.8,GO:0002720,positive regulation of cytokine production involved in immune response,M111,3,0
1,1,1,-13,-13,-7.5,GO:0007420,brain development,M111,3,0
1,1,1,-4.3,-6.2,-3.9,R-HSA-112315,Transmission across Chemical Synapses,M111,3,0
1,1,1,-5.1,-6.2,-4.8,GO:0060173,limb development,M111,3,0
1,1,1,-2.3,-2.2,-3.1,WP4222,Phosphodiesterases in neuronal function,M111,3,0
1,1,1,-5.2,-3.8,-5.3,M7,PID FCER1 PATHWAY,M111,3,0
1,1,1,-3,-3.7,-4,WP5417,Cell lineage map for neuronal differentiation,M111,3,0
1,1,1,-3,-2.2,-3.1,GO:0021780,glial cell fate specification,M111,3,0
1,1,1,-6.6,-7.7,-4.5,GO:0050866,negative regulation of cell activation,M111,3,0
1,1,1,-3.3,-4.8,-3.3,WP75,Toll like receptor signaling pathway,M111,3,0
1,1,1,-12,-17,-13,GO:0042110,T cell activation,M111,3,0
1,1,1,-4,-2.5,-3.4,R-HSA-512988,"Interleukin-3, Interleukin-5 and GM-CSF signaling",M111,3,0
1,1,1,-4.7,-8.3,-4.6,hsa04724,Glutamatergic synapse,M111,3,0
1,1,1,-4.2,-4.8,-3.4,GO:0051897,positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction,M111,3,0
1,1,1,-2.6,-4,-3.9,GO:0034204,lipid translocation,M111,3,0
1,1,1,-2.7,-4.1,-2.2,R-HSA-2172127,DAP12 interactions,M111,3,0
1,1,1,-4.1,-3.3,-2.5,GO:0050680,negative regulation of epithelial cell proliferation,M111,3,0
1,1,1,-6.2,-4.8,-2.5,GO:0002698,negative regulation of immune effector process,M111,3,0
1,1,1,-2.1,-2.5,-2.8,R-HSA-9705462,Inactivation of CSF3 (G-CSF) signaling,M111,3,0
1,1,1,-6.3,-6.8,-5,GO:0043583,ear development,M111,3,0
1,1,1,-10,-8.5,-5.3,GO:0002009,morphogenesis of an epithelium,M111,3,0
1,1,1,-3.8,-3.9,-2.8,GO:0006959,humoral immune response,M111,3,0
1,1,1,-3.8,-4.4,-6,hsa04072,Phospholipase D signaling pathway,M111,3,0
1,1,1,-5.1,-4.1,-3.1,GO:1903557,positive regulation of tumor necrosis factor superfamily cytokine production,M111,3,0
1,1,1,-5.4,-4.3,-3.8,GO:0003205,cardiac chamber development,M111,3,0
1,1,1,-5.4,-3.1,-3,GO:0035909,aorta morphogenesis,M111,3,0
1,1,1,-12,-18,-8.9,GO:0050865,regulation of cell activation,M111,3,0
1,1,1,-4.4,-2.1,-3.1,GO:0043502,regulation of muscle adaptation,M111,3,0
1,1,1,-2.8,-3.5,-2.8,WP3995,Prion disease pathway,M111,3,0
1,1,1,-4.1,-5.1,-4.2,GO:0097485,neuron projection guidance,M111,3,0
1,1,1,-5.4,-5.1,-4,R-HSA-198725,Nuclear Events (kinase and transcription factor activation),M111,3,0
1,1,1,-13,-12,-7.3,GO:0010720,positive regulation of cell development,M111,3,0
1,1,1,-2.5,-3.2,-4.2,GO:0022029,telencephalon cell migration,M111,3,0
1,1,1,-3,-3.2,-2.2,GO:0043433,negative regulation of DNA-binding transcription factor activity,M111,3,0
1,1,1,-6.6,-5,-4.9,GO:0045765,regulation of angiogenesis,M111,3,0
1,1,1,-4.8,-2.9,-2.4,GO:0030278,regulation of ossification,M111,3,0
1,1,1,-2,-2.4,-2.2,WP4559,Interactions between immune cells and microRNAs in tumor microenvironment,M111,3,0
1,1,1,-5.6,-6.5,-6,M183,PID IL6 7 PATHWAY,M111,3,0
1,1,1,-7.8,-8.1,-12,GO:1901699,cellular response to nitrogen compound,M111,3,0
1,1,1,-2.8,-2.5,-2.8,GO:2000379,positive regulation of reactive oxygen species metabolic process,M111,3,0
1,1,1,-8.5,-8.3,-6.3,GO:0003007,heart morphogenesis,M111,3,0
1,1,1,-5.1,-2.5,-2.5,WP2203,Thymic stromal lymphopoietin TSLP signaling pathway,M111,3,0
1,1,1,-4.6,-3.5,-2.6,GO:0001892,embryonic placenta development,M111,3,0
1,1,1,-8.2,-5.3,-3.7,GO:0050900,leukocyte migration,M111,3,0
1,1,1,-4.9,-7.4,-2.7,GO:0070663,regulation of leukocyte proliferation,M111,3,0
1,1,1,-13,-10,-5.6,hsa05167,Kaposi sarcoma-associated herpesvirus infection,M111,3,0
1,1,1,-3.2,-2.1,-2.5,GO:0060441,epithelial tube branching involved in lung morphogenesis,M111,3,0
1,1,1,-2.6,-3.2,-3.9,WP2526,PDGF pathway,M111,3,0
1,1,1,-5.8,-7.8,-4.9,GO:0045619,regulation of lymphocyte differentiation,M111,3,0
1,1,1,-5.9,-4.4,-3.5,GO:0035137,hindlimb morphogenesis,M111,3,0
1,1,1,-5,-5.2,-3.5,GO:0030336,negative regulation of cell migration,M111,3,0
1,1,1,-2.3,-5.8,-3.6,GO:0007156,homophilic cell adhesion via plasma membrane adhesion molecules,M111,3,0
1,1,1,-4.1,-3.9,-3.2,M272,PID CD8 TCR DOWNSTREAM PATHWAY,M111,3,0
1,1,1,-3.5,-3.5,-3.8,WP4304,Oligodendrocyte specification and differentiation leading to myelin components for CNS,M111,3,0
1,1,1,-3.8,-3,-2.6,R-HSA-983705,Signaling by the B Cell Receptor (BCR),M111,3,0
1,1,1,-6.1,-3.1,-4,GO:0003279,cardiac septum development,M111,3,0
1,1,1,-5.7,-3.1,-4,R-HSA-400253,Circadian Clock,M111,3,0
1,1,1,-5.6,-2.7,-2.6,GO:0003176,aortic valve development,M111,3,0
1,1,1,-2.7,-2.1,-2.2,GO:0052652,cyclic purine nucleotide metabolic process,M111,3,0
1,1,1,-3.5,-6.3,-2.1,GO:0032946,positive regulation of mononuclear cell proliferation,M111,3,0
1,1,1,-2.9,-4.3,-2.5,GO:0002824,positive regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains,M111,3,0
1,1,1,-3.9,-2.5,-2.3,WP399,Wnt signaling pathway and pluripotency,M111,3,0
1,1,1,-5.2,-5.1,-2.6,GO:0030595,leukocyte chemotaxis,M111,3,0
1,1,1,-2.5,-2.1,-2.3,GO:0051145,smooth muscle cell differentiation,M111,3,0
1,1,1,-9.8,-9.5,-6.1,GO:1902105,regulation of leukocyte differentiation,M111,3,0
1,1,1,-5.9,-6.2,-5,GO:0045621,positive regulation of lymphocyte differentiation,M111,3,0
1,1,1,-3.8,-2.4,-2.1,R-HSA-9758941,Gastrulation,M111,3,0
1,1,1,-4.9,-4.9,-5.7,GO:0021988,olfactory lobe development,M111,3,0
1,1,1,-2.4,-3.7,-2.5,GO:0035306,positive regulation of dephosphorylation,M111,3,0
1,1,1,-3.1,-4.8,-3.7,GO:0046643,regulation of gamma-delta T cell activation,M111,3,0
1,1,1,-2.9,-4.4,-2.1,R-HSA-2424491,DAP12 signaling,M111,3,0
1,1,1,-4.9,-7.8,-2.6,GO:0050670,regulation of lymphocyte proliferation,M111,3,0
1,1,1,-3.6,-2.3,-2.1,WP2118,Arrhythmogenic right ventricular cardiomyopathy,M111,3,0
1,1,1,-4.1,-3.2,-5.9,GO:0019932,second-messenger-mediated signaling,M111,3,0
1,1,1,-2.8,-3.6,-2.3,GO:0001101,response to acid chemical,M111,3,0
1,1,1,-5.8,-5.8,-2.6,hsa04921,Oxytocin signaling pathway,M111,3,0
1,1,1,-4.1,-4.1,-5.9,R-HSA-9013149,RAC1 GTPase cycle,M111,3,0
1,1,1,-5.2,-6.5,-3.9,GO:0032526,response to retinoic acid,M111,3,0
1,1,1,-6,-5.5,-2.5,GO:0002705,positive regulation of leukocyte mediated immunity,M111,3,0
1,1,1,-2.3,-4.4,-4.4,R-HSA-9607240,FLT3 Signaling,M111,3,0
1,1,1,-3.6,-4.1,-2.9,GO:0070670,response to interleukin-4,M111,3,0
1,1,1,-3.6,-2.7,-2.4,GO:0002886,regulation of myeloid leukocyte mediated immunity,M111,3,0
1,1,1,-4.5,-4.5,-5.2,GO:0021772,olfactory bulb development,M111,3,0
1,1,1,-4.3,-4.7,-4.7,GO:0007178,transmembrane receptor protein serine/threonine kinase signaling pathway,M111,3,0
1,1,1,-4.5,-4.1,-2.4,GO:0032663,regulation of interleukin-2 production,M111,3,0
1,1,1,-2.4,-2.1,-2.5,GO:0002053,positive regulation of mesenchymal cell proliferation,M111,3,0
1,1,1,-9.8,-5.1,-4.7,GO:0048844,artery morphogenesis,M111,3,0
1,1,1,-14,-19,-18,GO:0046649,lymphocyte activation,M111,3,0
1,1,1,-3.1,-2.5,-4.3,WP304,Kit receptor signaling pathway,M111,3,0
1,1,1,-2,-3.2,-4.5,hsa04750,Inflammatory mediator regulation of TRP channels,M111,3,0
1,1,1,-3.5,-2.8,-2.1,GO:0071621,granulocyte chemotaxis,M111,3,0
1,1,1,-3.1,-2.8,-2.6,M122,PID IL2 1PATHWAY,M111,3,0
1,1,1,-6,-2.2,-5.5,GO:0045444,fat cell differentiation,M111,3,0
1,1,1,-2.1,-3.2,-2.4,R-HSA-163685,Integration of energy metabolism,M111,3,0
1,1,1,-8,-6.1,-6.6,GO:0048705,skeletal system morphogenesis,M111,3,0
1,1,1,-3.8,-2.8,-2.8,M33,PID GLYPICAN 1PATHWAY,M111,3,0
1,1,1,-2.7,-3.2,-2.9,GO:0072189,ureter development,M111,3,0
1,1,1,-2.3,-2.6,-2.6,GO:0048015,phosphatidylinositol-mediated signaling,M111,3,0
1,1,1,-4.7,-6.6,-5.3,hsa05321,Inflammatory bowel disease,M111,3,0
1,1,1,-8.3,-7.3,-4.6,GO:0060562,epithelial tube morphogenesis,M111,3,0
1,1,1,-5.2,-4.8,-3.2,hsa04010,MAPK signaling pathway,M111,3,0
1,1,1,-4,-2.4,-2.4,GO:0097530,granulocyte migration,M111,3,0
1,1,1,-2.8,-3.5,-3.2,GO:0042093,T-helper cell differentiation,M111,3,0
1,1,1,-2.6,-3.2,-3.1,GO:0035115,embryonic forelimb morphogenesis,M111,3,0
1,1,1,-9.4,-7.4,-4.5,GO:0050767,regulation of neurogenesis,M111,3,0
1,1,1,-6.2,-6.5,-7.5,GO:0002764,immune response-regulating signaling pathway,M111,3,0
1,1,1,-4.1,-3.5,-2.6,GO:0072009,nephron epithelium development,M111,3,0
1,1,1,-2.6,-3.9,-2.4,hsa05140,Leishmaniasis,M111,3,0
1,1,1,-3.3,-3.9,-3.2,GO:0035136,forelimb morphogenesis,M111,3,0
1,1,1,-10,-9.8,-5.6,GO:0002697,regulation of immune effector process,M111,3,0
1,1,1,-3.3,-3.5,-2.4,GO:0061035,regulation of cartilage development,M111,3,0
1,1,1,-9.6,-17,-8.7,GO:0002694,regulation of leukocyte activation,M111,3,0
1,1,1,-7.3,-4.8,-6.7,GO:0045637,regulation of myeloid cell differentiation,M111,3,0
1,1,1,-6.7,-4.9,-4.8,GO:0002702,positive regulation of production of molecular mediator of immune response,M111,3,0
1,1,1,-5.6,-5.9,-2.9,hsa05224,Breast cancer,M111,3,0
1,1,1,-6.8,-4.6,-6.6,GO:0060348,bone development,M111,3,0
1,1,1,-5.5,-3.7,-3.7,WP706,Sudden infant death syndrome SIDS susceptibility pathways,M111,3,0
1,1,1,-4.9,-2.8,-3.7,GO:0048663,neuron fate commitment,M111,3,0
1,1,1,-17,-12,-9.8,GO:0035239,tube morphogenesis,M111,3,0
1,1,1,-8,-7.1,-5.3,WP23,B cell receptor signaling pathway,M111,3,0
1,1,1,-2.8,-3.5,-3.2,GO:0002294,"CD4-positive, alpha-beta T cell differentiation involved in immune response",M111,3,0
1,1,1,-7.1,-5,-3.9,GO:0051962,positive regulation of nervous system development,M111,3,0
1,1,1,-5.1,-4.7,-2.1,hsa04926,Relaxin signaling pathway,M111,3,0
1,1,1,-4.1,-2.5,-3.2,R-HSA-9664323,FCGR3A-mediated IL10 synthesis,M111,3,0
1,1,1,-5,-3.2,-6.4,WP69,T cell receptor signaling pathway,M111,3,0
1,1,1,-13,-7.9,-7.4,GO:0048514,blood vessel morphogenesis,M111,3,0
1,1,1,-5.1,-3.6,-5.6,hsa04935,"Growth hormone synthesis, secretion and action",M111,3,0
1,1,1,-8.9,-7.2,-5,GO:0001822,kidney development,M111,3,0
1,1,1,-7.8,-7.7,-5.3,GO:1903708,positive regulation of hemopoiesis,M111,3,0
1,1,1,-7.3,-3.9,-6.8,GO:0003151,outflow tract morphogenesis,M111,3,0
1,1,1,-2.2,-2.4,-3.2,GO:0071474,cellular hyperosmotic response,M111,3,0
1,1,1,-8,-5.1,-6.7,GO:0031348,negative regulation of defense response,M111,3,0
1,1,1,-7.3,-6.4,-3.8,GO:0002703,regulation of leukocyte mediated immunity,M111,3,0
1,1,1,-4.5,-4.3,-2.7,hsa04371,Apelin signaling pathway,M111,3,0
1,1,1,-3.5,-4.4,-3.5,R-HSA-168898,Toll-like Receptor Cascades,M111,3,0
1,1,1,-2.8,-2.3,-2.1,GO:0055017,cardiac muscle tissue growth,M111,3,0
1,1,1,-2.9,-3,-2,R-HSA-168188,Toll Like Receptor TLR6:TLR2 Cascade,M111,3,0
1,1,1,-5.1,-5.3,-3.5,GO:2000146,negative regulation of cell motility,M111,3,0
1,1,1,-4,-4.8,-2.6,GO:0061180,mammary gland epithelium development,M111,3,0
1,1,1,-4.5,-3.3,-2.2,GO:0001657,ureteric bud development,M111,3,0
1,1,1,-3.2,-4.7,-4.9,GO:0030183,B cell differentiation,M111,3,0
1,1,1,-6.1,-7.1,-3,GO:0030879,mammary gland development,M111,3,0
1,1,1,-3.2,-2.7,-2.3,GO:0007519,skeletal muscle tissue development,M111,3,0
1,1,1,-5.3,-4.1,-2.3,WP2324,AGE RAGE pathway,M111,3,0
1,1,1,-10,-9.3,-7.9,GO:0032870,cellular response to hormone stimulus,M111,3,0
1,1,1,-3,-2,-3.6,GO:0045665,negative regulation of neuron differentiation,M111,3,0
1,1,1,-5.5,-5.8,-3.9,GO:0072089,stem cell proliferation,M111,3,0
1,1,1,-5.4,-4.9,-4.9,WP437,EGF EGFR signaling pathway,M111,3,0
1,1,1,-2.3,-2,-2.8,hsa05231,Choline metabolism in cancer,M111,3,0
1,1,1,-6.6,-9.7,-4.8,GO:0002252,immune effector process,M111,3,0
1,1,1,-3.9,-3.9,-3.1,GO:0097305,response to alcohol,M111,3,0
1,1,1,-4.5,-4.7,-2.4,R-HSA-877300,Interferon gamma signaling,M111,3,0
1,1,1,-2.8,-2.7,-2.9,R-HSA-2219528,PI3K/AKT Signaling in Cancer,M111,3,0
1,1,1,-4.6,-3,-2.2,R-HSA-198933,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,M111,3,0
1,1,1,-2.1,-2.4,-2.9,R-HSA-6811558,"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",M111,3,0
1,1,1,-4.5,-4.6,-5.9,GO:0048738,cardiac muscle tissue development,M111,3,0
1,1,1,-7.9,-9.5,-6.7,M167,PID AP1 PATHWAY,M111,3,0
1,1,1,-4.9,-7.6,-3.1,hsa05221,Acute myeloid leukemia,M111,3,0
1,1,1,-6.8,-5.1,-2.8,GO:0048638,regulation of developmental growth,M111,3,0
1,1,1,-10,-7.9,-3.3,hsa05163,Human cytomegalovirus infection,M111,3,0
1,1,1,-17,-11,-13,GO:0001501,skeletal system development,M111,3,0
1,1,1,-4.1,-2.8,-4,GO:0045669,positive regulation of osteoblast differentiation,M111,3,0
1,1,1,-4.5,-3.1,-3,GO:2000648,positive regulation of stem cell proliferation,M111,3,0
1,1,1,-3.3,-3.7,-4.3,GO:0008064,regulation of actin polymerization or depolymerization,M111,3,0
1,1,1,-3.6,-3.8,-2.4,GO:0035914,skeletal muscle cell differentiation,M111,3,0
1,1,1,-3.8,-3.2,-3.6,R-HSA-9013148,CDC42 GTPase cycle,M111,3,0
1,1,1,-9.1,-5.1,-5.8,WP236,Adipogenesis,M111,3,0
1,1,1,-2.5,-2.7,-4.8,GO:0003143,embryonic heart tube morphogenesis,M111,3,0
1,1,1,-5.5,-5.4,-4.3,R-HSA-187037,Signaling by NTRK1 (TRKA),M111,3,0
1,1,1,-3,-3.4,-3.1,GO:0045588,positive regulation of gamma-delta T cell differentiation,M111,3,0
1,1,1,-7.7,-3.9,-4.2,GO:0034101,erythrocyte homeostasis,M111,3,0
1,1,1,-4.3,-3,-3.4,GO:0048565,digestive tract development,M111,3,0
1,1,1,-9.9,-11,-5.2,hsa05166,Human T-cell leukemia virus 1 infection,M111,3,0
1,1,1,-6.8,-4.3,-3.7,GO:0002065,columnar/cuboidal epithelial cell differentiation,M111,3,0
1,1,1,-6,-3.4,-4.4,GO:0060411,cardiac septum morphogenesis,M111,3,0
1,1,1,-3,-3.4,-4.5,R-HSA-8951671,RUNX3 regulates YAP1-mediated transcription,M111,3,0
1,1,1,-3.4,-3.5,-2.3,GO:0060443,mammary gland morphogenesis,M111,3,0
1,1,1,-6.6,-5.1,-3.4,GO:0032675,regulation of interleukin-6 production,M111,3,0
1,1,1,-5.9,-3.5,-3.6,GO:0002262,myeloid cell homeostasis,M111,3,0
1,1,1,-4.2,-2.8,-2.1,GO:0031343,positive regulation of cell killing,M111,3,0
1,1,1,-4.2,-6.6,-3.1,GO:0051250,negative regulation of lymphocyte activation,M111,3,0
1,1,1,-5,-3.9,-5.3,GO:1904018,positive regulation of vasculature development,M111,3,0
1,1,1,-6.5,-5.8,-3.6,hsa04915,Estrogen signaling pathway,M111,3,0
1,1,1,-3.1,-2.1,-2.8,GO:0050853,B cell receptor signaling pathway,M111,3,0
1,1,1,-8.9,-8.3,-7.4,GO:0051216,cartilage development,M111,3,0
1,1,1,-2.7,-3.2,-2.2,hsa04929,GnRH secretion,M111,3,0
1,1,1,-4.8,-5.6,-2.4,WP4262,Breast cancer pathway,M111,3,0
1,1,1,-2.4,-5.4,-3.7,GO:0032943,mononuclear cell proliferation,M111,3,0
1,1,1,-3,-3.9,-3.4,hsa04725,Cholinergic synapse,M111,3,0
1,1,1,-6.9,-5.4,-8,R-HSA-9012999,RHO GTPase cycle,M111,3,0
1,1,1,-3.1,-2.6,-2.6,GO:0035019,somatic stem cell population maintenance,M111,3,0
1,1,1,-8.3,-7.6,-9.9,GO:0048562,embryonic organ morphogenesis,M111,3,0
1,1,1,-4.4,-4.5,-2.6,GO:0002443,leukocyte mediated immunity,M111,3,0
1,1,1,-5,-3.2,-3.5,hsa04662,B cell receptor signaling pathway,M111,3,0
1,1,1,-4,-4.8,-2.7,GO:0001764,neuron migration,M111,3,0
1,1,1,-5.2,-3.1,-3.7,GO:0010232,vascular transport,M111,3,0
1,1,1,-2,-2.4,-2.9,GO:0071354,cellular response to interleukin-6,M111,3,0
1,1,1,-4.1,-2.8,-4.1,WP395,IL 4 signaling pathway,M111,3,0
1,1,1,-3.3,-2.6,-3,R-HSA-8980692,RHOA GTPase cycle,M111,3,0
1,1,1,-5.5,-6.1,-5,GO:0021543,pallium development,M111,3,0
1,1,1,-2.6,-2.5,-2.1,GO:0030225,macrophage differentiation,M111,3,0
1,1,1,-4.4,-2.6,-2.6,R-HSA-5621481,C-type lectin receptors (CLRs),M111,3,0
1,1,1,-5.8,-8.1,-4.5,GO:0045580,regulation of T cell differentiation,M111,3,0
1,1,1,-7.2,-14,-6.8,GO:0050863,regulation of T cell activation,M111,3,0
1,1,1,-4,-4.7,-5,WP286,IL 3 signaling pathway,M111,3,0
1,1,1,-4.5,-5.3,-6,GO:0042471,ear morphogenesis,M111,3,0
1,1,1,-2.3,-2.1,-2.9,GO:0032677,regulation of interleukin-8 production,M111,3,0
1,1,1,-2.7,-3.2,-2.9,GO:0048596,embryonic camera-type eye morphogenesis,M111,3,0
1,1,1,-2,-3.2,-2.9,GO:0097581,lamellipodium organization,M111,3,0
1,1,1,-2.6,-4.5,-2.6,R-HSA-112314,Neurotransmitter receptors and postsynaptic signal transmission,M111,3,0
1,1,1,-2.6,-3.1,-3.2,WP4844,Influence of laminopathies on Wnt signaling,M111,3,0
1,1,1,-5.3,-5.1,-2.2,GO:0002520,immune system development,M111,3,0
1,1,1,-2.2,-2.4,-3.6,GO:0051282,regulation of sequestering of calcium ion,M111,3,0
1,1,1,-3.8,-3.8,-3.7,WP1544,MicroRNAs in cardiomyocyte hypertrophy,M111,3,0
1,1,1,-2.3,-2.8,-4.6,GO:0010976,positive regulation of neuron projection development,M111,3,0
1,1,1,-4.3,-3.2,-3.1,GO:0060037,pharyngeal system development,M111,3,0
1,1,1,-6.5,-3.6,-4.4,GO:0072132,mesenchyme morphogenesis,M111,3,0
1,1,1,-4.2,-3.5,-3,GO:0010634,positive regulation of epithelial cell migration,M111,3,0
1,1,1,-5,-5.9,-3.6,GO:0071383,cellular response to steroid hormone stimulus,M111,3,0
1,1,1,-2.3,-2.8,-2.2,GO:1900015,regulation of cytokine production involved in inflammatory response,M111,3,0
1,1,1,-2.2,-2.4,-3.2,GO:1902170,cellular response to reactive nitrogen species,M111,3,0
1,1,1,-3.8,-2.1,-2.2,R-HSA-1368108,"BMAL1:CLOCK,NPAS2 activates circadian gene expression",M111,3,0
1,1,1,-2.8,-2.1,-2.6,R-HSA-202403,TCR signaling,M111,3,0
1,1,1,-7.5,-6.3,-2.5,GO:2000629,negative regulation of miRNA metabolic process,M111,3,0
1,1,1,-3,-2.2,-2.1,M26,PID NFKAPPAB ATYPICAL PATHWAY,M111,3,0
1,1,1,-9.5,-12,-7.9,GO:0050678,regulation of epithelial cell proliferation,M111,3,0
1,1,1,-3.8,-3.1,-5.8,GO:0050851,antigen receptor-mediated signaling pathway,M111,3,0
1,1,1,-13,-9.8,-5.4,R-HSA-6785807,Interleukin-4 and Interleukin-13 signaling,M111,3,0
1,1,1,-3.3,-3.5,-3.3,GO:0002292,T cell differentiation involved in immune response,M111,3,0
1,1,1,-12,-9.3,-6.7,GO:0009725,response to hormone,M111,3,0
1,1,1,-7.8,-7.9,-12,GO:0071417,cellular response to organonitrogen compound,M111,3,0
1,1,1,-2.5,-3.3,-3.3,GO:0043367,"CD4-positive, alpha-beta T cell differentiation",M111,3,0
1,1,1,-3.2,-3.8,-4.1,GO:0061437,renal system vasculature development,M111,3,0
1,1,1,-2,-2.6,-2.8,hsa04911,Insulin secretion,M111,3,0
1,1,1,-6.7,-6.1,-5.3,WP3929,Chemokine signaling pathway,M111,3,0
1,1,1,-8.9,-4.5,-5.3,GO:0060021,roof of mouth development,M111,3,0
1,1,1,-8.8,-7.3,-5.4,GO:0071695,anatomical structure maturation,M111,3,0
1,1,1,-13,-12,-7.8,GO:0140747,regulation of ncRNA transcription,M111,3,0
1,1,1,-3.5,-3.5,-3.3,WP3937,Microglia pathogen phagocytosis pathway,M111,3,0
1,1,1,-3,-4.1,-2.2,GO:0031960,response to corticosteroid,M111,3,0
1,1,1,-3.1,-3.8,-4.4,GO:0042531,positive regulation of tyrosine phosphorylation of STAT protein,M111,3,0
1,1,1,-5.2,-3.1,-2.8,GO:0048709,oligodendrocyte differentiation,M111,3,0
1,1,1,-2.3,-2.1,-2.6,GO:0070741,response to interleukin-6,M111,3,0
1,1,1,-5.4,-5.1,-3.1,GO:0046635,positive regulation of alpha-beta T cell activation,M111,3,0
1,1,1,-2.4,-3.6,-3.4,GO:0035710,"CD4-positive, alpha-beta T cell activation",M111,3,0
1,1,1,-5.1,-6.4,-7.7,GO:0019221,cytokine-mediated signaling pathway,M111,3,0
1,1,1,-3.6,-3.4,-2.7,GO:0045787,positive regulation of cell cycle,M111,3,0
1,1,1,-6.3,-4.8,-5.1,WP5098,T cell activation SARS CoV 2,M111,3,0
1,1,1,-5.4,-4.4,-3.4,GO:0035265,organ growth,M111,3,0
1,1,1,-3.4,-4.1,-2.3,GO:0071300,cellular response to retinoic acid,M111,3,0
1,1,1,-2.9,-2.5,-3.7,GO:0048339,paraxial mesoderm development,M111,3,0
1,1,1,-5.4,-5.5,-3.2,hsa04550,Signaling pathways regulating pluripotency of stem cells,M111,3,0
1,1,1,-15,-9.4,-9.2,GO:0001568,blood vessel development,M111,3,0
1,1,1,-5.5,-2.8,-2.8,GO:1905314,semi-lunar valve development,M111,3,0
1,1,1,-2.1,-2.5,-2.7,GO:0030859,polarized epithelial cell differentiation,M111,3,0
1,1,1,-2.9,-4.4,-2.8,hsa04514,Cell adhesion molecules,M111,3,0
1,1,1,-9.9,-12,-7.3,GO:0030900,forebrain development,M111,3,0
1,1,1,-6.6,-3.6,-4.9,GO:0030218,erythrocyte differentiation,M111,3,0
1,1,1,-4.6,-6.2,-2.2,GO:0002822,regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains,M111,3,0
1,1,1,-4.8,-4.9,-3.7,R-HSA-166520,Signaling by NTRKs,M111,3,0
1,1,1,-5.1,-4.3,-2.7,GO:2000177,regulation of neural precursor cell proliferation,M111,3,0
1,1,1,-11,-7.9,-6.4,R-HSA-9006934,Signaling by Receptor Tyrosine Kinases,M111,3,0
1,1,1,-3.1,-2.5,-2.7,GO:0042474,middle ear morphogenesis,M111,3,0
1,1,1,-7.6,-6.9,-3,hsa05169,Epstein-Barr virus infection,M111,3,0
1,1,1,-2.2,-2.1,-2.3,M115,PID REG GR PATHWAY,M111,3,0
1,1,1,-8,-6.5,-4.8,R-HSA-9824443,Parasitic Infection Pathways,M111,3,0
1,1,1,-2,-2.4,-3.1,GO:0042088,T-helper 1 type immune response,M111,3,0
1,1,1,-4.9,-7.8,-2.7,GO:0032944,regulation of mononuclear cell proliferation,M111,3,0
1,1,1,-5.6,-6.4,-3.8,GO:0002695,negative regulation of leukocyte activation,M111,3,0
1,1,1,-13,-12,-7.8,GO:0060322,head development,M111,3,0
1,1,1,-3.2,-3.8,-2.7,GO:0048048,embryonic eye morphogenesis,M111,3,0
1,1,1,-5.2,-5.8,-7.9,GO:0002768,immune response-regulating cell surface receptor signaling pathway,M111,3,0
1,1,1,-5,-6.5,-6.5,WP4541,Hippo Merlin signaling dysregulation,M111,3,0
1,1,1,-4.5,-4.6,-3.6,hsa04630,JAK-STAT signaling pathway,M111,3,0
1,1,1,-6.2,-7.5,-4.4,WP4172,PI3K Akt signaling pathway,M111,3,0
1,1,1,-9.5,-6.4,-6.8,WP4149,White fat cell differentiation,M111,3,0
1,1,1,-5.3,-5.5,-4.2,GO:1903555,regulation of tumor necrosis factor superfamily cytokine production,M111,3,0
1,1,1,-4.7,-5.3,-5.9,M290,PID IL12 STAT4 PATHWAY,M111,3,0
1,1,1,-4.6,-4,-2.9,GO:0002244,hematopoietic progenitor cell differentiation,M111,3,0
1,1,1,-10,-9.4,-9.2,GO:0071363,cellular response to growth factor stimulus,M111,3,0
1,1,1,-6.5,-6.4,-5.3,GO:0032835,glomerulus development,M111,3,0
1,1,1,-5.6,-4.9,-4.3,GO:0071559,response to transforming growth factor beta,M111,3,0
1,1,1,-3.6,-4.9,-5.1,GO:0050731,positive regulation of peptidyl-tyrosine phosphorylation,M111,3,0
1,1,1,-2.9,-2.3,-2.3,GO:0007626,locomotory behavior,M111,3,0
1,1,1,-5.3,-5.1,-4,GO:0072073,kidney epithelium development,M111,3,0
1,1,1,-3.1,-3.8,-2.5,GO:0033077,T cell differentiation in thymus,M111,3,0
1,1,1,-5.1,-3.7,-2.4,GO:0043535,regulation of blood vessel endothelial cell migration,M111,3,0
1,1,1,-13,-12,-9.3,GO:0007423,sensory organ development,M111,3,0
1,1,1,-3.5,-2.7,-2.8,hsa04919,Thyroid hormone signaling pathway,M111,3,0
1,1,1,-3.8,-4.5,-3.7,GO:0007193,adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway,M111,3,0
1,1,1,-2.8,-2.1,-2.1,GO:1903305,regulation of regulated secretory pathway,M111,3,0
1,1,1,-9.3,-9.8,-11,GO:0030099,myeloid cell differentiation,M111,3,0
1,1,1,-3,-3.4,-3.1,GO:0034616,response to laminar fluid shear stress,M111,3,0
1,1,1,-2.8,-5.5,-2.1,GO:0071277,cellular response to calcium ion,M111,3,0
1,1,1,-2.5,-4.4,-2.6,GO:0030888,regulation of B cell proliferation,M111,3,0
1,1,1,-4.7,-4.5,-3.2,GO:0097529,myeloid leukocyte migration,M111,3,0
1,1,1,-2.3,-2.1,-2.6,R-HSA-202433,Generation of second messenger molecules,M111,3,0
1,1,1,-5.9,-8.5,-5.6,GO:0051056,regulation of small GTPase mediated signal transduction,M111,3,0
1,1,1,-2.9,-2.8,-3.7,GO:0140467,integrated stress response signaling,M111,3,0
1,1,1,-4.4,-4.9,-2.2,hsa05152,Tuberculosis,M111,3,0
1,1,1,-11,-15,-10,GO:0022407,regulation of cell-cell adhesion,M111,3,0
1,1,1,-3.8,-3.6,-6.4,GO:0030509,BMP signaling pathway,M111,3,0
1,1,1,-5.5,-2.8,-2.1,GO:0014015,positive regulation of gliogenesis,M111,3,0
1,1,1,-3,-4.5,-2.8,GO:0021766,hippocampus development,M111,3,0
1,1,1,-7.3,-8.1,-6.1,GO:2000630,positive regulation of miRNA metabolic process,M111,3,0
1,1,1,-3.5,-2.1,-2.3,WP4482,Vitamin D in inflammatory diseases,M111,3,0
1,1,1,-5.5,-4,-3.1,GO:0035116,embryonic hindlimb morphogenesis,M111,3,0
1,1,1,-6.3,-4.8,-3.2,GO:0050769,positive regulation of neurogenesis,M111,3,0
1,1,1,-9,-11,-6.9,GO:0022409,positive regulation of cell-cell adhesion,M111,3,0
1,1,1,-2.9,-2.5,-4.8,R-HSA-186763,Downstream signal transduction,M111,3,0
1,1,1,-6,-6.3,-8.7,WP2849,Hematopoietic stem cell differentiation,M111,3,0
1,1,1,-5.5,-5,-2.1,WP2853,Endoderm differentiation,M111,3,0
1,1,1,-7.3,-5.4,-3,GO:0061138,morphogenesis of a branching epithelium,M111,3,0
1,1,1,-12,-11,-10,GO:0070848,response to growth factor,M111,3,0
1,1,1,-8,-6.5,-4.8,R-HSA-9658195,Leishmania infection,M111,3,0
1,1,1,-2.5,-3.1,-2.5,GO:0030101,natural killer cell activation,M111,3,0
1,1,1,-2.3,-2.9,-4.3,hsa04540,Gap junction,M111,3,0
1,1,1,-3.4,-5.6,-3.9,GO:1903038,negative regulation of leukocyte cell-cell adhesion,M111,3,0
1,1,1,-5,-4.2,-3.3,GO:0002067,glandular epithelial cell differentiation,M111,3,0
1,1,1,-3.5,-2.9,-2.3,GO:0098581,detection of external biotic stimulus,M111,3,0
1,1,1,-5.1,-4.5,-6.5,GO:0014706,striated muscle tissue development,M111,3,0
1,1,1,-3.3,-3.2,-3.1,GO:0045471,response to ethanol,M111,3,0
1,1,1,-3,-3.1,-3.3,GO:2000377,regulation of reactive oxygen species metabolic process,M111,3,0
1,1,1,-5,-5.2,-6.4,M54,PID IL12 2PATHWAY,M111,3,0
1,1,1,-3.6,-3.5,-4.5,GO:0072012,glomerulus vasculature development,M111,3,0
1,1,1,-3.8,-2.3,-2.5,hsa04613,Neutrophil extracellular trap formation,M111,3,0
1,1,1,-3.8,-4.8,-3.2,hsa04936,Alcoholic liver disease,M111,3,0
1,1,1,-4,-4.1,-3.2,R-HSA-9679191,Potential therapeutics for SARS,M111,3,0
1,1,1,-4.5,-4.5,-3,GO:0002066,columnar/cuboidal epithelial cell development,M111,3,0
1,1,1,-7.6,-4.8,-3.8,hsa05417,Lipid and atherosclerosis,M111,3,0
1,1,1,-3.1,-2.5,-2.7,R-HSA-2032785,YAP1- and WWTR1 (TAZ)-stimulated gene expression,M111,3,0
1,1,1,-2.4,-5.4,-3.7,GO:0046651,lymphocyte proliferation,M111,3,0
1,1,1,-5.8,-7.5,-5.8,GO:0002573,myeloid leukocyte differentiation,M111,3,0
1,1,1,-2.1,-2.8,-2.3,GO:0016064,immunoglobulin mediated immune response,M111,3,0
1,1,1,-4.7,-3.4,-7,M124,PID CXCR4 PATHWAY,M111,3,0
1,1,1,-2.5,-3.8,-2.6,GO:0043406,positive regulation of MAP kinase activity,M111,3,0
1,1,1,-6.7,-6.1,-6,hsa04928,"Parathyroid hormone synthesis, secretion and action",M111,3,0
1,1,1,-2.6,-5.8,-2.3,GO:1901655,cellular response to ketone,M111,3,0
1,1,1,-2.8,-2.9,-2.1,GO:0032653,regulation of interleukin-10 production,M111,3,0
1,1,1,-5.5,-5.8,-4.5,GO:0072006,nephron development,M111,3,0
1,1,1,-4.6,-5.6,-4.4,R-HSA-9031628,NGF-stimulated transcription,M111,3,0
1,1,1,-9.4,-5.8,-3.9,GO:0072091,regulation of stem cell proliferation,M111,3,0
1,1,1,-2.3,-2.2,-2.5,GO:0090102,cochlea development,M111,3,0
1,1,1,-3,-3.8,-3.5,GO:0002293,alpha-beta T cell differentiation involved in immune response,M111,3,0
1,1,1,-8.5,-6,-4.3,hsa05161,Hepatitis B,M111,3,0
1,1,1,-2.9,-2.6,-2.4,GO:0001938,positive regulation of endothelial cell proliferation,M111,3,0
1,1,1,-3.5,-3.7,-2.6,GO:0051961,negative regulation of nervous system development,M111,3,0
1,1,1,-3.5,-2.9,-3.1,WP3931,Embryonic stem cell pluripotency pathways,M111,3,0
1,1,1,-3.5,-2.6,-2.6,GO:0060396,growth hormone receptor signaling pathway,M111,3,0
1,1,1,-3,-2.2,-2.1,GO:0098543,detection of other organism,M111,3,0
1,1,1,-3.9,-2.5,-3.3,M164,PID ERBB1 DOWNSTREAM PATHWAY,M111,3,0
1,1,1,-3.2,-3.7,-3.3,WP4585,Cancer immunotherapy by PD 1 blockade,M111,3,0
1,1,1,-4,-4.8,-3.6,GO:0032655,regulation of interleukin-12 production,M111,3,0
1,1,1,-3.2,-5.3,-3.4,GO:0050868,negative regulation of T cell activation,M111,3,0
1,1,1,-4.3,-4.3,-8.5,GO:0071772,response to BMP,M111,3,0
1,1,1,-2.4,-2.8,-3.3,R-HSA-9674555,Signaling by CSF3 (G-CSF),M111,3,0
1,1,1,-7.9,-4.9,-5.3,GO:0007517,muscle organ development,M111,3,0
1,1,1,-4.4,-2.6,-2.8,WP2380,Brain derived neurotrophic factor BDNF signaling pathway,M111,3,0
1,1,1,-3.8,-6.7,-2.5,GO:0070665,positive regulation of leukocyte proliferation,M111,3,0
1,1,1,-5.2,-6.3,-3.5,GO:0043370,"regulation of CD4-positive, alpha-beta T cell differentiation",M111,3,0
1,1,1,-6.5,-5.6,-4.2,GO:0002718,regulation of cytokine production involved in immune response,M111,3,0
1,1,1,-3.5,-3.9,-2.6,WP4337,ncRNAs involved in STAT3 signaling in hepatocellular carcinoma,M111,3,0
1,1,1,-3,-4.4,-4.4,GO:0097035,regulation of membrane lipid distribution,M111,3,0
1,1,1,-6.8,-4.8,-7.3,GO:0002253,activation of immune response,M111,3,0
1,1,1,-5.5,-7.5,-7.6,hsa04658,Th1 and Th2 cell differentiation,M111,3,0
1,1,1,-3.5,-2.6,-2.3,GO:0060538,skeletal muscle organ development,M111,3,0
1,1,1,-4.6,-4.1,-2.6,GO:0002763,positive regulation of myeloid leukocyte differentiation,M111,3,0
1,1,1,-5.3,-5.5,-5.1,hsa04062,Chemokine signaling pathway,M111,3,0
1,1,1,-4,-2.3,-2.8,WP5090,Complement system in neuronal development and plasticity,M111,3,0
1,1,1,-3.5,-2.6,-2.6,GO:0071378,cellular response to growth hormone stimulus,M111,3,0
1,1,1,-2.5,-2.1,-2.3,GO:0120033,negative regulation of plasma membrane bounded cell projection assembly,M111,3,0
1,1,1,-4.3,-4.5,-5.3,GO:0030326,embryonic limb morphogenesis,M111,3,0
1,1,1,-3.7,-2.6,-2.8,GO:0060412,ventricular septum morphogenesis,M111,3,0
1,1,1,-7.3,-6.8,-6,GO:0032102,negative regulation of response to external stimulus,M111,3,0
1,1,1,-4.3,-4.5,-5.3,GO:0035113,embryonic appendage morphogenesis,M111,3,0
1,1,1,-5.7,-3.1,-2.9,GO:0031341,regulation of cell killing,M111,3,0
1,1,1,-2.5,-3.1,-2.9,M285,PID HNF3A PATHWAY,M111,3,0
1,1,1,-8.3,-6.2,-4.7,GO:0048469,cell maturation,M111,3,0
1,1,1,-6.7,-6,-5.6,GO:0060485,mesenchyme development,M111,3,0
1,1,1,-5.3,-3.7,-2.4,hsa05131,Shigellosis,M111,3,0
1,1,1,-4.7,-7.9,-4.4,GO:0002366,leukocyte activation involved in immune response,M111,3,0
1,1,1,-4,-4.6,-4.4,GO:0046632,alpha-beta T cell differentiation,M111,3,0
1,1,1,-8.1,-6.2,-4.2,GO:0001525,angiogenesis,M111,3,0
1,1,1,-3.4,-3.5,-2.4,GO:0032330,regulation of chondrocyte differentiation,M111,3,0
1,1,1,-2.6,-4,-2.4,GO:0007215,glutamate receptor signaling pathway,M111,3,0
1,1,1,-3,-3.2,-4.3,GO:0021885,forebrain cell migration,M111,3,0
1,1,1,-2.6,-2.4,-3.1,GO:0010464,regulation of mesenchymal cell proliferation,M111,3,0
1,1,1,-4.5,-3.3,-2.2,GO:0072164,mesonephric tubule development,M111,3,0
1,1,1,-6.3,-4.2,-3.3,hsa05170,Human immunodeficiency virus 1 infection,M111,3,0
1,1,1,-7.5,-6.3,-2.5,GO:1902894,negative regulation of miRNA transcription,M111,3,0
1,1,1,-3.3,-3,-2.9,GO:0043536,positive regulation of blood vessel endothelial cell migration,M111,3,0
1,1,1,-3.9,-3.8,-6,WP5198,Inflammatory bowel disease signaling,M111,3,0
1,1,1,-6.4,-5.4,-5.2,GO:0048704,embryonic skeletal system morphogenesis,M111,3,0
1,1,1,-3.1,-4.5,-3.8,GO:0001961,positive regulation of cytokine-mediated signaling pathway,M111,3,0
1,1,1,-7.5,-9.2,-6.2,hsa04659,Th17 cell differentiation,M111,3,0
1,1,1,-2.8,-2.7,-2,GO:0060070,canonical Wnt signaling pathway,M111,3,0
1,1,1,-2.9,-2.7,-2.7,GO:0051048,negative regulation of secretion,M111,3,0
1,1,1,-4.6,-3.5,-2.3,R-HSA-9664433,Leishmania parasite growth and survival,M111,3,0
1,1,1,-7.9,-7.9,-6.7,GO:1902895,positive regulation of miRNA transcription,M111,3,0
1,1,1,-2.3,-3.5,-2.6,GO:0021872,forebrain generation of neurons,M111,3,0
1,1,1,-4.1,-2.9,-3.1,GO:0055123,digestive system development,M111,3,0
1,1,1,-7.9,-6.7,-5.7,GO:0048706,embryonic skeletal system development,M111,3,0
1,1,1,-4,-4,-3.1,hsa04611,Platelet activation,M111,3,0
1,1,1,-6.4,-9.6,-5,GO:0050870,positive regulation of T cell activation,M111,3,0
1,1,1,-7.3,-5.4,-4.3,WP4666,Hepatitis B infection,M111,3,0
1,1,1,-13,-10,-8,GO:0045596,negative regulation of cell differentiation,M111,3,0
1,1,1,-6.4,-6.2,-3.1,GO:0022612,gland morphogenesis,M111,3,0
1,1,1,-4.5,-5.4,-2.5,GO:0045622,regulation of T-helper cell differentiation,M111,3,0
1,1,1,-3.5,-4.6,-5.4,GO:0042472,inner ear morphogenesis,M111,3,0
1,1,1,-15,-12,-8.9,GO:0001819,positive regulation of cytokine production,M111,3,0
1,1,1,-2.6,-2.9,-2.5,GO:0060397,growth hormone receptor signaling pathway via JAK-STAT,M111,3,0
1,1,1,-5.1,-3.6,-2.1,WP4255,Non small cell lung cancer,M111,3,0
1,1,1,-9.1,-7.7,-7.2,WP2857,Mesodermal commitment pathway,M111,3,0
1,1,1,-3.6,-2.2,-3,R-HSA-112040,G-protein mediated events,M111,3,0
1,1,1,-8.2,-7.4,-3.2,hsa05207,Chemical carcinogenesis - receptor activation,M111,3,0
1,1,1,-4,-5.7,-6.1,GO:0045664,regulation of neuron differentiation,M111,3,0
1,1,1,-6.2,-2.4,-3.4,GO:0035904,aorta development,M111,3,0
1,1,1,-2.3,-2.9,-3.2,hsa04916,Melanogenesis,M111,3,0
1,1,1,-3.9,-2.5,-5.3,WP4341,Non genomic actions of 1 25 dihydroxyvitamin D3,M111,3,0
1,1,1,-4.8,-4.4,-4.1,GO:0060326,cell chemotaxis,M111,3,0
1,1,1,-14,-21,-18,GO:0045321,leukocyte activation,M111,3,0
1,1,1,-3.3,-4.1,-4.2,WP3527,Pre implantation embryo,M111,3,0
1,1,1,-7.8,-6.8,-8.4,GO:0060537,muscle tissue development,M111,3,0
1,1,1,-11,-10,-9.2,GO:0007507,heart development,M111,3,0
1,1,1,-8.2,-16,-7,GO:0051249,regulation of lymphocyte activation,M111,3,0
1,1,1,-16,-14,-8.8,R-HSA-1280215,Cytokine Signaling in Immune system,M111,3,0
1,1,1,-5.6,-4.1,-3.1,GO:0050777,negative regulation of immune response,M111,3,0
1,1,1,-3.3,-2.3,-2.9,GO:2000736,regulation of stem cell differentiation,M111,3,0
1,1,1,-2.8,-2.3,-3.4,WP5094,Orexin receptor pathway,M111,3,0
1,1,1,-3.6,-3.5,-3.7,M8626,SIG BCR SIGNALING PATHWAY,M111,3,0
1,1,1,-2.7,-2.1,-3.1,GO:0097154,GABAergic neuron differentiation,M111,3,0
1,1,1,-3.8,-5.4,-3.6,GO:2000514,"regulation of CD4-positive, alpha-beta T cell activation",M111,3,0
1,1,1,-3.1,-2.6,-2.3,GO:0055010,ventricular cardiac muscle tissue morphogenesis,M111,3,0
1,1,1,-2.6,-3.2,-2.4,WP3893,Development and heterogeneity of the ILC family,M111,3,0
1,1,1,-2.8,-2.6,-2.6,GO:0003229,ventricular cardiac muscle tissue development,M111,3,0
1,1,1,-14,-8.8,-8.4,GO:0001944,vasculature development,M111,3,0
1,1,1,-4.8,-3.4,-5.9,GO:0071375,cellular response to peptide hormone stimulus,M111,3,0
1,1,1,-2.9,-3,-2,R-HSA-166058,MyD88:MAL(TIRAP) cascade initiated on plasma membrane,M111,3,0
1,1,1,-3.3,-4.1,-2.1,hsa04713,Circadian entrainment,M111,3,0
1,1,1,-2.7,-2.1,-2.2,GO:0038095,Fc-epsilon receptor signaling pathway,M111,3,0
1,1,1,-11,-8,-6,GO:0050727,regulation of inflammatory response,M111,3,0
1,1,1,-7,-5.1,-5.3,GO:1904888,cranial skeletal system development,M111,3,0
1,1,1,-3.3,-2.1,-3.6,WP560,TGF beta receptor signaling,M111,3,0
1,1,1,-3.3,-2.7,-2.6,GO:0060041,retina development in camera-type eye,M111,3,0
1,1,1,-2.6,-3.1,-2.7,GO:0038093,Fc receptor signaling pathway,M111,3,0
1,1,1,-3.5,-3.5,-3.8,hsa04912,GnRH signaling pathway,M111,3,0
1,1,1,-18,-11,-7.9,R-HSA-449147,Signaling by Interleukins,M111,3,0
1,1,1,-4.3,-4.3,-5.2,GO:0035108,limb morphogenesis,M111,3,0
1,1,1,-3.1,-3.2,-3.8,GO:0042509,regulation of tyrosine phosphorylation of STAT protein,M111,3,0
1,1,1,-4.1,-3.9,-2.4,GO:0002704,negative regulation of leukocyte mediated immunity,M111,3,0
1,1,1,-4,-4.1,-3.2,GO:0046638,positive regulation of alpha-beta T cell differentiation,M111,3,0
1,1,1,-4.8,-3.9,-2.8,GO:0032760,positive regulation of tumor necrosis factor production,M111,3,0
1,1,1,-4.7,-4.5,-2.2,hsa01522,Endocrine resistance,M111,3,0
1,1,1,-4.9,-4.4,-2.6,GO:0060541,respiratory system development,M111,3,0
1,1,1,-7.2,-5.2,-2.8,WP4659,Gastrin signaling pathway,M111,3,0
1,1,1,-8,-5.3,-4.1,GO:0010632,regulation of epithelial cell migration,M111,3,0
1,1,1,-2.7,-3.2,-2.9,WP3640,Imatinib and chronic myeloid leukemia,M111,3,0
1,1,1,-11,-7.1,-7.2,WP5083,Neuroinflammation and glutamatergic signaling,M111,3,0
1,1,1,-4.1,-4.9,-4.9,M60,PID NFAT TFPATHWAY,M111,3,0
1,1,1,-2.8,-2.3,-2.8,GO:0015914,phospholipid transport,M111,3,0
1,1,1,-4.1,-3.3,-6,GO:0035050,embryonic heart tube development,M111,3,0
1,1,1,-8.2,-6,-5.2,GO:0043010,camera-type eye development,M111,3,0
1,1,1,-3.6,-4.6,-5.4,GO:0030031,cell projection assembly,M111,3,0
1,1,1,-4.4,-2.3,-2.5,WP5236,Markers of kidney cell lineage,M111,3,0
1,1,1,-2.3,-2.4,-2.3,GO:0060491,regulation of cell projection assembly,M111,3,0
1,1,1,-9.5,-7.1,-6.7,GO:0150063,visual system development,M111,3,0
1,1,1,-2,-3.2,-3.1,WP2795,Cardiac hypertrophic response,M111,3,0
1,1,1,-2.7,-4.3,-3.1,GO:0045586,regulation of gamma-delta T cell differentiation,M111,3,0
1,1,1,-2.8,-2.8,-4,GO:0021795,cerebral cortex cell migration,M111,3,0
1,1,1,-2.3,-2.4,-2.3,GO:0120032,regulation of plasma membrane bounded cell projection assembly,M111,3,0
1,1,1,-3.6,-2.8,-2.8,hsa05223,Non-small cell lung cancer,M111,3,0
1,1,1,-4,-2.9,-2.4,R-HSA-111885,Opioid Signalling,M111,3,0
1,1,1,-15,-20,-19,GO:0001775,cell activation,M111,3,0
1,1,1,-8.7,-6.6,-5.7,GO:0001654,eye development,M111,3,0
1,1,1,-2.6,-3.9,-2.4,hsa04714,Thermogenesis,M111,3,0
1,1,1,-2.9,-3,-2,R-HSA-168179,Toll Like Receptor TLR1:TLR2 Cascade,M111,3,0
1,1,1,-3.9,-2.5,-4.8,R-HSA-2871796,FCERI mediated MAPK activation,M111,3,0
1,1,1,-3.1,-2.1,-2.6,hsa04927,Cortisol synthesis and secretion,M111,3,0
1,1,1,-7.1,-7.9,-6.9,WP3932,Focal adhesion PI3K Akt mTOR signaling pathway,M111,3,0
1,1,1,-3.1,-3.6,-4,GO:0021987,cerebral cortex development,M111,3,0
1,1,1,-3.8,-3.4,-3.4,GO:0051091,positive regulation of DNA-binding transcription factor activity,M111,3,0
1,1,1,-8.6,-9.5,-3.9,WP5087,Pleural mesothelioma,M111,3,0
1,1,1,-4.3,-6.4,-5.1,GO:0022408,negative regulation of cell-cell adhesion,M111,3,0
1,1,1,-4.6,-2.7,-3.2,GO:0003170,heart valve development,M111,3,0
1,1,1,-4.9,-4.5,-7.4,GO:0002429,immune response-activating cell surface receptor signaling pathway,M111,3,0
1,1,1,-3.8,-2.4,-3.2,GO:0008593,regulation of Notch signaling pathway,M111,3,0
1,1,1,-4.3,-5.1,-4.2,WP2858,Ectoderm differentiation,M111,3,0
1,1,1,-5.4,-5.5,-4.9,GO:0045582,positive regulation of T cell differentiation,M111,3,0
1,1,1,-2.9,-3.3,-3.6,GO:0050921,positive regulation of chemotaxis,M111,3,0
1,1,1,-2.2,-2.4,-2.2,GO:0031214,biomineral tissue development,M111,3,0
1,1,1,-6.3,-5.5,-3.6,GO:0048863,stem cell differentiation,M111,3,0
1,1,1,-2.3,-2.8,-2.6,WP3858,Toll like receptor signaling related to MyD88,M111,3,0
1,1,1,-3.9,-3,-3.6,GO:0051147,regulation of muscle cell differentiation,M111,3,0
1,1,1,-5.2,-7.1,-4.1,GO:0046637,regulation of alpha-beta T cell differentiation,M111,3,0
1,1,1,-7.8,-6,-3.8,GO:0001763,morphogenesis of a branching structure,M111,3,0
1,1,1,-3.8,-2.8,-2.1,R-HSA-9018519,Estrogen-dependent gene expression,M111,3,0
1,1,1,-4,-4.6,-2.5,GO:0051384,response to glucocorticoid,M111,3,0
1,1,1,-4.4,-3.1,-2.9,hsa04625,C-type lectin receptor signaling pathway,M111,3,0
1,1,1,-12,-17,-16,GO:0002521,leukocyte differentiation,M111,3,0
1,1,1,-4.2,-3.5,-2.5,hsa05206,MicroRNAs in cancer,M111,3,0
1,1,1,-2.5,-2.9,-2.3,WP2023,Cell differentiation expanded index,M111,3,0
1,1,1,-4.1,-3.5,-5.7,hsa05235,PD-L1 expression and PD-1 checkpoint pathway in cancer,M111,3,0
1,1,1,-2,-2.1,-2.3,R-HSA-416482,G alpha (12/13) signalling events,M111,3,0
1,1,1,-4.7,-7.9,-4.4,GO:0002263,cell activation involved in immune response,M111,3,0
1,1,1,-3,-3.8,-3.5,GO:0002287,alpha-beta T cell activation involved in immune response,M111,3,0
1,1,1,-5.9,-7.4,-4.8,GO:0050679,positive regulation of epithelial cell proliferation,M111,3,0
1,1,1,-6.4,-4.6,-5,WP366,TGF beta signaling pathway,M111,3,0
1,1,1,-4.6,-5,-3.5,GO:0021953,central nervous system neuron differentiation,M111,3,0
1,1,1,-6.5,-5.9,-3.8,GO:0030036,actin cytoskeleton organization,M111,3,0
1,1,1,-7.1,-4.5,-4.5,GO:0007405,neuroblast proliferation,M111,3,0
1,1,1,-3.5,-2.9,-3.2,WP3599,Transcription factor regulation in adipogenesis,M111,3,0
1,1,1,-3.1,-4.6,-4.3,GO:0045332,phospholipid translocation,M111,3,0
1,1,1,-5.1,-4.4,-3.7,GO:0071560,cellular response to transforming growth factor beta stimulus,M111,3,0
1,1,1,-6.1,-4.1,-3.3,hsa04650,Natural killer cell mediated cytotoxicity,M111,3,0
1,1,1,-3.9,-4.4,-3.7,WP3972,PDGFR beta pathway,M111,3,0
1,1,1,-4.7,-3.5,-5.8,hsa04660,T cell receptor signaling pathway,M111,3,0
1,1,1,-2.7,-2.4,-3.8,WP5102,Familial partial lipodystrophy,M111,3,0
1,1,1,-4.3,-4.3,-8.5,GO:0071773,cellular response to BMP stimulus,M111,3,0
1,1,1,-3.5,-3.9,-3.7,GO:0046645,positive regulation of gamma-delta T cell activation,M111,3,0
1,1,1,-7.2,-9.7,-7,GO:0098609,cell-cell adhesion,M111,3,0
1,1,1,-2.7,-3.1,-3.1,WP5174,Ulcerative colitis signaling,M111,3,0
1,1,1,-5.5,-3.6,-3.7,GO:0045667,regulation of osteoblast differentiation,M111,3,0
1,1,1,-3.3,-4.3,-3.1,GO:0002821,positive regulation of adaptive immune response,M111,3,0
1,1,1,-2.1,-2.2,-4.2,hsa04666,Fc gamma R-mediated phagocytosis,M111,3,0
1,1,1,-7.9,-4.7,-5.4,GO:0090596,sensory organ morphogenesis,M111,3,0
1,1,1,-2.9,-2.5,-3.9,hsa04024,cAMP signaling pathway,M111,3,0
1,1,1,-3.1,-3.5,-4.1,GO:0030832,regulation of actin filament length,M111,3,0
1,1,1,-5.8,-6.6,-5,GO:0048839,inner ear development,M111,3,0
1,1,1,-6.7,-2.9,-4.3,WP5130,Th17 cell differentiation pathway,M111,3,0
1,1,1,-2.5,-3.2,-4.5,GO:0061515,myeloid cell development,M111,3,0
1,1,1,-4.1,-5.3,-4.2,GO:0002285,lymphocyte activation involved in immune response,M111,3,0
1,1,1,-5.9,-4.5,-4,WP4331,Neovascularisation processes,M111,3,0
1,1,1,-5.6,-4.4,-4.3,R-HSA-9006925,Intracellular signaling by second messengers,M111,3,0
1,1,1,-4.9,-5.4,-4.1,GO:0002286,T cell activation involved in immune response,M111,3,0
1,1,1,-6.1,-4.7,-7.7,GO:1901653,cellular response to peptide,M111,3,0
1,1,1,-7.7,-6.2,-8,WP2064,Neural crest differentiation,M111,3,0
1,1,1,-4.3,-4.3,-5.2,GO:0035107,appendage morphogenesis,M111,3,0
1,1,1,-6.8,-12,-5.7,GO:0051251,positive regulation of lymphocyte activation,M111,3,0
1,1,1,-2.3,-2.8,-3.4,GO:0002063,chondrocyte development,M111,3,0
1,1,1,-6.8,-5.2,-4.9,GO:1901342,regulation of vasculature development,M111,3,0
1,1,1,-3.8,-3.8,-4.4,WP5072,Modulators of TCR signaling and T cell activation,M111,3,0
1,1,1,-2.6,-2.4,-3.1,GO:0021895,cerebral cortex neuron differentiation,M111,3,0
1,1,1,-5.8,-4.4,-2.9,WP289,Myometrial relaxation and contraction pathways,M111,3,0
1,1,1,-2.8,-4.8,-3.2,GO:0045666,positive regulation of neuron differentiation,M111,3,0
1,1,1,-6.6,-8.9,-9.2,GO:0021537,telencephalon development,M111,3,0
1,1,1,-5.2,-3.1,-3.7,GO:0150104,transport across blood-brain barrier,M111,3,0
1,1,1,-2.9,-2.8,-2.3,R-HSA-1912408,Pre-NOTCH Transcription and Translation,M111,3,0
1,1,1,-11,-11,-7.2,GO:2000628,regulation of miRNA metabolic process,M111,3,0
1,1,1,-8.6,-12,-9.1,GO:0006954,inflammatory response,M111,3,0
1,1,1,-3.4,-3.6,-2.2,GO:0050768,negative regulation of neurogenesis,M111,3,0
1,1,1,-8,-11,-6.6,GO:1903039,positive regulation of leukocyte cell-cell adhesion,M111,3,0
1,1,1,-3.2,-2.1,-3.3,M36,PID IL27 PATHWAY,M111,3,0
1,1,1,-3.5,-3.9,-3.2,R-HSA-9006335,Signaling by Erythropoietin,M111,3,0
1,1,1,-10,-4.5,-6.4,GO:0061351,neural precursor cell proliferation,M111,3,0
1,1,1,-7.3,-6.9,-2.3,WP2355,Corticotropin releasing hormone signaling pathway,M111,3,0
1,1,1,-6.3,-4.1,-2.7,hsa05215,Prostate cancer,M111,3,0
1,1,1,-2.1,-3.2,-2.4,GO:0042116,macrophage activation,M111,3,0
1,1,1,-2.1,-2.5,-2.1,WP4871,Kisspeptin kisspeptin receptor system in the ovary,M111,3,0
1,1,1,-2,-2.1,-3.4,GO:0043030,regulation of macrophage activation,M111,3,0
1,1,1,-6.8,-3.5,-3.7,GO:0048872,homeostasis of number of cells,M111,3,0
1,1,1,-14,-12,-12,GO:0048568,embryonic organ development,M111,3,0
1,1,1,-8.6,-6.4,-5,WP2840,Hair follicle development cytodifferentiation part 3 of 3,M111,3,0
1,1,1,-2.3,-3.5,-2.8,WP4538,Regulatory circuits of the STAT3 signaling pathway,M111,3,0
1,1,1,-2.1,-3.3,-3.7,GO:0021544,subpallium development,M111,3,0
1,1,1,-3.9,-2.5,-2.8,WP5144,NRP1 triggered signaling pathways in pancreatic cancer,M111,3,0
1,1,1,-2.9,-3.3,-3.7,R-HSA-912631,Regulation of signaling by CBL,M111,3,0
1,1,1,-4,-2.9,-2.4,R-HSA-9707616,Heme signaling,M111,3,0
1,1,1,-2.5,-2.5,-2.2,GO:1904035,regulation of epithelial cell apoptotic process,M111,3,0
1,1,1,-2.6,-2.9,-3.8,GO:0055057,neuroblast division,M111,3,0
1,1,1,-5.8,-5.3,-4.8,GO:0002700,regulation of production of molecular mediator of immune response,M111,3,0
1,1,1,-2.3,-2.2,-3.7,WP2018,RANKL RANK signaling pathway,M111,3,0
1,1,1,-4.1,-2.4,-2.4,hsa05415,Diabetic cardiomyopathy,M111,3,0
1,1,1,-4.9,-4.1,-4.9,M28,PID IL4 2PATHWAY,M111,3,0
1,1,1,-4.3,-2.8,-3.3,WP4211,Transcriptional cascade regulating adipogenesis,M111,3,0
1,1,1,-3.5,-5.8,-2.8,hsa05145,Toxoplasmosis,M111,3,0
1,1,1,-4.6,-7.2,-4.8,GO:1902075,cellular response to salt,M111,3,0
1,1,1,-5.1,-4.1,-4.2,R-HSA-381340,Transcriptional regulation of white adipocyte differentiation,M111,3,0
1,1,1,-4.4,-4.4,-3.6,GO:0001936,regulation of endothelial cell proliferation,M111,3,0
1,1,1,-5.1,-3.6,-4.2,hsa05142,Chagas disease,M111,3,0
1,1,1,-15,-14,-9.6,hsa05200,Pathways in cancer,M111,3,0
1,1,1,-5.4,-3.9,-5.5,GO:0045639,positive regulation of myeloid cell differentiation,M111,3,0
1,1,1,-10,-6.2,-6.5,GO:0001701,in utero embryonic development,M111,3,0
1,1,1,-5.2,-4.5,-4.5,GO:0048701,embryonic cranial skeleton morphogenesis,M111,3,0
1,1,1,-12,-8.1,-8.8,GO:0045165,cell fate commitment,M111,3,0
1,1,1,-4.3,-3.8,-2.4,GO:0060350,endochondral bone morphogenesis,M111,3,0
1,1,1,-16,-17,-19,GO:0030097,hemopoiesis,M111,3,0
1,1,1,-7,-13,-6.7,GO:0002696,positive regulation of leukocyte activation,M111,3,0
1,1,1,-6.1,-3.5,-2.4,WP4239,Epithelial to mesenchymal transition in colorectal cancer,M111,3,0
1,1,1,-6.1,-3.5,-3.2,GO:0002761,regulation of myeloid leukocyte differentiation,M111,3,0
1,1,1,-2.5,-5.3,-4.5,GO:0045058,T cell selection,M111,3,0
1,1,1,-4.5,-8.5,-8.4,WP4540,Hippo signaling regulation pathways,M111,3,0
1,1,1,-5.7,-4.1,-4.1,WP2374,Oncostatin M signaling pathway,M111,3,0
1,1,1,-9.3,-13,-13,GO:0030098,lymphocyte differentiation,M111,3,0
1,1,1,-7.8,-7.7,-5.3,GO:1902107,positive regulation of leukocyte differentiation,M111,3,0
1,1,1,-3.4,-2.4,-3.1,R-HSA-983695,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,M111,3,0
1,1,1,-6.5,-5.3,-2.2,GO:0048754,branching morphogenesis of an epithelial tube,M111,3,0
1,1,1,-7.8,-6.8,-6.2,GO:0021700,developmental maturation,M111,3,0
1,1,1,-6.3,-6.2,-4,GO:0002699,positive regulation of immune effector process,M111,3,0
1,1,1,-2.3,-2.4,-3.2,R-HSA-2219530,Constitutive Signaling by Aberrant PI3K in Cancer,M111,3,0
1,1,1,-3.5,-4.5,-3.6,M186,PID PDGFRB PATHWAY,M111,3,0
1,1,1,-2.3,-2.6,-2.6,GO:0060872,semicircular canal development,M111,3,0
1,1,1,-9.2,-4.1,-4.9,GO:0060840,artery development,M111,3,0
1,1,1,-4.9,-2.3,-4.1,GO:0001709,cell fate determination,M111,3,0
1,1,1,-3.8,-2.1,-3.1,GO:0003208,cardiac ventricle morphogenesis,M111,3,0
1,1,1,-3.7,-6,-4,GO:0051966,"regulation of synaptic transmission, glutamatergic",M111,3,0
1,1,1,-3.8,-3.6,-3.4,R-HSA-166016,Toll Like Receptor 4 (TLR4) Cascade,M111,3,0
1,1,1,-2.3,-2.4,-3.8,R-HSA-2029480,Fcgamma receptor (FCGR) dependent phagocytosis,M111,3,0
1,1,1,-8.6,-8.9,-6.5,GO:0071407,cellular response to organic cyclic compound,M111,3,0
1,1,1,-10,-12,-7.8,GO:0045785,positive regulation of cell adhesion,M111,3,0
1,1,1,-10,-6.1,-7.6,WP3945,TYROBP causal network in microglia,M111,3,0
1,1,1,-3,-4.6,-3.3,GO:0050864,regulation of B cell activation,M111,3,0
1,1,1,-4.6,-3.5,-2.3,R-HSA-9662851,Anti-inflammatory response favouring Leishmania parasite infection,M111,3,0
1,1,1,-7.1,-7.1,-3.8,R-HSA-9616222,Transcriptional regulation of granulopoiesis,M111,3,0
1,1,1,-3.2,-3.7,-3.3,GO:0071353,cellular response to interleukin-4,M111,3,0
1,1,1,-9.6,-15,-14,GO:1903131,mononuclear cell differentiation,M111,3,0
1,1,1,-4.1,-4,-3.7,GO:0007498,mesoderm development,M111,3,0
1,1,1,-12,-9.9,-6.1,GO:0048729,tissue morphogenesis,M111,3,0
1,1,1,-3.6,-4.1,-2.2,WP127,IL 5 signaling pathway,M111,3,0
1,1,1,-4.3,-3.2,-3.4,M10,PID BCR 5PATHWAY,M111,3,0
1,1,1,-11,-11,-9.2,GO:0061448,connective tissue development,M111,3,0
1,1,1,-3.8,-5.7,-2,GO:0042129,regulation of T cell proliferation,M111,3,0
1,1,1,-4.6,-3.1,-2.5,WP5115,Network map of SARS CoV 2 signaling pathway,M111,3,0
1,1,1,-4.5,-7.1,-2.9,WP5293,Acute myeloid leukemia,M111,3,0
1,1,1,-4.1,-8.4,-5,GO:0002274,myeloid leukocyte activation,M111,3,0
1,1,1,-2.7,-2.4,-2.2,GO:0006929,substrate-dependent cell migration,M111,3,0
1,1,1,-9.3,-9.7,-6.8,GO:0002250,adaptive immune response,M111,3,0
1,1,1,-12,-11,-7.7,GO:1902893,regulation of miRNA transcription,M111,3,0
1,1,1,-4.9,-3.2,-4.3,GO:0001837,epithelial to mesenchymal transition,M111,3,0
1,1,1,-5.2,-4.7,-4,GO:0048762,mesenchymal cell differentiation,M111,3,0
1,1,1,-2.6,-2.4,-3.9,M88,PID CD8 TCR PATHWAY,M111,3,0
1,1,1,-4.2,-5,-2.7,hsa05032,Morphine addiction,M111,3,0
1,1,1,-2.8,-4.8,-3.3,WP4321,Thermogenesis,M111,3,0
1,1,1,-3.6,-3.2,-3.8,hsa04664,Fc epsilon RI signaling pathway,M111,3,0
1,1,1,-2.6,-2,-2.2,GO:0030500,regulation of bone mineralization,M111,3,0
1,1,1,-2.8,-2.5,-2.2,GO:0090068,positive regulation of cell cycle process,M111,3,0
1,1,0,-12,-9.7,0,GO:0008285,negative regulation of cell population proliferation,M110,2,0
1,1,0,-2.3,-2.1,0,WP4329,miRNA role in immune response in sepsis,M110,2,0
1,1,0,-2.6,-3.8,0,R-HSA-4086398,Ca2+ pathway,M110,2,0
1,0,1,-3.1,0,-2.2,R-HSA-157118,Signaling by NOTCH,M101,2,0
0,1,1,0,-4.9,-5.1,GO:0050803,regulation of synapse structure or activity,M011,2,0
1,0,1,-2.6,0,-2.9,M288,PID HES HEY PATHWAY,M101,2,0
1,0,1,-2,0,-2.4,R-HSA-350054,Notch-HLH transcription pathway,M101,2,0
1,0,1,-3.9,0,-2.4,GO:0051101,regulation of DNA binding,M101,2,0
1,1,0,-2.8,-2.5,0,GO:0010543,regulation of platelet activation,M110,2,0
0,1,1,0,-2.5,-3,GO:0022898,regulation of transmembrane transporter activity,M011,2,0
1,1,0,-2.3,-2.6,0,R-HSA-8951430,RUNX3 regulates WNT signaling,M110,2,0
1,1,0,-3,-2.4,0,hsa05220,Chronic myeloid leukemia,M110,2,0
1,1,0,-2.5,-2.2,0,GO:0061045,negative regulation of wound healing,M110,2,0
0,1,1,0,-3.2,-2.6,GO:0050766,positive regulation of phagocytosis,M011,2,0
1,1,0,-3.1,-2.6,0,GO:0045778,positive regulation of ossification,M110,2,0
1,1,0,-2.2,-2.4,0,GO:0003418,growth plate cartilage chondrocyte differentiation,M110,2,0
1,0,1,-2.5,0,-2.1,R-HSA-2122947,NOTCH1 Intracellular Domain Regulates Transcription,M101,2,0
1,1,0,-2.1,-3.8,0,WP428,Wnt signaling,M110,2,0
0,1,1,0,-3.2,-2.2,WP3678,Amplification and expansion of oncogenic pathways as metastatic traits,M011,2,0
0,1,1,0,-2.1,-2.2,M165,PID SYNDECAN 4 PATHWAY,M011,2,0
1,1,0,-2.1,-2.5,0,R-HSA-9659787,Aberrant regulation of mitotic G1/S transition in cancer due to RB1 defects,M110,2,0
0,1,1,0,-2.5,-2.7,GO:0014742,positive regulation of muscle hypertrophy,M011,2,0
1,1,0,-7.3,-4.1,0,GO:0030522,intracellular receptor signaling pathway,M110,2,0
1,1,0,-5.2,-3,0,GO:0001910,regulation of leukocyte mediated cytotoxicity,M110,2,0
0,1,1,0,-2.5,-3.7,GO:0060099,"regulation of phagocytosis, engulfment",M011,2,0
1,0,1,-3.8,0,-2.1,GO:0010718,positive regulation of epithelial to mesenchymal transition,M101,2,0
0,1,1,0,-8.9,-5.8,GO:0000902,cell morphogenesis,M011,2,0
1,1,0,-3.6,-4.3,0,hsa04940,Type I diabetes mellitus,M110,2,0
1,1,0,-2.3,-2.2,0,GO:0045124,regulation of bone resorption,M110,2,0
1,0,1,-3.6,0,-2.1,M166,PID ATF2 PATHWAY,M101,2,0
1,1,0,-3.5,-3.9,0,GO:0002347,response to tumor cell,M110,2,0
1,1,0,-4.3,-3.2,0,GO:0031342,negative regulation of cell killing,M110,2,0
1,1,0,-2.9,-2.5,0,GO:0002726,positive regulation of T cell cytokine production,M110,2,0
1,1,0,-3,-2.3,0,GO:0055008,cardiac muscle tissue morphogenesis,M110,2,0
0,1,1,0,-4,-3.7,GO:0001959,regulation of cytokine-mediated signaling pathway,M011,2,0
1,1,0,-2.8,-2.6,0,GO:0032945,negative regulation of mononuclear cell proliferation,M110,2,0
1,0,1,-2.8,0,-3.7,GO:0098727,maintenance of cell number,M101,2,0
0,1,1,0,-5.5,-5.3,GO:0040007,growth,M011,2,0
1,1,0,-5.1,-3.6,0,GO:0001911,negative regulation of leukocyte mediated cytotoxicity,M110,2,0
1,1,0,-2.5,-2.9,0,R-HSA-451326,Activation of kainate receptors upon glutamate binding,M110,2,0
1,1,0,-2.2,-2.4,0,GO:0060534,trachea cartilage development,M110,2,0
1,1,0,-6.2,-3.7,0,M2,PID SMAD2 3NUCLEAR PATHWAY,M110,2,0
0,1,1,0,-2.6,-2.1,GO:0019724,B cell mediated immunity,M011,2,0
1,0,1,-3.3,0,-4,WP3863,T cell antigen receptor TCR pathway during Staphylococcus aureus infection,M101,2,0
0,1,1,0,-2.3,-2.1,GO:0007224,smoothened signaling pathway,M011,2,0
1,0,1,-3.5,0,-2.3,hsa05412,Arrhythmogenic right ventricular cardiomyopathy,M101,2,0
1,0,1,-2.3,0,-2.1,GO:0072210,metanephric nephron development,M101,2,0
1,1,0,-2,-2.6,0,GO:0045620,negative regulation of lymphocyte differentiation,M110,2,0
0,1,1,0,-4.4,-3,WP536,Calcium regulation in cardiac cells,M011,2,0
0,1,1,0,-2.2,-2.1,GO:0008356,asymmetric cell division,M011,2,0
0,1,1,0,-5.3,-3.5,GO:0040013,negative regulation of locomotion,M011,2,0
1,1,0,-3.1,-2.1,0,R-HSA-168142,Toll Like Receptor 10 (TLR10) Cascade,M110,2,0
0,1,1,0,-6.5,-6.3,GO:0007610,behavior,M011,2,0
1,1,0,-2.3,-2.1,0,WP5269,Genetic causes of porto sinusoidal vascular disease,M110,2,0
0,1,1,0,-3.8,-5.7,GO:0001818,negative regulation of cytokine production,M011,2,0
1,1,0,-3.5,-2.6,0,GO:0007406,negative regulation of neuroblast proliferation,M110,2,0
1,1,0,-2.3,-2.8,0,GO:0046456,icosanoid biosynthetic process,M110,2,0
1,0,1,-2.6,0,-2.5,GO:0002887,negative regulation of myeloid leukocyte mediated immunity,M101,2,0
1,1,0,-4,-2,0,hsa04668,TNF signaling pathway,M110,2,0
1,0,1,-2.3,0,-2.6,GO:0070102,interleukin-6-mediated signaling pathway,M101,2,0
1,1,0,-3.1,-2.1,0,GO:0007159,leukocyte cell-cell adhesion,M110,2,0
1,1,0,-2.9,-2.2,0,GO:0016525,negative regulation of angiogenesis,M110,2,0
1,0,1,-3.1,0,-2.7,GO:0048821,erythrocyte development,M101,2,0
0,1,1,0,-2.1,-2.5,R-HSA-2029485,Role of phospholipids in phagocytosis,M011,2,0
1,1,0,-2.2,-2.4,0,GO:0022028,tangential migration from the subventricular zone to the olfactory bulb,M110,2,0
1,0,1,-3,0,-2.8,hsa05414,Dilated cardiomyopathy,M101,2,0
1,1,0,-3.5,-3,0,R-HSA-975155,MyD88 dependent cascade initiated on endosome,M110,2,0
1,1,0,-2,-2.4,0,GO:0045981,positive regulation of nucleotide metabolic process,M110,2,0
1,0,1,-4.8,0,-2.8,GO:0003197,endocardial cushion development,M101,2,0
0,1,1,0,-3.5,-3.2,GO:2000107,negative regulation of leukocyte apoptotic process,M011,2,0
1,1,0,-2,-2.4,0,GO:0071548,response to dexamethasone,M110,2,0
0,1,1,0,-4.8,-3.2,GO:1902074,response to salt,M011,2,0
1,1,0,-2.9,-2.2,0,GO:0002724,regulation of T cell cytokine production,M110,2,0
1,1,0,-2.5,-2.1,0,GO:0060438,trachea development,M110,2,0
0,1,1,0,-2.1,-2.2,GO:0021952,central nervous system projection neuron axonogenesis,M011,2,0
1,1,0,-2.3,-2.9,0,GO:1904036,negative regulation of epithelial cell apoptotic process,M110,2,0
1,1,0,-4,-3.3,0,GO:0030323,respiratory tube development,M110,2,0
0,1,1,0,-2.1,-2.5,GO:0001738,morphogenesis of a polarized epithelium,M011,2,0
1,0,1,-5.4,0,-2.6,GO:0048592,eye morphogenesis,M101,2,0
1,1,0,-4.3,-3.4,0,hsa04933,AGE-RAGE signaling pathway in diabetic complications,M110,2,0
1,1,0,-4.5,-3.5,0,GO:0050729,positive regulation of inflammatory response,M110,2,0
1,1,0,-3,-2.8,0,GO:0031663,lipopolysaccharide-mediated signaling pathway,M110,2,0
1,1,0,-2.8,-2.3,0,GO:0070664,negative regulation of leukocyte proliferation,M110,2,0
1,0,1,-4.3,0,-3.9,WP585,Interferon type I signaling pathways,M101,2,0
1,0,1,-5.2,0,-2.1,R-HSA-1489509,DAG and IP3 signaling,M101,2,0
1,1,0,-3.6,-3.2,0,GO:2000178,negative regulation of neural precursor cell proliferation,M110,2,0
1,1,0,-4.4,-2.6,0,WP3611,Photodynamic therapy induced AP 1 survival signaling,M110,2,0
0,1,1,0,-2.9,-3.2,WP3892,Development of pulmonary dendritic cells and macrophage subsets,M011,2,0
1,0,1,-2,0,-3.2,GO:0061371,determination of heart left/right asymmetry,M101,2,0
1,1,0,-2.1,-2.5,0,R-HSA-397795,G-protein beta:gamma signalling,M110,2,0
1,1,0,-2.6,-3.9,0,M100,PID SHP2 PATHWAY,M110,2,0
0,1,1,0,-3,-2.1,hsa04148,Efferocytosis,M011,2,0
0,1,1,0,-4.9,-3.1,GO:0034329,cell junction assembly,M011,2,0
1,0,1,-2.8,0,-3.4,GO:0045599,negative regulation of fat cell differentiation,M101,2,0
1,1,0,-2.2,-2.4,0,GO:0090009,primitive streak formation,M110,2,0
0,1,1,0,-3.4,-2.9,GO:0110053,regulation of actin filament organization,M011,2,0
1,1,0,-2.1,-2.3,0,GO:0044344,cellular response to fibroblast growth factor stimulus,M110,2,0
1,1,0,-2.6,-2.5,0,GO:0032735,positive regulation of interleukin-12 production,M110,2,0
1,1,0,-4.8,-3.8,0,hsa05418,Fluid shear stress and atherosclerosis,M110,2,0
0,1,1,0,-3.6,-3.1,hsa05017,Spinocerebellar ataxia,M011,2,0
0,1,1,0,-2.5,-2.1,GO:0035418,protein localization to synapse,M011,2,0
1,1,0,-3.8,-3.1,0,WP4658,Small cell lung cancer,M110,2,0
1,1,0,-3.8,-2.1,0,WP4263,Pancreatic adenocarcinoma pathway,M110,2,0
1,1,0,-2,-4,0,GO:0002825,regulation of T-helper 1 type immune response,M110,2,0
1,1,0,-2.5,-2.8,0,WP3915,Angiopoietin like protein 8 regulatory pathway,M110,2,0
1,0,1,-4.7,0,-4.6,GO:0003018,vascular process in circulatory system,M101,2,0
1,1,0,-4,-2.5,0,GO:0032652,regulation of interleukin-1 production,M110,2,0
1,0,1,-2.3,0,-3.4,GO:0001947,heart looping,M101,2,0
1,1,0,-3.2,-2.8,0,GO:0046641,positive regulation of alpha-beta T cell proliferation,M110,2,0
1,1,0,-2.9,-2.2,0,GO:2000181,negative regulation of blood vessel morphogenesis,M110,2,0
0,1,1,0,-6.5,-7.5,GO:0003013,circulatory system process,M011,2,0
1,1,0,-2.7,-2.8,0,hsa04210,Apoptosis,M110,2,0
0,1,1,0,-2.5,-2.3,GO:1990869,cellular response to chemokine,M011,2,0
1,1,0,-2.7,-2.1,0,WP4481,Resistin as a regulator of inflammation,M110,2,0
1,1,0,-3.3,-3,0,hsa05416,Viral myocarditis,M110,2,0
1,1,0,-2.4,-2.1,0,GO:0043500,muscle adaptation,M110,2,0
1,1,0,-2.3,-2.2,0,GO:0030811,regulation of nucleotide catabolic process,M110,2,0
0,1,1,0,-2.2,-2.4,GO:0007416,synapse assembly,M011,2,0
1,1,0,-5.5,-2.8,0,hsa05205,Proteoglycans in cancer,M110,2,0
0,1,1,0,-6.6,-7.6,GO:0099536,synaptic signaling,M011,2,0
0,1,1,0,-7.9,-4.7,GO:0048812,neuron projection morphogenesis,M011,2,0
1,1,0,-2.5,-2.3,0,WP4806,EGFR tyrosine kinase inhibitor resistance,M110,2,0
1,1,0,-3,-2.1,0,GO:0032753,positive regulation of interleukin-4 production,M110,2,0
1,0,1,-2,0,-3.1,R-HSA-9725370,Signaling by ALK fusions and activated point mutants,M101,2,0
1,1,0,-3,-2.2,0,GO:0030889,negative regulation of B cell proliferation,M110,2,0
0,1,1,0,-2.3,-3.2,GO:0006813,potassium ion transport,M011,2,0
1,1,0,-2,-3.2,0,GO:0035304,regulation of protein dephosphorylation,M110,2,0
0,1,1,0,-5.6,-5.4,GO:0050804,modulation of chemical synaptic transmission,M011,2,0
1,0,1,-3.3,0,-2.5,R-HSA-112043,PLC beta mediated events,M101,2,0
1,1,0,-3.1,-2.1,0,R-HSA-168176,Toll Like Receptor 5 (TLR5) Cascade,M110,2,0
1,0,1,-2.6,0,-2.5,GO:0021892,cerebral cortex GABAergic interneuron differentiation,M101,2,0
1,0,1,-4.4,0,-2.6,GO:0060420,regulation of heart growth,M101,2,0
1,1,0,-2.3,-2.1,0,WP1772,Apoptosis modulation and signaling,M110,2,0
1,0,1,-2.4,0,-2.1,GO:0023061,signal release,M101,2,0
1,1,0,-2.9,-3.3,0,WP4630,Measles virus infection,M110,2,0
1,0,1,-3.9,0,-2.3,GO:0120161,regulation of cold-induced thermogenesis,M101,2,0
1,0,1,-4.6,0,-2.6,GO:0003203,endocardial cushion morphogenesis,M101,2,0
1,1,0,-3,-2.8,0,GO:0002068,glandular epithelial cell development,M110,2,0
1,1,0,-2.3,-2.2,0,GO:0033121,regulation of purine nucleotide catabolic process,M110,2,0
1,1,0,-9.1,-8.3,0,GO:0030855,epithelial cell differentiation,M110,2,0
1,1,0,-2.6,-4,0,hsa05332,Graft-versus-host disease,M110,2,0
1,1,0,-3.1,-2,0,GO:0010660,regulation of muscle cell apoptotic process,M110,2,0
1,0,1,-5,0,-3.1,GO:0048593,camera-type eye morphogenesis,M101,2,0
0,1,1,0,-2.2,-3.1,R-HSA-888590,"GABA synthesis, release, reuptake and degradation",M011,2,0
0,1,1,0,-2.4,-2.8,GO:0007605,sensory perception of sound,M011,2,0
0,1,1,0,-2.6,-3.4,GO:0018212,peptidyl-tyrosine modification,M011,2,0
1,1,0,-5.6,-5.5,0,GO:0071216,cellular response to biotic stimulus,M110,2,0
1,1,0,-3.1,-2.5,0,GO:2001053,regulation of mesenchymal cell apoptotic process,M110,2,0
0,1,1,0,-3.4,-3.8,hsa04020,Calcium signaling pathway,M011,2,0
1,1,0,-3.5,-2.1,0,hsa04932,Non-alcoholic fatty liver disease,M110,2,0
1,0,1,-5,0,-2.9,WP474,Endochondral ossification,M101,2,0
1,1,0,-2.3,-2.8,0,GO:0031641,regulation of myelination,M110,2,0
1,0,1,-5.5,0,-4.8,GO:0045598,regulation of fat cell differentiation,M101,2,0
1,0,1,-2.3,0,-3.1,GO:1900274,regulation of phospholipase C activity,M101,2,0
1,1,0,-4.1,-3,0,hsa05132,Salmonella infection,M110,2,0
0,1,1,0,-3.3,-2.1,GO:0071902,positive regulation of protein serine/threonine kinase activity,M011,2,0
0,1,1,0,-5.4,-6.5,GO:0034762,regulation of transmembrane transport,M011,2,0
1,1,0,-2.6,-2.9,0,CORUM:5233,TNF-alpha/NF-kappa B signaling complex 5,M110,2,0
1,0,1,-2.5,0,-2.4,GO:0009914,hormone transport,M101,2,0
1,1,0,-2.1,-2.5,0,R-HSA-9675126,Diseases of mitotic cell cycle,M110,2,0
1,1,0,-2.8,-2.4,0,GO:0002707,negative regulation of lymphocyte mediated immunity,M110,2,0
1,1,0,-4.2,-2.3,0,M229,PID P38 ALPHA BETA DOWNSTREAM PATHWAY,M110,2,0
1,0,1,-2.3,0,-2.6,R-HSA-9669938,Signaling by KIT in disease,M101,2,0
0,1,1,0,-3.5,-3,GO:0043368,positive T cell selection,M011,2,0
1,1,0,-2.8,-2.6,0,GO:0050672,negative regulation of lymphocyte proliferation,M110,2,0
0,1,1,0,-3.9,-4.1,GO:0043087,regulation of GTPase activity,M011,2,0
0,1,1,0,-2.2,-3.7,GO:0007259,receptor signaling pathway via JAK-STAT,M011,2,0
1,1,0,-2.8,-3.4,0,GO:0002758,innate immune response-activating signaling pathway,M110,2,0
1,0,1,-3,0,-4,WP4816,TGF beta receptor signaling in skeletal dysplasias,M101,2,0
1,0,1,-6,0,-4.7,hsa04810,Regulation of actin cytoskeleton,M101,2,0
1,0,1,-6.6,0,-6.2,GO:0051345,positive regulation of hydrolase activity,M101,2,0
1,0,1,-3.5,0,-2.5,GO:0060421,positive regulation of heart growth,M101,2,0
0,1,1,0,-2.8,-2.5,WP4223,Ras signaling,M011,2,0
1,1,0,-2.8,-3.5,0,GO:0045581,negative regulation of T cell differentiation,M110,2,0
1,1,0,-2.1,-3.5,0,WP4698,Vitamin D sensitive calcium signaling in depression,M110,2,0
0,1,1,0,-2.8,-2.6,R-HSA-6794362,Protein-protein interactions at synapses,M011,2,0
0,1,1,0,-6.5,-4.7,GO:0009617,response to bacterium,M011,2,0
1,1,0,-3.1,-3.1,0,hsa05162,Measles,M110,2,0
1,0,1,-2.6,0,-2.5,GO:0048340,paraxial mesoderm morphogenesis,M101,2,0
1,0,1,-3.1,0,-2.7,GO:0040034,"regulation of development, heterochronic",M101,2,0
0,1,1,0,-2.2,-3,GO:0032271,regulation of protein polymerization,M011,2,0
1,1,0,-3.3,-2.3,0,R-HSA-937061,TRIF(TICAM1)-mediated TLR4 signaling,M110,2,0
1,1,0,-6.5,-4.7,0,GO:0030856,regulation of epithelial cell differentiation,M110,2,0
1,1,0,-5,-4.6,0,R-HSA-8939211,ESR-mediated signaling,M110,2,0
0,1,1,0,-3.5,-2.8,WP481,Insulin signaling,M011,2,0
1,0,1,-6.1,0,-2.9,GO:0046620,regulation of organ growth,M101,2,0
1,0,1,-2.5,0,-3.1,GO:0090100,positive regulation of transmembrane receptor protein serine/threonine kinase signaling pathway,M101,2,0
0,1,1,0,-3.2,-3.2,GO:0008037,cell recognition,M011,2,0
1,1,0,-3.2,-3.8,0,GO:0045913,positive regulation of carbohydrate metabolic process,M110,2,0
1,1,0,-2.6,-2.9,0,M135,PID IL5 PATHWAY,M110,2,0
0,1,1,0,-2.1,-2.5,M22,PID GMCSF PATHWAY,M011,2,0
0,1,1,0,-2,-3,GO:0032890,regulation of organic acid transport,M011,2,0
1,1,0,-2.4,-2.1,0,GO:0070633,transepithelial transport,M110,2,0
1,0,1,-4.1,0,-2.5,M141,PID PI3KCI PATHWAY,M101,2,0
0,1,1,0,-3.1,-3.1,GO:0045061,thymic T cell selection,M011,2,0
1,1,0,-3.5,-2.6,0,WP4141,PI3K AKT mTOR vitamin D3 signaling,M110,2,0
1,1,0,-4,-2.1,0,R-HSA-9664424,Cell recruitment (pro-inflammatory response),M110,2,0
1,1,0,-3,-2.1,0,GO:2000647,negative regulation of stem cell proliferation,M110,2,0
0,1,1,0,-4.4,-3.2,GO:0051347,positive regulation of transferase activity,M011,2,0
0,1,1,0,-2.6,-3.4,GO:0018108,peptidyl-tyrosine phosphorylation,M011,2,0
0,1,1,0,-4.9,-5.1,GO:0050807,regulation of synapse organization,M011,2,0
1,1,0,-3,-4.5,0,R-HSA-2559583,Cellular Senescence,M110,2,0
1,1,0,-4.3,-2.6,0,GO:0062013,positive regulation of small molecule metabolic process,M110,2,0
1,1,0,-7.2,-5.6,0,WP4674,Head and neck squamous cell carcinoma,M110,2,0
1,1,0,-3.1,-3.8,0,hsa04727,GABAergic synapse,M110,2,0
1,1,0,-2.8,-2.2,0,GO:0036294,cellular response to decreased oxygen levels,M110,2,0
1,1,0,-2.8,-3.5,0,GO:0043255,regulation of carbohydrate biosynthetic process,M110,2,0
1,1,0,-2,-2.7,0,GO:0016049,cell growth,M110,2,0
1,1,0,-2.3,-2.8,0,GO:0043371,"negative regulation of CD4-positive, alpha-beta T cell differentiation",M110,2,0
0,1,1,0,-2.1,-2.2,GO:0099024,plasma membrane invagination,M011,2,0
1,1,0,-2,-2.1,0,GO:1905332,positive regulation of morphogenesis of an epithelium,M110,2,0
1,1,0,-2.4,-2.1,0,GO:0072080,nephron tubule development,M110,2,0
1,1,0,-2,-2.6,0,GO:0070301,cellular response to hydrogen peroxide,M110,2,0
1,1,0,-6.1,-4.3,0,GO:0032755,positive regulation of interleukin-6 production,M110,2,0
1,1,0,-2.7,-3.1,0,GO:0045628,regulation of T-helper 2 cell differentiation,M110,2,0
0,1,1,0,-3.4,-3.1,GO:0002320,lymphoid progenitor cell differentiation,M011,2,0
1,1,0,-3,-2.7,0,WP4216,Chromosomal and microsatellite instability in colorectal cancer,M110,2,0
0,1,1,0,-2.1,-2.6,GO:0010463,mesenchymal cell proliferation,M011,2,0
0,1,1,0,-2.2,-3.1,WP5153,N glycan biosynthesis,M011,2,0
0,1,1,0,-6.1,-4.2,GO:0051046,regulation of secretion,M011,2,0
0,1,1,0,-2.2,-3,GO:2001222,regulation of neuron migration,M011,2,0
1,1,0,-2.6,-3.9,0,GO:0061036,positive regulation of cartilage development,M110,2,0
0,1,1,0,-2.2,-2.6,hsa04261,Adrenergic signaling in cardiomyocytes,M011,2,0
1,0,1,-4.1,0,-2.8,GO:0046622,positive regulation of organ growth,M101,2,0
1,1,0,-4.2,-3.5,0,M92,PID ANGIOPOIETIN RECEPTOR PATHWAY,M110,2,0
1,1,0,-4.4,-4.8,0,GO:0002708,positive regulation of lymphocyte mediated immunity,M110,2,0
1,1,0,-5.4,-2.2,0,hsa05160,Hepatitis C,M110,2,0
1,0,1,-2,0,-2.2,R-HSA-112310,Neurotransmitter release cycle,M101,2,0
1,1,0,-5,-4.8,0,GO:0009755,hormone-mediated signaling pathway,M110,2,0
1,1,0,-3.2,-2.1,0,GO:0002716,negative regulation of natural killer cell mediated immunity,M110,2,0
1,1,0,-2.5,-2.9,0,WP53,ID signaling pathway,M110,2,0
0,1,1,0,-3.2,-2.2,hsa04310,Wnt signaling pathway,M011,2,0
1,1,0,-3.3,-3.6,0,GO:0051402,neuron apoptotic process,M110,2,0
1,1,0,-2.3,-2.1,0,GO:0002639,positive regulation of immunoglobulin production,M110,2,0
0,1,1,0,-4.5,-4.8,GO:0051051,negative regulation of transport,M011,2,0
0,1,1,0,-6.4,-4.4,R-HSA-388396,GPCR downstream signalling,M011,2,0
1,1,0,-4.4,-3,0,GO:0043401,steroid hormone mediated signaling pathway,M110,2,0
1,1,0,-3.8,-2.6,0,GO:0017157,regulation of exocytosis,M110,2,0
0,1,1,0,-2.5,-3.4,GO:0046425,regulation of receptor signaling pathway via JAK-STAT,M011,2,0
1,1,0,-2.1,-3.5,0,GO:0035307,positive regulation of protein dephosphorylation,M110,2,0
1,1,0,-4.3,-2.7,0,GO:0010633,negative regulation of epithelial cell migration,M110,2,0
1,0,1,-2.3,0,-2.3,M279,PID RB 1PATHWAY,M101,2,0
0,1,1,0,-3.5,-4,GO:1904892,regulation of receptor signaling pathway via STAT,M011,2,0
1,0,1,-2.3,0,-4.9,GO:0010517,regulation of phospholipase activity,M101,2,0
1,1,0,-4.6,-3,0,GO:1902692,regulation of neuroblast proliferation,M110,2,0
1,1,0,-2.5,-2,0,GO:0060419,heart growth,M110,2,0
0,1,1,0,-2.1,-2.3,GO:0030851,granulocyte differentiation,M011,2,0
1,0,1,-2.8,0,-2.1,GO:0051153,regulation of striated muscle cell differentiation,M101,2,0
0,1,1,0,-2.2,-2.1,R-HSA-9706369,Negative regulation of FLT3,M011,2,0
0,1,1,0,-4.2,-3.7,R-HSA-1500931,Cell-Cell communication,M011,2,0
0,1,1,0,-6.8,-5.2,GO:0048667,cell morphogenesis involved in neuron differentiation,M011,2,0
1,1,0,-2.5,-4.5,0,hsa05150,Staphylococcus aureus infection,M110,2,0
0,1,1,0,-2.6,-4.9,GO:0019722,calcium-mediated signaling,M011,2,0
1,1,0,-2.3,-2.8,0,WP2873,Aryl hydrocarbon receptor pathway,M110,2,0
0,1,1,0,-2.2,-2.3,WP195,IL 1 signaling pathway,M011,2,0
0,1,1,0,-8.7,-5.8,GO:0007162,negative regulation of cell adhesion,M011,2,0
0,1,1,0,-3.6,-3,R-HSA-1257604,PIP3 activates AKT signaling,M011,2,0
0,1,1,0,-4.8,-2.6,hsa04080,Neuroactive ligand-receptor interaction,M011,2,0
0,1,1,0,-2.7,-2.4,GO:1903034,regulation of response to wounding,M011,2,0
1,1,0,-3.3,-3,0,hsa05222,Small cell lung cancer,M110,2,0
0,1,1,0,-3.6,-3.4,GO:0032956,regulation of actin cytoskeleton organization,M011,2,0
0,1,1,0,-2.4,-3.2,R-HSA-975577,N-Glycan antennae elongation,M011,2,0
0,1,1,0,-3.3,-4.2,GO:0032409,regulation of transporter activity,M011,2,0
1,1,0,-2.2,-2.4,0,CORUM:2084,NFKB1-NFKB2-REL-RELA-RELB complex,M110,2,0
1,1,0,-3.5,-2.2,0,R-HSA-4090294,SUMOylation of intracellular receptors,M110,2,0
1,0,1,-2.7,0,-4.2,GO:0035051,cardiocyte differentiation,M101,2,0
1,1,0,-4.5,-2.8,0,GO:0001945,lymph vessel development,M110,2,0
1,1,0,-2.8,-2.2,0,WP5300,TROP2 regulatory signaling,M110,2,0
1,1,0,-4.7,-2.4,0,WP3967,miR 509 3p alteration of YAP1 ECM axis,M110,2,0
1,1,0,-2.2,-2.4,0,GO:0045630,positive regulation of T-helper 2 cell differentiation,M110,2,0
0,1,1,0,-2.6,-3,GO:0030510,regulation of BMP signaling pathway,M011,2,0
0,1,1,0,-3.6,-5.2,GO:0031346,positive regulation of cell projection organization,M011,2,0
0,1,1,0,-2.9,-2.3,R-HSA-9683701,Translation of Structural Proteins,M011,2,0
0,1,1,0,-4,-4.5,GO:0120031,plasma membrane bounded cell projection assembly,M011,2,0
1,1,0,-2,-2.4,0,GO:1900544,positive regulation of purine nucleotide metabolic process,M110,2,0
1,1,0,-3.5,-6.3,0,GO:0050671,positive regulation of lymphocyte proliferation,M110,2,0
0,1,1,0,-3.3,-2.5,R-HSA-76002,"Platelet activation, signaling and aggregation",M011,2,0
1,0,1,-2.8,0,-2.3,R-HSA-1980143,Signaling by NOTCH1,M101,2,0
1,1,0,-3.5,-2.1,0,GO:0048644,muscle organ morphogenesis,M110,2,0
1,0,1,-4.8,0,-2.1,GO:0001704,formation of primary germ layer,M101,2,0
1,1,0,-3.1,-2.5,0,GO:0009187,cyclic nucleotide metabolic process,M110,2,0
1,1,0,-2.8,-2,0,WP4685,Melanoma,M110,2,0
1,1,0,-5.4,-5.4,0,GO:0010721,negative regulation of cell development,M110,2,0
1,1,0,-4,-2.1,0,R-HSA-9660826,Purinergic signaling in leishmaniasis infection,M110,2,0
0,1,1,0,-5.9,-6.7,GO:0098916,anterograde trans-synaptic signaling,M011,2,0
1,0,1,-10,0,-6.4,GO:0007389,pattern specification process,M101,2,0
1,1,0,-2.7,-2.4,0,GO:0060603,mammary gland duct morphogenesis,M110,2,0
0,1,1,0,-6.8,-5.6,GO:0002683,negative regulation of immune system process,M011,2,0
1,0,1,-2,0,-5.3,GO:0045646,regulation of erythrocyte differentiation,M101,2,0
1,0,1,-2.5,0,-4.3,GO:0010518,positive regulation of phospholipase activity,M101,2,0
1,1,0,-2.8,-3.5,0,GO:1904705,regulation of vascular associated smooth muscle cell proliferation,M110,2,0
1,1,0,-5.4,-3.9,0,WP5353,A network map of Macrophage stimulating protein MSP signaling,M110,2,0
1,1,0,-3.1,-2.5,0,hsa04150,mTOR signaling pathway,M110,2,0
0,1,1,0,-5.1,-4.8,GO:0050730,regulation of peptidyl-tyrosine phosphorylation,M011,2,0
1,0,1,-3.1,0,-3.7,GO:0021846,cell proliferation in forebrain,M101,2,0
0,1,1,0,-2.1,-3.1,GO:1905155,positive regulation of membrane invagination,M011,2,0
1,1,0,-2.4,-3.2,0,hsa05146,Amoebiasis,M110,2,0
1,1,0,-5.3,-4.5,0,GO:0006109,regulation of carbohydrate metabolic process,M110,2,0
1,1,0,-2.2,-2.4,0,WP4269,Ethanol metabolism production of ROS by CYP2E1,M110,2,0
1,1,0,-3.7,-2.1,0,R-HSA-1592230,Mitochondrial biogenesis,M110,2,0
1,1,0,-3.4,-3.2,0,GO:0051058,negative regulation of small GTPase mediated signal transduction,M110,2,0
1,1,0,-2.3,-2.6,0,hsa04612,Antigen processing and presentation,M110,2,0
1,1,0,-2,-2.7,0,GO:0048588,developmental cell growth,M110,2,0
1,0,1,-2.7,0,-2.9,GO:1904752,regulation of vascular associated smooth muscle cell migration,M101,2,0
1,1,0,-2.1,-3.3,0,R-HSA-432040,Vasopressin regulates renal water homeostasis via Aquaporins,M110,2,0
0,1,1,0,-4.7,-4.1,GO:0043254,regulation of protein-containing complex assembly,M011,2,0
1,1,0,-2.3,-2.8,0,GO:0046639,negative regulation of alpha-beta T cell differentiation,M110,2,0
1,1,0,-2.7,-3.2,0,GO:0048384,retinoic acid receptor signaling pathway,M110,2,0
1,1,0,-3.8,-2.5,0,GO:0002711,positive regulation of T cell mediated immunity,M110,2,0
1,0,1,-2,0,-2.1,GO:0032757,positive regulation of interleukin-8 production,M101,2,0
1,1,0,-3.4,-2.9,0,GO:0010596,negative regulation of endothelial cell migration,M110,2,0
0,1,1,0,-5.9,-6.7,GO:0007268,chemical synaptic transmission,M011,2,0
0,1,1,0,-8.8,-7.3,GO:0010562,positive regulation of phosphorus metabolic process,M011,2,0
0,1,1,0,-5.3,-3.4,GO:0070661,leukocyte proliferation,M011,2,0
1,0,1,-3.8,0,-2,GO:0051098,regulation of binding,M101,2,0
1,1,0,-2.3,-2.3,0,WP35,G protein signaling pathways,M110,2,0
0,1,1,0,-3.1,-2.2,WP2112,IL 17 signaling pathway,M011,2,0
1,1,0,-2.5,-2.5,0,R-HSA-168643,"Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways",M110,2,0
0,1,1,0,-2.3,-2.1,R-HSA-388841,Costimulation by the CD28 family,M011,2,0
1,1,0,-3.3,-2.8,0,R-HSA-975138,TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation,M110,2,0
1,1,0,-3.5,-3,0,GO:0032651,regulation of interleukin-1 beta production,M110,2,0
0,1,1,0,-2.5,-2.3,GO:1990868,response to chemokine,M011,2,0
0,1,1,0,-8.1,-4.6,GO:0120039,plasma membrane bounded cell projection morphogenesis,M011,2,0
1,0,1,-2.1,0,-2.9,GO:0051963,regulation of synapse assembly,M101,2,0
1,1,0,-2.8,-2.2,0,hsa05164,Influenza A,M110,2,0
0,1,1,0,-2,-2.3,GO:0050773,regulation of dendrite development,M011,2,0
1,1,0,-2.6,-3.5,0,R-HSA-202733,Cell surface interactions at the vascular wall,M110,2,0
0,1,1,0,-3.8,-2.3,GO:0071385,cellular response to glucocorticoid stimulus,M011,2,0
1,1,0,-2.7,-3.1,0,WP2814,Mammary gland development pathway Puberty Stage 2 of 4,M110,2,0
0,1,1,0,-4.6,-3.9,GO:0045860,positive regulation of protein kinase activity,M011,2,0
1,1,0,-2.3,-2.3,0,GO:0030501,positive regulation of bone mineralization,M110,2,0
1,1,0,-3.3,-2.1,0,hsa05212,Pancreatic cancer,M110,2,0
1,0,1,-2.7,0,-2.2,GO:0062043,positive regulation of cardiac epithelial to mesenchymal transition,M101,2,0
1,0,1,-2.8,0,-2.1,GO:1990266,neutrophil migration,M101,2,0
1,1,0,-2.8,-2.3,0,GO:0048708,astrocyte differentiation,M110,2,0
0,1,1,0,-7.4,-8.1,GO:0050808,synapse organization,M011,2,0
0,1,1,0,-6.4,-3.8,GO:0022604,regulation of cell morphogenesis,M011,2,0
1,1,0,-2.7,-4.1,0,GO:0032332,positive regulation of chondrocyte differentiation,M110,2,0
1,1,0,-2.3,-2.3,0,GO:0060395,SMAD protein signal transduction,M110,2,0
0,1,1,0,-11,-7.2,GO:0034330,cell junction organization,M011,2,0
1,1,0,-3,-3.4,0,GO:0002357,defense response to tumor cell,M110,2,0
0,1,1,0,-4,-3.6,GO:0007611,learning or memory,M011,2,0
1,1,0,-2.9,-2.2,0,GO:1901343,negative regulation of vasculature development,M110,2,0
1,0,1,-2.6,0,-2.5,GO:0055023,positive regulation of cardiac muscle tissue growth,M101,2,0
1,1,0,-7.5,-2.9,0,R-HSA-383280,Nuclear Receptor transcription pathway,M110,2,0
0,1,1,0,-2.5,-2.1,M63,PID AVB3 OPN PATHWAY,M011,2,0
0,1,1,0,-3,-2.4,GO:0043200,response to amino acid,M011,2,0
1,1,0,-2.5,-3,0,GO:0003158,endothelium development,M110,2,0
0,1,1,0,-3.4,-2.1,GO:2001187,"positive regulation of CD8-positive, alpha-beta T cell activation",M011,2,0
1,1,0,-4.5,-3.4,0,GO:0001823,mesonephros development,M110,2,0
0,1,1,0,-2.1,-2.5,GO:0090103,cochlea morphogenesis,M011,2,0
1,1,0,-3.1,-2.1,0,R-HSA-975871,MyD88 cascade initiated on plasma membrane,M110,2,0
0,1,1,0,-2.1,-2.1,R-HSA-418990,Adherens junctions interactions,M011,2,0
1,0,1,-3.1,0,-2.7,GO:0048505,regulation of timing of cell differentiation,M101,2,0
1,0,1,-3.7,0,-3.4,GO:0010611,regulation of cardiac muscle hypertrophy,M101,2,0
1,0,1,-2,0,-2.2,GO:0043516,"regulation of DNA damage response, signal transduction by p53 class mediator",M101,2,0
1,1,0,-2.9,-2.2,0,GO:0042269,regulation of natural killer cell mediated cytotoxicity,M110,2,0
1,1,0,-4.3,-2.5,0,M143,PID IL2 PI3K PATHWAY,M110,2,0
1,1,0,-3.1,-2.5,0,GO:0032673,regulation of interleukin-4 production,M110,2,0
1,1,0,-2.5,-2.1,0,GO:0045623,negative regulation of T-helper cell differentiation,M110,2,0
1,1,0,-5.6,-2.5,0,M162,PID RXR VDR PATHWAY,M110,2,0
1,1,0,-2.3,-2.1,0,WP4830,GDNF RET signaling axis,M110,2,0
1,1,0,-2.8,-2.2,0,GO:0014074,response to purine-containing compound,M110,2,0
1,1,0,-2.2,-2.4,0,WP3926,ApoE and miR 146 in inflammation and atherosclerosis,M110,2,0
1,1,0,-4,-2.4,0,GO:0048483,autonomic nervous system development,M110,2,0
1,1,0,-2.3,-2.1,0,GO:1990849,vacuolar localization,M110,2,0
1,1,0,-4.1,-3.9,0,hsa04390,Hippo signaling pathway,M110,2,0
1,1,0,-2.5,-2.1,0,GO:0060416,response to growth hormone,M110,2,0
1,1,0,-2.5,-2.1,0,GO:0002820,negative regulation of adaptive immune response,M110,2,0
0,1,1,0,-4.1,-4.2,GO:0030111,regulation of Wnt signaling pathway,M011,2,0
1,1,0,-3.5,-2.4,0,GO:0060415,muscle tissue morphogenesis,M110,2,0
1,1,0,-5.8,-2.9,0,GO:0014013,regulation of gliogenesis,M110,2,0
1,1,0,-2.4,-2.1,0,GO:0046580,negative regulation of Ras protein signal transduction,M110,2,0
1,1,0,-3.3,-2.3,0,R-HSA-166166,MyD88-independent TLR4 cascade,M110,2,0
1,1,0,-2.2,-2.4,0,GO:0033173,calcineurin-NFAT signaling cascade,M110,2,0
1,0,1,-3.4,0,-2.8,hsa05203,Viral carcinogenesis,M101,2,0
0,1,1,0,-6,-4.7,GO:0061564,axon development,M011,2,0
0,1,1,0,-3.9,-2.5,GO:0051896,regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction,M011,2,0
1,1,0,-3.3,-3.1,0,GO:0009595,detection of biotic stimulus,M110,2,0
0,1,1,0,-2.4,-2.9,WP4787,Osteoblast differentiation and related diseases,M011,2,0
1,1,0,-2.1,-2.5,0,R-HSA-9661069,"Defective binding of RB1 mutants to E2F1,(E2F2, E2F3)",M110,2,0
1,1,0,-2.3,-2.6,0,GO:0048009,insulin-like growth factor receptor signaling pathway,M110,2,0
1,1,0,-2.6,-2.4,0,GO:0032703,negative regulation of interleukin-2 production,M110,2,0
1,1,0,-3.1,-4.5,0,GO:0021954,central nervous system neuron development,M110,2,0
1,1,0,-2.8,-2.2,0,GO:2000179,positive regulation of neural precursor cell proliferation,M110,2,0
0,1,1,0,-2.1,-3.3,GO:0032412,regulation of monoatomic ion transmembrane transporter activity,M011,2,0
1,1,0,-2.1,-2.5,0,GO:1901722,regulation of cell proliferation involved in kidney development,M110,2,0
1,0,1,-2.6,0,-2.9,GO:0042475,odontogenesis of dentin-containing tooth,M101,2,0
0,1,1,0,-3.3,-2.2,GO:0071675,regulation of mononuclear cell migration,M011,2,0
1,1,0,-4.6,-4.3,0,GO:0071222,cellular response to lipopolysaccharide,M110,2,0
0,1,1,0,-8.8,-7.3,GO:0045937,positive regulation of phosphate metabolic process,M011,2,0
1,1,0,-2.8,-2.2,0,R-HSA-9707564,Cytoprotection by HMOX1,M110,2,0
1,1,0,-3.1,-3.4,0,GO:0048639,positive regulation of developmental growth,M110,2,0
0,1,1,0,-3.1,-2.2,GO:0035235,ionotropic glutamate receptor signaling pathway,M011,2,0
1,1,0,-2.7,-2.4,0,WP363,Wnt signaling pathway,M110,2,0
1,1,0,-3.5,-4.5,0,GO:0032729,positive regulation of type II interferon production,M110,2,0
1,0,1,-9.8,0,-4.6,GO:0003002,regionalization,M101,2,0
1,0,1,-4.5,0,-2.2,WP3594,Circadian rhythm genes,M101,2,0
1,1,0,-3.5,-2.2,0,GO:0001912,positive regulation of leukocyte mediated cytotoxicity,M110,2,0
1,1,0,-2.3,-2.8,0,GO:0045576,mast cell activation,M110,2,0
0,1,1,0,-2.2,-3.1,GO:0098883,synapse pruning,M011,2,0
0,1,1,0,-4,-3.1,GO:0097028,dendritic cell differentiation,M011,2,0
1,1,0,-2.3,-2.3,0,GO:0007266,Rho protein signal transduction,M110,2,0
0,1,1,0,-3.1,-2.5,GO:0007200,phospholipase C-activating G protein-coupled receptor signaling pathway,M011,2,0
1,1,0,-2.3,-2.2,0,GO:0043470,regulation of carbohydrate catabolic process,M110,2,0
1,1,0,-3,-4,0,GO:0021761,limbic system development,M110,2,0
1,1,0,-3.4,-2.3,0,WP3303,RAC1 PAK1 p38 MMP2 pathway,M110,2,0
1,1,0,-3.1,-2.5,0,M94,PID FAS PATHWAY,M110,2,0
1,1,0,-4,-2.9,0,hsa04934,Cushing syndrome,M110,2,0
0,1,1,0,-5.6,-3.8,GO:0007409,axonogenesis,M011,2,0
1,0,1,-2.1,0,-2.7,WP1528,Physiological and pathological hypertrophy of the heart,M101,2,0
1,1,0,-6.4,-5.2,0,GO:0048545,response to steroid hormone,M110,2,0
1,1,0,-2.1,-3.5,0,GO:0042119,neutrophil activation,M110,2,0
1,1,0,-2.9,-3.3,0,GO:0046847,filopodium assembly,M110,2,0
0,1,1,0,-2.5,-2.1,GO:1990806,ligand-gated ion channel signaling pathway,M011,2,0
1,1,0,-2,-2.1,0,hsa04726,Serotonergic synapse,M110,2,0
1,1,0,-2.8,-3.1,0,GO:0071774,response to fibroblast growth factor,M110,2,0
1,0,1,-8.9,0,-5.6,GO:0030335,positive regulation of cell migration,M101,2,0
1,0,1,-3.5,0,-2.2,WP3584,MECP2 and associated Rett syndrome,M101,2,0
1,1,0,-3.1,-2,0,WP2037,Prolactin signaling pathway,M110,2,0
1,0,1,-2.9,0,-2.8,GO:0021781,glial cell fate commitment,M101,2,0
1,1,0,-5.4,-3.4,0,WP170,Nuclear receptors,M110,2,0
1,1,0,-2.5,-2.6,0,WP231,TNF alpha signaling pathway,M110,2,0
0,1,1,0,-2.5,-2.5,GO:0014896,muscle hypertrophy,M011,2,0
1,1,0,-2.1,-2.8,0,GO:0042542,response to hydrogen peroxide,M110,2,0
1,1,0,-2.8,-2.4,0,GO:0007589,body fluid secretion,M110,2,0
1,1,0,-5.3,-3.1,0,hsa04218,Cellular senescence,M110,2,0
0,1,1,0,-3.3,-2.5,GO:0070588,calcium ion transmembrane transport,M011,2,0
1,1,0,-9.5,-7.5,0,GO:0048732,gland development,M110,2,0
0,1,1,0,-4.8,-2.5,GO:0009100,glycoprotein metabolic process,M011,2,0
1,1,0,-3.6,-2.3,0,hsa04728,Dopaminergic synapse,M110,2,0
1,1,0,-4.1,-3.5,0,GO:0001649,osteoblast differentiation,M110,2,0
1,0,1,-3.2,0,-2.7,GO:0003272,endocardial cushion formation,M101,2,0
0,1,1,0,-4.7,-3,GO:0060627,regulation of vesicle-mediated transport,M011,2,0
0,1,1,0,-2.1,-2.2,GO:0010324,membrane invagination,M011,2,0
1,0,1,-2.9,0,-2.4,WP51,Regulation of actin cytoskeleton,M101,2,0
1,1,0,-4.3,-2.3,0,hsa04350,TGF-beta signaling pathway,M110,2,0
1,1,0,-3.8,-3,0,hsa05225,Hepatocellular carcinoma,M110,2,0
1,1,0,-4,-2.4,0,GO:0030857,negative regulation of epithelial cell differentiation,M110,2,0
1,0,1,-3.2,0,-2.5,GO:0061041,regulation of wound healing,M101,2,0
1,1,0,-3.5,-3,0,R-HSA-168181,Toll Like Receptor 7/8 (TLR7/8) Cascade,M110,2,0
1,0,1,-5.3,0,-5.6,GO:0043434,response to peptide hormone,M101,2,0
1,0,1,-4.2,0,-2.1,hsa04510,Focal adhesion,M101,2,0
1,1,0,-3,-2.8,0,GO:0032743,positive regulation of interleukin-2 production,M110,2,0
0,1,1,0,-5.6,-7.2,GO:0099537,trans-synaptic signaling,M011,2,0
1,1,0,-2,-2.4,0,GO:0038084,vascular endothelial growth factor signaling pathway,M110,2,0
0,1,1,0,-2.5,-2.1,GO:0002224,toll-like receptor signaling pathway,M011,2,0
1,1,0,-2.5,-2.9,0,GO:0060351,cartilage development involved in endochondral bone morphogenesis,M110,2,0
1,1,0,-3.5,-2.9,0,R-HSA-8853884,Transcriptional Regulation by VENTX,M110,2,0
1,1,0,-2.6,-3.2,0,GO:0002828,regulation of type 2 immune response,M110,2,0
1,0,1,-6.9,0,-7.6,GO:1901652,response to peptide,M101,2,0
0,1,1,0,-2,-2.6,GO:0031644,regulation of nervous system process,M011,2,0
1,1,0,-2.3,-2,0,hsa01521,EGFR tyrosine kinase inhibitor resistance,M110,2,0
1,1,0,-3.8,-2.5,0,WP1541,Energy metabolism,M110,2,0
1,1,0,-4.1,-2.3,0,WP2034,Leptin signaling pathway,M110,2,0
1,0,1,-2.3,0,-2.6,R-HSA-9670439,"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants",M101,2,0
1,1,0,-2.2,-2.4,0,GO:0007196,adenylate cyclase-inhibiting G protein-coupled glutamate receptor signaling pathway,M110,2,0
0,1,1,0,-5.6,-5.4,GO:0099177,regulation of trans-synaptic signaling,M011,2,0
0,1,1,0,-2.1,-2.2,GO:0050832,defense response to fungus,M011,2,0
1,1,0,-4.1,-4.5,0,GO:0002706,regulation of lymphocyte mediated immunity,M110,2,0
0,1,1,0,-3.2,-3.6,hsa04640,Hematopoietic cell lineage,M011,2,0
1,1,0,-2.3,-2.6,0,WP2881,Estrogen receptor pathway,M110,2,0
0,1,1,0,-2.1,-2.1,GO:0043279,response to alkaloid,M011,2,0
1,0,1,-2.7,0,-2.2,M196,PID IL23 PATHWAY,M101,2,0
0,1,1,0,-3.5,-2.3,GO:0071384,cellular response to corticosteroid stimulus,M011,2,0
0,1,1,0,-4.7,-5,GO:0050890,cognition,M011,2,0
1,1,0,-3.5,-3.9,0,GO:0003417,growth plate cartilage development,M110,2,0
1,1,0,-3.3,-3.1,0,GO:0002709,regulation of T cell mediated immunity,M110,2,0
0,1,1,0,-4.2,-3.8,GO:0050764,regulation of phagocytosis,M011,2,0
1,1,0,-3.1,-2.7,0,GO:0001890,placenta development,M110,2,0
1,1,0,-2.3,-2,0,GO:0043491,phosphatidylinositol 3-kinase/protein kinase B signal transduction,M110,2,0
1,0,1,-4.5,0,-2.8,WP306,Focal adhesion,M101,2,0
1,1,0,-2,-2.5,0,GO:0046636,negative regulation of alpha-beta T cell activation,M110,2,0
0,1,1,0,-3.6,-3.1,GO:0030100,regulation of endocytosis,M011,2,0
1,1,0,-2,-2,0,WP98,Prostaglandin synthesis and regulation,M110,2,0
1,1,0,-2.9,-3.3,0,WP710,DNA damage response only ATM dependent,M110,2,0
1,1,0,-3.6,-3.2,0,R-HSA-5607764,CLEC7A (Dectin-1) signaling,M110,2,0
1,0,1,-2.3,0,-2.6,R-HSA-1433559,Regulation of KIT signaling,M101,2,0
1,0,1,-2,0,-2.1,WP4549,Fragile X syndrome,M101,2,0
1,1,0,-2.3,-2.1,0,GO:1900542,regulation of purine nucleotide metabolic process,M110,2,0
0,1,1,0,-2.5,-2.7,GO:0001773,myeloid dendritic cell activation,M011,2,0
1,1,0,-3.9,-2.5,0,GO:0045953,negative regulation of natural killer cell mediated cytotoxicity,M110,2,0
1,0,1,-2.3,0,-2.6,GO:0150146,cell junction disassembly,M101,2,0
1,1,0,-2.5,-2.1,0,R-HSA-622312,Inflammasomes,M110,2,0
1,0,1,-4,0,-3.2,GO:0014743,regulation of muscle hypertrophy,M101,2,0
1,1,0,-3.3,-3.7,0,GO:0048864,stem cell development,M110,2,0
0,1,1,0,-4.8,-4.2,GO:0033674,positive regulation of kinase activity,M011,2,0
0,1,1,0,-2.5,-2.2,GO:0050954,sensory perception of mechanical stimulus,M011,2,0
1,1,0,-3,-3.9,0,WP2328,Allograft rejection,M110,2,0
0,1,1,0,-2.5,-3.7,GO:1905153,regulation of membrane invagination,M011,2,0
0,1,1,0,-5.4,-5.2,WP5218,Extrafollicular and follicular B cell activation by SARS CoV 2,M011,2,0
1,0,1,-3.4,0,-2.5,GO:0007163,establishment or maintenance of cell polarity,M101,2,0
1,0,1,-2.9,0,-2.2,GO:0010717,regulation of epithelial to mesenchymal transition,M101,2,0
1,0,1,-2,0,-3.1,R-HSA-9700206,Signaling by ALK in cancer,M101,2,0
0,1,1,0,-3.5,-3.4,GO:0007264,small GTPase mediated signal transduction,M011,2,0
1,1,0,-3.2,-3,0,GO:0002449,lymphocyte mediated immunity,M110,2,0
1,0,1,-2.3,0,-2.8,hsa04144,Endocytosis,M101,2,0
1,0,1,-3.1,0,-2.5,GO:0043300,regulation of leukocyte degranulation,M101,2,0
1,1,0,-3.4,-3.1,0,hsa05226,Gastric cancer,M110,2,0
1,1,0,-2.9,-2.2,0,GO:0060425,lung morphogenesis,M110,2,0
1,1,0,-2.3,-2.8,0,hsa04392,Hippo signaling pathway - multiple species,M110,2,0
1,1,0,-2.1,-3.5,0,M234,PID IL2 STAT5 PATHWAY,M110,2,0
1,1,0,-4.4,-4.2,0,hsa04066,HIF-1 signaling pathway,M110,2,0
0,1,1,0,-2.2,-3.7,GO:0097696,receptor signaling pathway via STAT,M011,2,0
0,1,1,0,-2.8,-3.3,GO:0030032,lamellipodium assembly,M011,2,0
1,1,0,-3.3,-4.8,0,GO:0071674,mononuclear cell migration,M110,2,0
1,1,0,-3.1,-2.8,0,GO:0002218,activation of innate immune response,M110,2,0
1,0,1,-2.6,0,-2.5,GO:0043313,regulation of neutrophil degranulation,M101,2,0
1,1,0,-2.5,-3.2,0,WP4155,Endometrial cancer,M110,2,0
1,1,0,-4,-3.6,0,M1315,SIG PIP3 SIGNALING IN B LYMPHOCYTES,M110,2,0
0,1,1,0,-2.5,-2.7,GO:0010613,positive regulation of cardiac muscle hypertrophy,M011,2,0
1,1,0,-4.4,-6.4,0,GO:0048660,regulation of smooth muscle cell proliferation,M110,2,0
1,1,0,-2.3,-2.1,0,hsa04720,Long-term potentiation,M110,2,0
1,0,1,-4.3,0,-3.6,GO:0090257,regulation of muscle system process,M101,2,0
1,0,1,-2.1,0,-2.1,GO:0010885,regulation of cholesterol storage,M101,2,0
0,1,1,0,-3.1,-2.2,hsa05033,Nicotine addiction,M011,2,0
1,1,0,-2.1,-2.5,0,GO:0071391,cellular response to estrogen stimulus,M110,2,0
1,1,0,-2.1,-3.3,0,R-HSA-445717,Aquaporin-mediated transport,M110,2,0
1,1,0,-2.7,-3.3,0,GO:0000302,response to reactive oxygen species,M110,2,0
0,1,1,0,-6.6,-5.1,R-HSA-109582,Hemostasis,M011,2,0
1,1,0,-3.3,-2.8,0,R-HSA-168138,Toll Like Receptor 9 (TLR9) Cascade,M110,2,0
0,1,1,0,-2.5,-2.5,GO:0032733,positive regulation of interleukin-10 production,M011,2,0
1,1,0,-2.3,-2.1,0,GO:0032418,lysosome localization,M110,2,0
1,1,0,-2.3,-2.1,0,WP5205,Clock controlled autophagy in bone metabolism,M110,2,0
0,1,1,0,-2.8,-2.3,R-HSA-421270,Cell-cell junction organization,M011,2,0
1,0,1,-2.6,0,-3.4,GO:0010863,positive regulation of phospholipase C activity,M101,2,0
0,1,1,0,-2.2,-2.1,GO:0086064,cell communication by electrical coupling involved in cardiac conduction,M011,2,0
0,1,1,0,-3.9,-4,hsa04730,Long-term depression,M011,2,0
1,1,0,-5.6,-3.7,0,GO:0062197,cellular response to chemical stress,M110,2,0
1,1,0,-2.3,-2.2,0,GO:0030593,neutrophil chemotaxis,M110,2,0
1,0,1,-3.4,0,-2.4,GO:0060795,cell fate commitment involved in formation of primary germ layer,M101,2,0
1,1,0,-4.2,-4.4,0,GO:0071219,cellular response to molecule of bacterial origin,M110,2,0
0,1,1,0,-2.9,-2.3,GO:0009620,response to fungus,M011,2,0
1,1,0,-2.3,-2.1,0,GO:0035883,enteroendocrine cell differentiation,M110,2,0
0,1,1,0,-2.2,-2.1,GO:2000463,positive regulation of excitatory postsynaptic potential,M011,2,0
1,1,0,-6.9,-5.2,0,GO:0048511,rhythmic process,M110,2,0
0,1,1,0,-2.5,-2.9,R-HSA-9772573,Late SARS-CoV-2 Infection Events,M011,2,0
1,1,0,-2.4,-2.3,0,GO:1903053,regulation of extracellular matrix organization,M110,2,0
1,1,0,-2.3,-2.3,0,M99,PID TXA2PATHWAY,M110,2,0
1,0,1,-5,0,-2.9,WP4808,Endochondral ossification with skeletal dysplasias,M101,2,0
1,1,0,-2.6,-2.5,0,GO:1904707,positive regulation of vascular associated smooth muscle cell proliferation,M110,2,0
1,1,0,-2.4,-2.7,0,GO:0014032,neural crest cell development,M110,2,0
1,1,0,-4.8,-2.8,0,hsa05135,Yersinia infection,M110,2,0
1,1,0,-3.9,-3,0,hsa05210,Colorectal cancer,M110,2,0
0,1,1,0,-3.3,-2.8,R-HSA-202427,Phosphorylation of CD3 and TCR zeta chains,M011,2,0
0,1,1,0,-6.9,-3.9,hsa04151,PI3K-Akt signaling pathway,M011,2,0
0,1,1,0,-3.8,-2.9,hsa04970,Salivary secretion,M011,2,0
1,1,0,-3,-2.2,0,GO:0045602,negative regulation of endothelial cell differentiation,M110,2,0
1,1,0,-3.5,-5.2,0,GO:0048661,positive regulation of smooth muscle cell proliferation,M110,2,0
1,1,0,-3.5,-3.4,0,GO:0030902,hindbrain development,M110,2,0
1,0,1,-5.4,0,-4,R-HSA-5663202,Diseases of signal transduction by growth factor receptors and second messengers,M101,2,0
0,1,1,0,-3.7,-3.4,GO:1902903,regulation of supramolecular fiber organization,M011,2,0
1,1,0,-2.6,-3.2,0,GO:0002861,regulation of inflammatory response to antigenic stimulus,M110,2,0
0,1,1,0,-4.3,-4.2,GO:0060759,regulation of response to cytokine stimulus,M011,2,0
0,1,1,0,-4.6,-3.2,GO:0043269,regulation of monoatomic ion transport,M011,2,0
0,1,1,0,-2.2,-2.8,R-HSA-199418,Negative regulation of the PI3K/AKT network,M011,2,0
1,1,0,-3.8,-2.5,0,GO:1903531,negative regulation of secretion by cell,M110,2,0
1,1,0,-2.1,-2.5,0,R-HSA-9687139,Aberrant regulation of mitotic cell cycle due to RB1 defects,M110,2,0
1,1,0,-3.5,-4.6,0,GO:0042102,positive regulation of T cell proliferation,M110,2,0
1,1,0,-2.3,-2.8,0,GO:0002448,mast cell mediated immunity,M110,2,0
0,1,1,0,-4.7,-4.1,GO:0098742,cell-cell adhesion via plasma-membrane adhesion molecules,M011,2,0
1,0,1,-3.5,0,-2.7,hsa05211,Renal cell carcinoma,M101,2,0
0,1,1,0,-2.2,-2.1,R-HSA-76009,Platelet Aggregation (Plug Formation),M011,2,0
1,1,0,-3.1,-2.6,0,GO:0034614,cellular response to reactive oxygen species,M110,2,0
1,1,0,-2.1,-3.3,0,GO:0002675,positive regulation of acute inflammatory response,M110,2,0
1,0,1,-8.3,0,-5.9,GO:0032103,positive regulation of response to external stimulus,M101,2,0
1,1,0,-5.1,-2.1,0,GO:0003180,aortic valve morphogenesis,M110,2,0
0,1,1,0,-6.6,-6.2,GO:0009611,response to wounding,M011,2,0
1,0,1,-2.9,0,-2.5,GO:0042476,odontogenesis,M101,2,0
1,1,0,-3.3,-2,0,WP4018,Clear cell renal cell carcinoma pathways,M110,2,0
1,0,1,-3.3,0,-2.8,GO:0055021,regulation of cardiac muscle tissue growth,M101,2,0
1,1,0,-2.9,-2.5,0,GO:0007179,transforming growth factor beta receptor signaling pathway,M110,2,0
0,1,1,0,-5.5,-5.3,GO:0048589,developmental growth,M011,2,0
1,0,1,-2.6,0,-2.3,GO:0007368,determination of left/right symmetry,M101,2,0
0,1,1,0,-3.1,-2.9,M8,PID ENDOTHELIN PATHWAY,M011,2,0
1,1,0,-2.2,-2.4,0,GO:0032819,positive regulation of natural killer cell proliferation,M110,2,0
1,1,0,-3,-2.4,0,GO:0071456,cellular response to hypoxia,M110,2,0
1,0,1,-3.3,0,-2.5,GO:0003177,pulmonary valve development,M101,2,0
1,1,0,-2.1,-3.8,0,GO:0006022,aminoglycan metabolic process,M110,2,0
0,1,1,0,-4.1,-2.7,GO:0007015,actin filament organization,M011,2,0
0,1,1,0,-2.1,-2.2,GO:0098926,postsynaptic signal transduction,M011,2,0
1,1,0,-2,-2.4,0,GO:0002279,mast cell activation involved in immune response,M110,2,0
0,1,1,0,-4.8,-2.6,GO:0042098,T cell proliferation,M011,2,0
1,0,1,-2.6,0,-2,GO:0045600,positive regulation of fat cell differentiation,M101,2,0
1,1,0,-3.5,-2.4,0,GO:0032722,positive regulation of chemokine production,M110,2,0
0,1,1,0,-2.6,-2.6,GO:0043011,myeloid dendritic cell differentiation,M011,2,0
1,1,0,-2,-2.4,0,GO:0043303,mast cell degranulation,M110,2,0
1,1,0,-4.4,-2.6,0,WP4754,IL 18 signaling pathway,M110,2,0
1,1,0,-3.8,-2.5,0,GO:0032731,positive regulation of interleukin-1 beta production,M110,2,0
1,1,0,-3.5,-2.1,0,GO:0043586,tongue development,M110,2,0
1,1,0,-3.4,-2.9,0,R-HSA-9009391,Extra-nuclear estrogen signaling,M110,2,0
1,1,0,-4.5,-4.8,0,GO:1901654,response to ketone,M110,2,0
1,0,1,-2.8,0,-2.2,GO:0060972,left/right pattern formation,M101,2,0
0,1,1,0,-3,-3.1,WP4217,Ebola virus infection in host,M011,2,0
0,1,1,0,-3.1,-2.2,GO:0002827,positive regulation of T-helper 1 type immune response,M011,2,0
1,1,0,-4.5,-2.1,0,WP4879,Overlap between signal transduction pathways contributing to LMNA laminopathies,M110,2,0
1,1,0,-3.5,-2.3,0,hsa05134,Legionellosis,M110,2,0
1,0,1,-3.4,0,-2.3,GO:0045747,positive regulation of Notch signaling pathway,M101,2,0
0,1,1,0,-2.1,-2.3,GO:0098815,modulation of excitatory postsynaptic potential,M011,2,0
0,1,1,0,-2.2,-3.1,GO:0032695,negative regulation of interleukin-12 production,M011,2,0
1,0,1,-3.9,0,-5.3,hsa04015,Rap1 signaling pathway,M101,2,0
1,1,0,-2.8,-3.3,0,GO:0032649,regulation of type II interferon production,M110,2,0
0,1,1,0,-3.1,-3.7,GO:1904062,regulation of monoatomic cation transmembrane transport,M011,2,0
1,0,1,-13,0,-6.6,GO:0048598,embryonic morphogenesis,M101,2,0
1,1,0,-5.1,-3.5,0,GO:0034599,cellular response to oxidative stress,M110,2,0
1,1,0,-2.1,-2.5,0,GO:0021955,central nervous system neuron axonogenesis,M110,2,0
1,1,0,-5,-2.7,0,GO:0030216,keratinocyte differentiation,M110,2,0
1,0,1,-2.1,0,-3.1,GO:0060191,regulation of lipase activity,M101,2,0
1,1,0,-7,-5.4,0,R-HSA-9006931,Signaling by Nuclear Receptors,M110,2,0
1,0,1,-2.6,0,-2.5,GO:0072239,metanephric glomerulus vasculature development,M101,2,0
0,1,1,0,-3.8,-3.9,GO:0007188,adenylate cyclase-modulating G protein-coupled receptor signaling pathway,M011,2,0
1,0,1,-6.5,0,-4,GO:0042063,gliogenesis,M101,2,0
1,1,0,-2.9,-2.2,0,GO:0032642,regulation of chemokine production,M110,2,0
1,1,0,-2.3,-2.2,0,hsa05216,Thyroid cancer,M110,2,0
0,1,1,0,-2.5,-2.7,M175,PID ERBB2 ERBB3 PATHWAY,M011,2,0
1,1,0,-3.3,-2.9,0,GO:0007565,female pregnancy,M110,2,0
1,0,1,-2.5,0,-4.3,M231,PID KIT PATHWAY,M101,2,0
1,1,0,-4.3,-4.2,0,WP254,Apoptosis,M110,2,0
1,0,1,-5.5,0,-2.2,GO:0007369,gastrulation,M101,2,0
0,1,1,0,-2.3,-2.1,R-HSA-1912422,Pre-NOTCH Expression and Processing,M011,2,0
1,1,0,-2.3,-2.1,0,GO:0006140,regulation of nucleotide metabolic process,M110,2,0
1,1,0,-2.3,-2.6,0,GO:0002830,positive regulation of type 2 immune response,M110,2,0
1,0,1,-2.7,0,-2.2,GO:0062042,regulation of cardiac epithelial to mesenchymal transition,M101,2,0
1,1,0,-2.3,-2.2,0,WP314,Fas ligand pathway and stress induction of heat shock proteins,M110,2,0
1,0,1,-2.3,0,-2.2,GO:0061081,positive regulation of myeloid leukocyte cytokine production involved in immune response,M101,2,0
0,1,1,0,-8,-4.5,GO:0048858,cell projection morphogenesis,M011,2,0
0,1,1,0,-2.1,-2.2,GO:0010922,positive regulation of phosphatase activity,M011,2,0
1,1,0,-2.3,-2.8,0,R-HSA-418597,G alpha (z) signalling events,M110,2,0
1,0,1,-2.8,0,-2.5,GO:0030513,positive regulation of BMP signaling pathway,M101,2,0
1,1,0,-2.8,-2.2,0,GO:0090183,regulation of kidney development,M110,2,0
1,0,1,-3.3,0,-2.8,GO:0001708,cell fate specification,M101,2,0
1,1,0,-2.3,-2.6,0,R-HSA-163359,Glucagon signaling in metabolic regulation,M110,2,0
1,0,1,-4.3,0,-2.2,GO:0007623,circadian rhythm,M101,2,0
1,0,1,-3,0,-3.5,R-HSA-9680350,Signaling by CSF1 (M-CSF) in myeloid cells,M101,2,0
1,0,1,-2.1,0,-2.1,WP3971,OSX and miRNAs in tooth development,M101,2,0
0,1,1,0,-2.2,-3.8,M34,PID TCR PATHWAY,M011,2,0
0,1,1,0,-5.7,-2.3,GO:0009101,glycoprotein biosynthetic process,M011,2,0
0,1,1,0,-3.5,-3.2,R-HSA-446728,Cell junction organization,M011,2,0
0,1,1,0,-2.1,-3.1,GO:0060100,"positive regulation of phagocytosis, engulfment",M011,2,0
1,1,0,-2.3,-2.2,0,GO:0006110,regulation of glycolytic process,M110,2,0
1,1,0,-4,-4.1,0,WP3646,Hepatitis C and hepatocellular carcinoma,M110,2,0
1,1,0,-2.4,-2.3,0,GO:0045055,regulated exocytosis,M110,2,0
0,1,1,0,-2.5,-4,GO:0034764,positive regulation of transmembrane transport,M011,2,0
1,1,0,-2.6,-2.4,0,WP2895,Differentiation of white and brown adipocyte,M110,2,0
0,0,1,0,0,-2.1,GO:0046629,gamma-delta T cell activation,M001,1,0
0,1,0,0,-3.1,0,GO:0060644,mammary gland epithelial cell differentiation,M010,1,0
1,0,0,-2.6,0,0,GO:0061008,hepaticobiliary system development,M100,1,0
0,1,0,0,-2.4,0,GO:0044772,mitotic cell cycle phase transition,M010,1,0
0,1,0,0,-2.8,0,GO:0008217,regulation of blood pressure,M010,1,0
0,0,1,0,0,-2.5,GO:0010959,regulation of metal ion transport,M001,1,0
1,0,0,-2.3,0,0,GO:0003184,pulmonary valve morphogenesis,M100,1,0
0,0,1,0,0,-2.6,GO:0051964,negative regulation of synapse assembly,M001,1,0
0,0,1,0,0,-4.6,GO:0043549,regulation of kinase activity,M001,1,0
1,0,0,-2.9,0,0,GO:0045685,regulation of glial cell differentiation,M100,1,0
1,0,0,-2.1,0,0,GO:0006953,acute-phase response,M100,1,0
1,0,0,-4,0,0,GO:0009267,cellular response to starvation,M100,1,0
1,0,0,-2.2,0,0,GO:0030010,establishment of cell polarity,M100,1,0
1,0,0,-2.8,0,0,R-HSA-4420097,VEGFA-VEGFR2 Pathway,M100,1,0
1,0,0,-2.8,0,0,GO:0051783,regulation of nuclear division,M100,1,0
0,0,1,0,0,-2.6,GO:0060363,cranial suture morphogenesis,M001,1,0
1,0,0,-2.2,0,0,CORUM:3045,hs4 enhancer complex (faster migrating complex),M100,1,0
1,0,0,-2.7,0,0,GO:0043153,entrainment of circadian clock by photoperiod,M100,1,0
1,0,0,-2.1,0,0,GO:0003407,neural retina development,M100,1,0
0,1,0,0,-2.9,0,R-HSA-373760,L1CAM interactions,M010,1,0
1,0,0,-2.8,0,0,GO:1990823,response to leukemia inhibitory factor,M100,1,0
0,0,1,0,0,-2.4,GO:0045197,establishment or maintenance of epithelial cell apical/basal polarity,M001,1,0
0,1,0,0,-2.6,0,hsa04960,Aldosterone-regulated sodium reabsorption,M010,1,0
0,0,1,0,0,-3.5,GO:0031349,positive regulation of defense response,M001,1,0
0,0,1,0,0,-2.5,GO:0015849,organic acid transport,M001,1,0
0,1,0,0,-2.5,0,GO:0031333,negative regulation of protein-containing complex assembly,M010,1,0
1,0,0,-2.6,0,0,WP5202,Alstrom syndrome,M100,1,0
0,0,1,0,0,-3.2,GO:0034765,regulation of monoatomic ion transmembrane transport,M001,1,0
0,0,1,0,0,-2.2,GO:0030178,negative regulation of Wnt signaling pathway,M001,1,0
1,0,0,-2.9,0,0,GO:0019080,viral gene expression,M100,1,0
1,0,0,-2,0,0,GO:0071470,cellular response to osmotic stress,M100,1,0
1,0,0,-2.3,0,0,GO:0090322,regulation of superoxide metabolic process,M100,1,0
1,0,0,-2.6,0,0,GO:0001942,hair follicle development,M100,1,0
0,1,0,0,-2.6,0,GO:0002223,stimulatory C-type lectin receptor signaling pathway,M010,1,0
1,0,0,-3.6,0,0,GO:0090130,tissue migration,M100,1,0
1,0,0,-2.9,0,0,GO:0002377,immunoglobulin production,M100,1,0
1,0,0,-2.5,0,0,GO:0060043,regulation of cardiac muscle cell proliferation,M100,1,0
1,0,0,-2.5,0,0,GO:0072171,mesonephric tubule morphogenesis,M100,1,0
0,0,1,0,0,-2.6,GO:0032763,regulation of mast cell cytokine production,M001,1,0
0,1,0,0,-2.7,0,R-HSA-6806834,Signaling by MET,M010,1,0
1,0,0,-2,0,0,GO:2000677,regulation of transcription regulatory region DNA binding,M100,1,0
1,0,0,-2.3,0,0,hsa04924,Renin secretion,M100,1,0
1,0,0,-2,0,0,WP3617,Photodynamic therapy induced NF kB survival signaling,M100,1,0
0,0,1,0,0,-4,GO:0090287,regulation of cellular response to growth factor stimulus,M001,1,0
0,0,1,0,0,-2.9,WP5362,TAR syndrome,M001,1,0
0,1,0,0,-2.1,0,R-HSA-392518,Signal amplification,M010,1,0
1,0,0,-2,0,0,M101,PID HDAC CLASSI PATHWAY,M100,1,0
0,1,0,0,-2.4,0,GO:0072126,positive regulation of glomerular mesangial cell proliferation,M010,1,0
0,1,0,0,-6.5,0,GO:0032989,cellular anatomical entity morphogenesis,M010,1,0
0,1,0,0,-3.2,0,GO:1903510,mucopolysaccharide metabolic process,M010,1,0
1,0,0,-3,0,0,R-HSA-168164,Toll Like Receptor 3 (TLR3) Cascade,M100,1,0
1,0,0,-3.1,0,0,GO:0003198,epithelial to mesenchymal transition involved in endocardial cushion formation,M100,1,0
0,1,0,0,-2.3,0,GO:0048678,response to axon injury,M010,1,0
0,0,1,0,0,-2.3,GO:0001504,neurotransmitter uptake,M001,1,0
0,1,0,0,-4,0,GO:0071241,cellular response to inorganic substance,M010,1,0
0,0,1,0,0,-2.5,GO:0007189,adenylate cyclase-activating G protein-coupled receptor signaling pathway,M001,1,0
0,1,0,0,-2.1,0,GO:0010508,positive regulation of autophagy,M010,1,0
0,1,0,0,-2.8,0,GO:0044331,cell-cell adhesion mediated by cadherin,M010,1,0
1,0,0,-2.1,0,0,R-HSA-389356,CD28 co-stimulation,M100,1,0
1,0,0,-2.1,0,0,GO:0035329,hippo signaling,M100,1,0
0,0,1,0,0,-3,GO:0044089,positive regulation of cellular component biogenesis,M001,1,0
0,1,0,0,-2.1,0,GO:0030540,female genitalia development,M010,1,0
0,0,1,0,0,-2.2,GO:0034391,regulation of smooth muscle cell apoptotic process,M001,1,0
1,0,0,-2.1,0,0,R-HSA-9660821,ADORA2B mediated anti-inflammatory cytokines production,M100,1,0
0,1,0,0,-2.1,0,GO:0071312,cellular response to alkaloid,M010,1,0
0,1,0,0,-2.7,0,hsa05130,Pathogenic Escherichia coli infection,M010,1,0
0,1,0,0,-5.5,0,hsa05322,Systemic lupus erythematosus,M010,1,0
1,0,0,-2.1,0,0,GO:0072182,regulation of nephron tubule epithelial cell differentiation,M100,1,0
1,0,0,-2.1,0,0,GO:0050873,brown fat cell differentiation,M100,1,0
1,0,0,-2.2,0,0,WP4876,Activation of NLRP3 inflammasome by SARS CoV 2,M100,1,0
1,0,0,-2.2,0,0,GO:0046015,regulation of transcription by glucose,M100,1,0
1,0,0,-2.1,0,0,GO:0006305,DNA alkylation,M100,1,0
0,1,0,0,-2.4,0,GO:0006883,intracellular sodium ion homeostasis,M010,1,0
0,0,1,0,0,-2.5,GO:0003298,physiological muscle hypertrophy,M001,1,0
1,0,0,-2.6,0,0,R-HSA-5607763,CLEC7A (Dectin-1) induces NFAT activation,M100,1,0
0,1,0,0,-2.9,0,GO:0006027,glycosaminoglycan catabolic process,M010,1,0
0,0,1,0,0,-2.2,hsa04014,Ras signaling pathway,M001,1,0
0,0,1,0,0,-5.9,GO:0040017,positive regulation of locomotion,M001,1,0
0,1,0,0,-2.1,0,R-HSA-2022928,HS-GAG biosynthesis,M010,1,0
0,0,1,0,0,-2.2,GO:0015718,monocarboxylic acid transport,M001,1,0
1,0,0,-2.5,0,0,GO:0048146,positive regulation of fibroblast proliferation,M100,1,0
0,0,1,0,0,-2.5,GO:0061049,cell growth involved in cardiac muscle cell development,M001,1,0
1,0,0,-3.2,0,0,R-HSA-450282,MAPK targets/ Nuclear events mediated by MAP kinases,M100,1,0
1,0,0,-2.1,0,0,GO:0034381,plasma lipoprotein particle clearance,M100,1,0
0,0,1,0,0,-5,GO:0001934,positive regulation of protein phosphorylation,M001,1,0
0,1,0,0,-2.8,0,GO:0021879,forebrain neuron differentiation,M010,1,0
0,1,0,0,-3.2,0,WP4336,ncRNAs involved in Wnt signaling in hepatocellular carcinoma,M010,1,0
0,1,0,0,-4.3,0,GO:0002399,MHC class II protein complex assembly,M010,1,0
0,1,0,0,-2.2,0,R-HSA-4411364,Binding of TCF/LEF:CTNNB1 to target gene promoters,M010,1,0
1,0,0,-2.2,0,0,GO:0048664,neuron fate determination,M100,1,0
1,0,0,-2.9,0,0,GO:0043280,positive regulation of cysteine-type endopeptidase activity involved in apoptotic process,M100,1,0
0,0,1,0,0,-2.6,WP3630,NAD metabolism sirtuins and aging,M001,1,0
0,0,1,0,0,-3.3,R-HSA-9013423,RAC3 GTPase cycle,M001,1,0
1,0,0,-2.3,0,0,GO:0010906,regulation of glucose metabolic process,M100,1,0
0,0,1,0,0,-2.3,hsa04270,Vascular smooth muscle contraction,M001,1,0
0,0,1,0,0,-2.2,GO:0071498,cellular response to fluid shear stress,M001,1,0
1,0,0,-2.9,0,0,GO:0045923,positive regulation of fatty acid metabolic process,M100,1,0
0,1,0,0,-2.2,0,R-HSA-9702518,STAT5 activation downstream of FLT3 ITD mutants,M010,1,0
0,1,0,0,-2.1,0,M12,PID RHOA PATHWAY,M010,1,0
1,0,0,-2.9,0,0,WP4535,Envelope proteins and their potential roles in EDMD physiopathology,M100,1,0
1,0,0,-2.1,0,0,M23,PID WNT NONCANONICAL PATHWAY,M100,1,0
1,0,0,-3,0,0,GO:1903707,negative regulation of hemopoiesis,M100,1,0
0,0,1,0,0,-2.2,GO:2000679,positive regulation of transcription regulatory region DNA binding,M001,1,0
0,1,0,0,-2.9,0,GO:0002438,acute inflammatory response to antigenic stimulus,M010,1,0
0,1,0,0,-2.2,0,GO:0006026,aminoglycan catabolic process,M010,1,0
1,0,0,-2.3,0,0,GO:0060563,neuroepithelial cell differentiation,M100,1,0
0,1,0,0,-2.5,0,GO:0035303,regulation of dephosphorylation,M010,1,0
0,1,0,0,-3.6,0,hsa05330,Allograft rejection,M010,1,0
0,1,0,0,-2.6,0,GO:0033673,negative regulation of kinase activity,M010,1,0
0,0,1,0,0,-2.5,GO:0099172,presynapse organization,M001,1,0
0,1,0,0,-2.5,0,GO:0002687,positive regulation of leukocyte migration,M010,1,0
0,1,0,0,-4.1,0,hsa04723,Retrograde endocannabinoid signaling,M010,1,0
1,0,0,-2.8,0,0,WP1591,Heart development,M100,1,0
0,1,0,0,-2.8,0,R-HSA-977443,GABA receptor activation,M010,1,0
0,1,0,0,-2.1,0,hsa00534,Glycosaminoglycan biosynthesis - heparan sulfate / heparin,M010,1,0
1,0,0,-4.2,0,0,M145,PID P53 DOWNSTREAM PATHWAY,M100,1,0
0,1,0,0,-2.2,0,GO:0021532,neural tube patterning,M010,1,0
0,1,0,0,-2.2,0,GO:0031016,pancreas development,M010,1,0
1,0,0,-2.8,0,0,GO:0043124,negative regulation of canonical NF-kappaB signal transduction,M100,1,0
0,0,1,0,0,-2.2,GO:0051092,positive regulation of NF-kappaB transcription factor activity,M001,1,0
1,0,0,-2.4,0,0,M270,PID MAPK TRK PATHWAY,M100,1,0
0,0,1,0,0,-2.8,R-HSA-373752,Netrin-1 signaling,M001,1,0
0,0,1,0,0,-2.1,GO:0035994,response to muscle stretch,M001,1,0
1,0,0,-3.1,0,0,GO:0002200,somatic diversification of immune receptors,M100,1,0
0,1,0,0,-2.4,0,GO:0010572,positive regulation of platelet activation,M010,1,0
0,0,1,0,0,-4.5,GO:0030029,actin filament-based process,M001,1,0
1,0,0,-3.4,0,0,GO:0001816,cytokine production,M100,1,0
0,0,1,0,0,-3,GO:0045936,negative regulation of phosphate metabolic process,M001,1,0
1,0,0,-2.8,0,0,GO:0022405,hair cycle process,M100,1,0
1,0,0,-2.2,0,0,GO:0010573,vascular endothelial growth factor production,M100,1,0
1,0,0,-2.6,0,0,WP4925,Unfolded protein response,M100,1,0
1,0,0,-2.4,0,0,GO:1901570,fatty acid derivative biosynthetic process,M100,1,0
1,0,0,-4,0,0,GO:0032732,positive regulation of interleukin-1 production,M100,1,0
0,0,1,0,0,-2.2,R-HSA-1855204,Synthesis of IP3 and IP4 in the cytosol,M001,1,0
1,0,0,-2.8,0,0,GO:0051588,regulation of neurotransmitter transport,M100,1,0
1,0,0,-2.5,0,0,M254,PID MYC REPRESS PATHWAY,M100,1,0
1,0,0,-2.8,0,0,hsa04621,NOD-like receptor signaling pathway,M100,1,0
0,1,0,0,-2.1,0,GO:0060291,long-term synaptic potentiation,M010,1,0
0,1,0,0,-3.3,0,GO:0048167,regulation of synaptic plasticity,M010,1,0
1,0,0,-2.9,0,0,R-HSA-9634597,GPER1 signaling,M100,1,0
0,1,0,0,-2.4,0,GO:0014910,regulation of smooth muscle cell migration,M010,1,0
0,0,1,0,0,-2.8,GO:0045089,positive regulation of innate immune response,M001,1,0
0,1,0,0,-2.4,0,GO:2001185,"regulation of CD8-positive, alpha-beta T cell activation",M010,1,0
0,1,0,0,-2.1,0,GO:0071346,cellular response to type II interferon,M010,1,0
0,1,0,0,-2,0,WP5348,11p11 2 copy number variation syndrome,M010,1,0
1,0,0,-2.6,0,0,GO:0009799,specification of symmetry,M100,1,0
1,0,0,-2.8,0,0,GO:0061384,heart trabecula morphogenesis,M100,1,0
0,1,0,0,-2.2,0,R-HSA-9703465,Signaling by FLT3 fusion proteins,M010,1,0
1,0,0,-2.2,0,0,GO:0021529,spinal cord oligodendrocyte cell differentiation,M100,1,0
0,1,0,0,-2.2,0,GO:0019370,leukotriene biosynthetic process,M010,1,0
0,1,0,0,-2.2,0,WP5216,Warburg effect modulated by deubiquitinating enzymes and their substrates,M010,1,0
1,0,0,-2,0,0,GO:0042490,mechanoreceptor differentiation,M100,1,0
1,0,0,-2.3,0,0,R-HSA-844456,The NLRP3 inflammasome,M100,1,0
1,0,0,-2.4,0,0,M278,PID RAC1 PATHWAY,M100,1,0
0,1,0,0,-2.1,0,GO:0071480,cellular response to gamma radiation,M010,1,0
1,0,0,-2.3,0,0,GO:0051785,positive regulation of nuclear division,M100,1,0
1,0,0,-2.2,0,0,GO:0061626,pharyngeal arch artery morphogenesis,M100,1,0
1,0,0,-2.5,0,0,GO:0060976,coronary vasculature development,M100,1,0
1,0,0,-2,0,0,GO:0060045,positive regulation of cardiac muscle cell proliferation,M100,1,0
0,0,1,0,0,-3.4,WP4205,MET in type 1 papillary renal cell carcinoma,M001,1,0
0,0,1,0,0,-3.7,GO:0071805,potassium ion transmembrane transport,M001,1,0
0,1,0,0,-2.8,0,GO:0034332,adherens junction organization,M010,1,0
0,1,0,0,-2.1,0,R-HSA-913709,O-linked glycosylation of mucins,M010,1,0
0,0,1,0,0,-2.7,GO:0003012,muscle system process,M001,1,0
0,0,1,0,0,-2.3,GO:0015748,organophosphate ester transport,M001,1,0
1,0,0,-3.1,0,0,WP4396,Nonalcoholic fatty liver disease,M100,1,0
0,1,0,0,-2.4,0,GO:0051414,response to cortisol,M010,1,0
1,0,0,-2.1,0,0,GO:1905063,regulation of vascular associated smooth muscle cell differentiation,M100,1,0
1,0,0,-3,0,0,GO:0009953,dorsal/ventral pattern formation,M100,1,0
1,0,0,-2.1,0,0,GO:0060444,branching involved in mammary gland duct morphogenesis,M100,1,0
1,0,0,-3,0,0,M223,PID BETA CATENIN NUC PATHWAY,M100,1,0
1,0,0,-3.5,0,0,GO:0062009,secondary palate development,M100,1,0
0,1,0,0,-2.8,0,GO:0050806,positive regulation of synaptic transmission,M010,1,0
0,1,0,0,-2.8,0,R-HSA-1793185,Chondroitin sulfate/dermatan sulfate metabolism,M010,1,0
0,1,0,0,-3.5,0,R-HSA-2559582,Senescence-Associated Secretory Phenotype (SASP),M010,1,0
1,0,0,-3.8,0,0,GO:0021602,cranial nerve morphogenesis,M100,1,0
0,0,1,0,0,-2.1,GO:1901888,regulation of cell junction assembly,M001,1,0
0,0,1,0,0,-2.5,WP3947,Serotonin and anxiety,M001,1,0
0,1,0,0,-2.5,0,R-HSA-202430,Translocation of ZAP-70 to Immunological synapse,M010,1,0
0,0,1,0,0,-3.2,R-HSA-9664407,Parasite infection,M001,1,0
0,0,1,0,0,-2.3,WP4746,Thyroid hormones production and peripheral downstream signaling effects,M001,1,0
1,0,0,-2.1,0,0,GO:0042698,ovulation cycle,M100,1,0
0,1,0,0,-3.5,0,GO:0002501,peptide antigen assembly with MHC protein complex,M010,1,0
1,0,0,-2.2,0,0,R-HSA-210500,Glutamate Neurotransmitter Release Cycle,M100,1,0
0,1,0,0,-2.1,0,R-HSA-2022870,Chondroitin sulfate biosynthesis,M010,1,0
1,0,0,-2.2,0,0,GO:0009214,cyclic nucleotide catabolic process,M100,1,0
1,0,0,-2,0,0,GO:2000351,regulation of endothelial cell apoptotic process,M100,1,0
1,0,0,-2.3,0,0,GO:0009299,mRNA transcription,M100,1,0
1,0,0,-2.2,0,0,GO:0046533,negative regulation of photoreceptor cell differentiation,M100,1,0
0,0,1,0,0,-2.4,GO:0071347,cellular response to interleukin-1,M001,1,0
0,1,0,0,-2.2,0,R-HSA-9703648,Signaling by FLT3 ITD and TKD mutants,M010,1,0
0,1,0,0,-2.2,0,GO:0010907,positive regulation of glucose metabolic process,M010,1,0
1,0,0,-3.4,0,0,GO:0060251,regulation of glial cell proliferation,M100,1,0
1,0,0,-2.6,0,0,GO:1902930,regulation of alcohol biosynthetic process,M100,1,0
0,1,0,0,-2.1,0,GO:1902931,negative regulation of alcohol biosynthetic process,M010,1,0
1,0,0,-2.6,0,0,GO:0033623,regulation of integrin activation,M100,1,0
1,0,0,-2.1,0,0,GO:1903306,negative regulation of regulated secretory pathway,M100,1,0
0,0,1,0,0,-2.2,R-HSA-2029482,Regulation of actin dynamics for phagocytic cup formation,M001,1,0
1,0,0,-3.1,0,0,GO:0048485,sympathetic nervous system development,M100,1,0
0,0,1,0,0,-2.1,GO:1905145,cellular response to acetylcholine,M001,1,0
0,1,0,0,-2.9,0,GO:0070100,negative regulation of chemokine-mediated signaling pathway,M010,1,0
0,0,1,0,0,-2.2,GO:0007632,visual behavior,M001,1,0
0,0,1,0,0,-2.6,GO:0038113,interleukin-9-mediated signaling pathway,M001,1,0
1,0,0,-2.9,0,0,GO:0032479,regulation of type I interferon production,M100,1,0
1,0,0,-3.5,0,0,GO:0021542,dentate gyrus development,M100,1,0
1,0,0,-2.2,0,0,R-HSA-425393,Transport of inorganic cations/anions and amino acids/oligopeptides,M100,1,0
1,0,0,-2.8,0,0,GO:0071453,cellular response to oxygen levels,M100,1,0
1,0,0,-2.3,0,0,GO:0036075,replacement ossification,M100,1,0
1,0,0,-2.3,0,0,GO:1901201,regulation of extracellular matrix assembly,M100,1,0
0,0,1,0,0,-2.6,GO:0097094,craniofacial suture morphogenesis,M001,1,0
0,1,0,0,-2.2,0,WP1991,SRF and miRs in smooth muscle differentiation and proliferation,M010,1,0
1,0,0,-2.6,0,0,R-HSA-6811438,Intra-Golgi traffic,M100,1,0
0,0,1,0,0,-2.1,GO:0090023,positive regulation of neutrophil chemotaxis,M001,1,0
0,0,1,0,0,-2.6,GO:0072103,glomerulus vasculature morphogenesis,M001,1,0
0,1,0,0,-2.4,0,GO:0009449,gamma-aminobutyric acid biosynthetic process,M010,1,0
1,0,0,-2.9,0,0,GO:1902337,regulation of apoptotic process involved in morphogenesis,M100,1,0
1,0,0,-2.3,0,0,hsa04520,Adherens junction,M100,1,0
1,0,0,-4.1,0,0,GO:0007229,integrin-mediated signaling pathway,M100,1,0
0,1,0,0,-2.9,0,M214,PID ERBB1 INTERNALIZATION PATHWAY,M010,1,0
0,1,0,0,-2.2,0,GO:0097475,motor neuron migration,M010,1,0
0,0,1,0,0,-2.5,GO:0046942,carboxylic acid transport,M001,1,0
0,1,0,0,-2.1,0,GO:0002076,osteoblast development,M010,1,0
0,0,1,0,0,-3.4,GO:0001503,ossification,M001,1,0
0,0,1,0,0,-2.8,GO:0045648,positive regulation of erythrocyte differentiation,M001,1,0
0,0,1,0,0,-3,GO:0060193,positive regulation of lipase activity,M001,1,0
1,0,0,-2.6,0,0,GO:1901983,regulation of protein acetylation,M100,1,0
1,0,0,-2.5,0,0,GO:0003094,glomerular filtration,M100,1,0
0,1,0,0,-2.4,0,GO:0097264,self proteolysis,M010,1,0
1,0,0,-2.1,0,0,GO:0007622,rhythmic behavior,M100,1,0
1,0,0,-2.3,0,0,WP2880,Glucocorticoid receptor pathway,M100,1,0
1,0,0,-2.9,0,0,R-HSA-3108232,SUMO E3 ligases SUMOylate target proteins,M100,1,0
1,0,0,-2.8,0,0,GO:0002040,sprouting angiogenesis,M100,1,0
0,1,0,0,-3.5,0,GO:0048662,negative regulation of smooth muscle cell proliferation,M010,1,0
0,1,0,0,-2.4,0,GO:0050886,endocrine process,M010,1,0
1,0,0,-2.8,0,0,R-HSA-450294,MAP kinase activation,M100,1,0
0,1,0,0,-2.4,0,GO:0002437,inflammatory response to antigenic stimulus,M010,1,0
1,0,0,-3.2,0,0,GO:0043281,regulation of cysteine-type endopeptidase activity involved in apoptotic process,M100,1,0
0,0,1,0,0,-2.6,GO:0055013,cardiac muscle cell development,M001,1,0
0,1,0,0,-2.1,0,WP5113,Antiviral and anti inflammatory effects of Nrf2 on SARS CoV 2 pathway,M010,1,0
0,0,1,0,0,-3.1,R-HSA-8941856,RUNX3 regulates NOTCH signaling,M001,1,0
1,0,0,-2.3,0,0,GO:0040014,regulation of multicellular organism growth,M100,1,0
0,0,1,0,0,-2.5,GO:0060986,endocrine hormone secretion,M001,1,0
0,1,0,0,-2.4,0,GO:0035924,cellular response to vascular endothelial growth factor stimulus,M010,1,0
0,0,1,0,0,-2.6,GO:0097120,receptor localization to synapse,M001,1,0
0,1,0,0,-3.5,0,GO:0030890,positive regulation of B cell proliferation,M010,1,0
1,0,0,-2.9,0,0,GO:0034198,cellular response to amino acid starvation,M100,1,0
1,0,0,-2.2,0,0,R-HSA-3304356,SMAD2/3 Phosphorylation Motif Mutants in Cancer,M100,1,0
1,0,0,-2,0,0,WP4534,Mechanoregulation and pathology of YAP TAZ via Hippo and non Hippo mechanisms,M100,1,0
1,0,0,-2.4,0,0,GO:0048486,parasympathetic nervous system development,M100,1,0
0,0,1,0,0,-2.6,GO:1905331,negative regulation of morphogenesis of an epithelium,M001,1,0
0,1,0,0,-2.1,0,R-HSA-991365,Activation of GABAB receptors,M010,1,0
0,0,1,0,0,-2.5,GO:0008038,neuron recognition,M001,1,0
1,0,0,-2.3,0,0,WP2855,Dopaminergic neurogenesis,M100,1,0
1,0,0,-2,0,0,GO:0060252,positive regulation of glial cell proliferation,M100,1,0
0,0,1,0,0,-2.5,GO:0055007,cardiac muscle cell differentiation,M001,1,0
1,0,0,-3.8,0,0,hsa04710,Circadian rhythm,M100,1,0
1,0,0,-2,0,0,GO:0014812,muscle cell migration,M100,1,0
1,0,0,-3.5,0,0,GO:0060841,venous blood vessel development,M100,1,0
0,1,0,0,-3.2,0,R-HSA-2132295,MHC class II antigen presentation,M010,1,0
0,0,1,0,0,-2.5,GO:0051279,regulation of release of sequestered calcium ion into cytosol,M001,1,0
0,0,1,0,0,-6,GO:0120035,regulation of plasma membrane bounded cell projection organization,M001,1,0
1,0,0,-2.3,0,0,GO:0046928,regulation of neurotransmitter secretion,M100,1,0
1,0,0,-2.9,0,0,GO:0021783,preganglionic parasympathetic fiber development,M100,1,0
1,0,0,-2,0,0,GO:0042908,xenobiotic transport,M100,1,0
1,0,0,-2.7,0,0,GO:0071402,cellular response to lipoprotein particle stimulus,M100,1,0
1,0,0,-2.8,0,0,WP3680,Physico chemical features and toxicity associated pathways,M100,1,0
0,1,0,0,-2.3,0,GO:0110110,positive regulation of animal organ morphogenesis,M010,1,0
0,1,0,0,-3.2,0,GO:0045807,positive regulation of endocytosis,M010,1,0
0,1,0,0,-2.1,0,M113,PID NFAT 3PATHWAY,M010,1,0
1,0,0,-3.2,0,0,GO:0055090,acylglycerol homeostasis,M100,1,0
1,0,0,-2.3,0,0,GO:0043301,negative regulation of leukocyte degranulation,M100,1,0
1,0,0,-2.6,0,0,GO:0071634,regulation of transforming growth factor beta production,M100,1,0
0,0,1,0,0,-2.7,GO:0042092,type 2 immune response,M001,1,0
0,1,0,0,-3.1,0,WP2817,Mammary gland development pathway Pregnancy and lactation Stage 3 of 4,M010,1,0
1,0,0,-2.6,0,0,GO:0007595,lactation,M100,1,0
0,1,0,0,-2.8,0,GO:0006023,aminoglycan biosynthetic process,M010,1,0
0,1,0,0,-2.8,0,hsa04216,Ferroptosis,M010,1,0
1,0,0,-2.8,0,0,GO:0002028,regulation of sodium ion transport,M100,1,0
1,0,0,-3.2,0,0,GO:0042594,response to starvation,M100,1,0
1,0,0,-2.1,0,0,GO:0060039,pericardium development,M100,1,0
0,1,0,0,-2.4,0,GO:0006486,protein glycosylation,M010,1,0
1,0,0,-3.5,0,0,M71,PID ILK PATHWAY,M100,1,0
0,1,0,0,-2.3,0,GO:1903670,regulation of sprouting angiogenesis,M010,1,0
0,0,1,0,0,-4.1,GO:0010975,regulation of neuron projection development,M001,1,0
1,0,0,-2.6,0,0,R-HSA-451927,Interleukin-2 family signaling,M100,1,0
1,0,0,-2.8,0,0,GO:0001937,negative regulation of endothelial cell proliferation,M100,1,0
0,0,1,0,0,-2.5,GO:0007265,Ras protein signal transduction,M001,1,0
0,0,1,0,0,-2.5,GO:0003301,physiological cardiac muscle hypertrophy,M001,1,0
1,0,0,-2.6,0,0,WP2870,Extracellular vesicle mediated signaling in recipient cells,M100,1,0
1,0,0,-2.1,0,0,R-HSA-909733,Interferon alpha/beta signaling,M100,1,0
0,1,0,0,-2.4,0,GO:0043378,"positive regulation of CD8-positive, alpha-beta T cell differentiation",M010,1,0
1,0,0,-2.3,0,0,R-HSA-8864260,Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors,M100,1,0
0,1,0,0,-2.6,0,GO:1903671,negative regulation of sprouting angiogenesis,M010,1,0
1,0,0,-2.2,0,0,GO:0001714,endodermal cell fate specification,M100,1,0
1,0,0,-3.9,0,0,GO:0036303,lymph vessel morphogenesis,M100,1,0
1,0,0,-2.3,0,0,GO:0016311,dephosphorylation,M100,1,0
0,1,0,0,-2.4,0,GO:0045446,endothelial cell differentiation,M010,1,0
1,0,0,-3.1,0,0,M47,PID INTEGRIN CS PATHWAY,M100,1,0
1,0,0,-2.2,0,0,GO:0042886,amide transport,M100,1,0
0,0,1,0,0,-2.6,R-HSA-2197563,NOTCH2 intracellular domain regulates transcription,M001,1,0
0,0,1,0,0,-3.8,GO:0021801,cerebral cortex radial glia-guided migration,M001,1,0
0,1,0,0,-3.3,0,GO:0001779,natural killer cell differentiation,M010,1,0
0,1,0,0,-3.5,0,GO:0002396,MHC protein complex assembly,M010,1,0
1,0,0,-2.3,0,0,GO:2001054,negative regulation of mesenchymal cell apoptotic process,M100,1,0
1,0,0,-2.3,0,0,GO:0060038,cardiac muscle cell proliferation,M100,1,0
1,0,0,-2.8,0,0,GO:0002052,positive regulation of neuroblast proliferation,M100,1,0
1,0,0,-3.9,0,0,R-HSA-111933,Calmodulin induced events,M100,1,0
0,1,0,0,-3.6,0,R-HSA-1630316,Glycosaminoglycan metabolism,M010,1,0
0,1,0,0,-2.1,0,GO:0071364,cellular response to epidermal growth factor stimulus,M010,1,0
0,0,1,0,0,-3,GO:0010563,negative regulation of phosphorus metabolic process,M001,1,0
1,0,0,-2.1,0,0,GO:0045995,regulation of embryonic development,M100,1,0
0,1,0,0,-2.1,0,GO:0051017,actin filament bundle assembly,M010,1,0
1,0,0,-2.2,0,0,R-HSA-2730905,Role of LAT2/NTAL/LAB on calcium mobilization,M100,1,0
0,1,0,0,-2.9,0,GO:0002548,monocyte chemotaxis,M010,1,0
1,0,0,-2.5,0,0,GO:0016445,somatic diversification of immunoglobulins,M100,1,0
0,1,0,0,-2.8,0,hsa04742,Taste transduction,M010,1,0
0,1,0,0,-2.5,0,GO:0035094,response to nicotine,M010,1,0
0,1,0,0,-2.4,0,GO:1903580,positive regulation of ATP metabolic process,M010,1,0
0,1,0,0,-2.5,0,R-HSA-6794361,Neurexins and neuroligins,M010,1,0
1,0,0,-2.1,0,0,GO:0061548,ganglion development,M100,1,0
0,1,0,0,-2.8,0,GO:0002714,positive regulation of B cell mediated immunity,M010,1,0
1,0,0,-2.7,0,0,GO:0002562,somatic diversification of immune receptors via germline recombination within a single locus,M100,1,0
0,0,1,0,0,-2.4,GO:0071229,cellular response to acid chemical,M001,1,0
0,0,1,0,0,-2.5,R-HSA-164952,The role of Nef in HIV-1 replication and disease pathogenesis,M001,1,0
0,1,0,0,-2.1,0,GO:0071676,negative regulation of mononuclear cell migration,M010,1,0
0,0,1,0,0,-3.8,GO:0022030,telencephalon glial cell migration,M001,1,0
1,0,0,-2.3,0,0,GO:0061326,renal tubule development,M100,1,0
0,0,1,0,0,-2.6,GO:0008347,glial cell migration,M001,1,0
0,1,0,0,-2.1,0,GO:0043666,regulation of phosphoprotein phosphatase activity,M010,1,0
1,0,0,-2.5,0,0,GO:2000136,regulation of cell proliferation involved in heart morphogenesis,M100,1,0
0,0,1,0,0,-5.5,GO:2000147,positive regulation of cell motility,M001,1,0
1,0,0,-2.1,0,0,GO:0016447,somatic recombination of immunoglobulin gene segments,M100,1,0
0,0,1,0,0,-3.5,GO:0098662,inorganic cation transmembrane transport,M001,1,0
1,0,0,-2.3,0,0,GO:2001014,regulation of skeletal muscle cell differentiation,M100,1,0
1,0,0,-2.1,0,0,GO:0002042,cell migration involved in sprouting angiogenesis,M100,1,0
0,1,0,0,-2.1,0,WP117,GPCRs other,M010,1,0
1,0,0,-2.6,0,0,GO:0043388,positive regulation of DNA binding,M100,1,0
1,0,0,-2.3,0,0,GO:0043537,negative regulation of blood vessel endothelial cell migration,M100,1,0
1,0,0,-2.1,0,0,GO:0042417,dopamine metabolic process,M100,1,0
1,0,0,-2.3,0,0,GO:0045103,intermediate filament-based process,M100,1,0
1,0,0,-2.9,0,0,GO:1904748,regulation of apoptotic process involved in development,M100,1,0
1,0,0,-2.1,0,0,GO:0033003,regulation of mast cell activation,M100,1,0
0,0,1,0,0,-2.4,GO:0006911,"phagocytosis, engulfment",M001,1,0
1,0,0,-2.4,0,0,GO:0042633,hair cycle,M100,1,0
0,0,1,0,0,-4.7,GO:0043068,positive regulation of programmed cell death,M001,1,0
0,1,0,0,-3.1,0,hsa05320,Autoimmune thyroid disease,M010,1,0
0,0,1,0,0,-2.3,GO:1902905,positive regulation of supramolecular fiber organization,M001,1,0
0,0,1,0,0,-4,GO:0042330,taxis,M001,1,0
0,1,0,0,-2.1,0,M5493,WNT SIGNALING,M010,1,0
1,0,0,-2.4,0,0,WP3413,NOTCH1 regulation of endothelial cell calcification,M100,1,0
1,0,0,-2.3,0,0,GO:0046889,positive regulation of lipid biosynthetic process,M100,1,0
1,0,0,-2.3,0,0,R-HSA-5362517,Signaling by Retinoic Acid,M100,1,0
0,1,0,0,-2.2,0,GO:1904031,positive regulation of cyclin-dependent protein kinase activity,M010,1,0
1,0,0,-3.1,0,0,GO:0035264,multicellular organism growth,M100,1,0
0,1,0,0,-2.1,0,GO:0061572,actin filament bundle organization,M010,1,0
0,0,1,0,0,-3.4,GO:0032970,regulation of actin filament-based process,M001,1,0
1,0,0,-3.9,0,0,R-HSA-111997,CaM pathway,M100,1,0
0,0,1,0,0,-5,GO:0043410,positive regulation of MAPK cascade,M001,1,0
1,0,0,-2,0,0,GO:0010614,negative regulation of cardiac muscle hypertrophy,M100,1,0
1,0,0,-2.5,0,0,GO:0010575,positive regulation of vascular endothelial growth factor production,M100,1,0
0,0,1,0,0,-2.7,GO:0009615,response to virus,M001,1,0
1,0,0,-3,0,0,GO:0007440,foregut morphogenesis,M100,1,0
0,1,0,0,-2.1,0,GO:0030201,heparan sulfate proteoglycan metabolic process,M010,1,0
0,0,1,0,0,-2.2,WP5033,Genes associated with the development of rheumatoid arthritis,M001,1,0
1,0,0,-2.3,0,0,GO:0045104,intermediate filament cytoskeleton organization,M100,1,0
0,1,0,0,-2.5,0,WP4760,PKC gamma calcium signaling pathway in ataxia,M010,1,0
1,0,0,-2.9,0,0,hsa04931,Insulin resistance,M100,1,0
0,1,0,0,-2.1,0,GO:0070570,regulation of neuron projection regeneration,M010,1,0
0,1,0,0,-5,0,GO:0051592,response to calcium ion,M010,1,0
0,1,0,0,-2.8,0,R-HSA-1236394,Signaling by ERBB4,M010,1,0
1,0,0,-2.5,0,0,GO:0003222,ventricular trabecula myocardium morphogenesis,M100,1,0
0,1,0,0,-2.8,0,GO:0006024,glycosaminoglycan biosynthetic process,M010,1,0
1,0,0,-2.5,0,0,WP5158,Urotensin II mediated signaling pathway,M100,1,0
0,0,1,0,0,-2.8,GO:0010469,regulation of signaling receptor activity,M001,1,0
0,0,1,0,0,-3,GO:0043547,positive regulation of GTPase activity,M001,1,0
1,0,0,-2.5,0,0,M274,PID LYMPH ANGIOGENESIS PATHWAY,M100,1,0
0,1,0,0,-3.9,0,GO:0071248,cellular response to metal ion,M010,1,0
0,1,0,0,-2,0,GO:0008306,associative learning,M010,1,0
1,0,0,-3.1,0,0,WP2586,Aryl hydrocarbon receptor pathway,M100,1,0
0,0,1,0,0,-2.6,GO:0045064,T-helper 2 cell differentiation,M001,1,0
1,0,0,-2.2,0,0,GO:0051133,regulation of NK T cell activation,M100,1,0
0,1,0,0,-2.1,0,GO:0044770,cell cycle phase transition,M010,1,0
0,0,1,0,0,-2.8,GO:0070542,response to fatty acid,M001,1,0
1,0,0,-4.5,0,0,GO:0009952,anterior/posterior pattern specification,M100,1,0
1,0,0,-2.7,0,0,WP299,Nuclear receptors in lipid metabolism and toxicity,M100,1,0
0,0,1,0,0,-2.2,R-HSA-9671555,Signaling by PDGFR in disease,M001,1,0
0,1,0,0,-2.1,0,GO:0001562,response to protozoan,M010,1,0
1,0,0,-2.5,0,0,GO:0007398,ectoderm development,M100,1,0
1,0,0,-2.1,0,0,R-HSA-9634638,Estrogen-dependent nuclear events downstream of ESR-membrane signaling,M100,1,0
0,0,1,0,0,-2.6,R-HSA-9673770,Signaling by PDGFRA extracellular domain mutants,M001,1,0
0,0,1,0,0,-2.6,R-HSA-9673767,"Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants",M001,1,0
1,0,0,-3.8,0,0,WP4241,Type 2 papillary renal cell carcinoma,M100,1,0
1,0,0,-2.3,0,0,GO:1904672,regulation of somatic stem cell population maintenance,M100,1,0
1,0,0,-2.5,0,0,GO:0046683,response to organophosphorus,M100,1,0
0,1,0,0,-3,0,GO:0006029,proteoglycan metabolic process,M010,1,0
1,0,0,-2.7,0,0,GO:0055094,response to lipoprotein particle,M100,1,0
0,1,0,0,-2.3,0,M53,PID INTEGRIN3 PATHWAY,M010,1,0
0,1,0,0,-2.4,0,GO:0031099,regeneration,M010,1,0
1,0,0,-2.4,0,0,GO:0060384,innervation,M100,1,0
1,0,0,-3.9,0,0,GO:0048806,genitalia development,M100,1,0
1,0,0,-2.6,0,0,GO:0060560,developmental growth involved in morphogenesis,M100,1,0
1,0,0,-3.1,0,0,GO:0048546,digestive tract morphogenesis,M100,1,0
0,1,0,0,-2.3,0,GO:0014911,positive regulation of smooth muscle cell migration,M010,1,0
0,0,1,0,0,-2.6,GO:0035470,positive regulation of vascular wound healing,M001,1,0
0,1,0,0,-2.1,0,R-HSA-977444,GABA B receptor activation,M010,1,0
1,0,0,-2.3,0,0,WP2263,Androgen receptor network in prostate cancer,M100,1,0
0,1,0,0,-2.1,0,R-HSA-202424,Downstream TCR signaling,M010,1,0
1,0,0,-3.4,0,0,hsa05133,Pertussis,M100,1,0
0,0,1,0,0,-2.1,GO:0030324,lung development,M001,1,0
1,0,0,-2,0,0,M197,PID HIV NEF PATHWAY,M100,1,0
0,0,1,0,0,-3.2,R-HSA-9664417,Leishmania phagocytosis,M001,1,0
1,0,0,-2,0,0,M161,PID IFNG PATHWAY,M100,1,0
0,1,0,0,-3.8,0,GO:0048002,antigen processing and presentation of peptide antigen,M010,1,0
1,0,0,-3.1,0,0,GO:0070167,regulation of biomineral tissue development,M100,1,0
0,0,1,0,0,-3.9,GO:0042692,muscle cell differentiation,M001,1,0
1,0,0,-3.8,0,0,WP2332,Interleukin 11 signaling pathway,M100,1,0
1,0,0,-2.7,0,0,GO:0006584,catecholamine metabolic process,M100,1,0
0,1,0,0,-2.1,0,WP5284,Cell interactions of the pancreatic cancer microenvironment,M010,1,0
1,0,0,-2.3,0,0,hsa05230,Central carbon metabolism in cancer,M100,1,0
1,0,0,-2.3,0,0,GO:0006633,fatty acid biosynthetic process,M100,1,0
1,0,0,-2.3,0,0,WP4206,Hereditary leiomyomatosis and renal cell carcinoma pathway,M100,1,0
0,1,0,0,-4.6,0,GO:0019886,antigen processing and presentation of exogenous peptide antigen via MHC class II,M010,1,0
0,1,0,0,-2.1,0,GO:0036336,dendritic cell migration,M010,1,0
1,0,0,-2.8,0,0,hsa04925,Aldosterone synthesis and secretion,M100,1,0
0,1,0,0,-2.3,0,GO:0035725,sodium ion transmembrane transport,M010,1,0
0,1,0,0,-2.1,0,GO:0010828,positive regulation of glucose transmembrane transport,M010,1,0
1,0,0,-2.2,0,0,GO:0001570,vasculogenesis,M100,1,0
0,1,0,0,-3.5,0,GO:0002444,myeloid leukocyte mediated immunity,M010,1,0
0,1,0,0,-2.1,0,GO:0070849,response to epidermal growth factor,M010,1,0
0,0,1,0,0,-2.3,GO:0015909,long-chain fatty acid transport,M001,1,0
0,0,1,0,0,-2.3,GO:0034767,positive regulation of monoatomic ion transmembrane transport,M001,1,0
0,1,0,0,-3.5,0,R-HSA-195721,Signaling by WNT,M010,1,0
0,0,1,0,0,-2.1,GO:0071624,positive regulation of granulocyte chemotaxis,M001,1,0
0,0,1,0,0,-3.1,R-HSA-9679506,SARS-CoV Infections,M001,1,0
0,1,0,0,-2.4,0,GO:0097012,response to granulocyte macrophage colony-stimulating factor,M010,1,0
0,1,0,0,-8.8,0,GO:0031175,neuron projection development,M010,1,0
0,1,0,0,-2.1,0,GO:0032656,regulation of interleukin-13 production,M010,1,0
0,0,1,0,0,-3,R-HSA-1296071,Potassium Channels,M001,1,0
1,0,0,-2.5,0,0,WP391,Mitochondrial gene expression,M100,1,0
1,0,0,-2,0,0,GO:0030518,intracellular steroid hormone receptor signaling pathway,M100,1,0
0,1,0,0,-3.2,0,GO:0002275,myeloid cell activation involved in immune response,M010,1,0
0,1,0,0,-2.4,0,GO:0071415,cellular response to purine-containing compound,M010,1,0
0,1,0,0,-3.1,0,GO:1903035,negative regulation of response to wounding,M010,1,0
0,1,0,0,-2.4,0,R-HSA-8939245,RUNX1 regulates transcription of genes involved in BCR signaling,M010,1,0
1,0,0,-2.1,0,0,GO:2000696,regulation of epithelial cell differentiation involved in kidney development,M100,1,0
1,0,0,-4.1,0,0,GO:0007492,endoderm development,M100,1,0
0,1,0,0,-4.1,0,GO:0003073,regulation of systemic arterial blood pressure,M010,1,0
1,0,0,-2.2,0,0,GO:0072011,glomerular endothelium development,M100,1,0
0,0,1,0,0,-2.6,CORUM:2536,PLC-gamma-2-SLP-76-Lyn-Grb2 complex,M001,1,0
0,1,0,0,-4.1,0,GO:0030203,glycosaminoglycan metabolic process,M010,1,0
0,0,1,0,0,-2.6,WP3877,MYD88 distinct input output pathway,M001,1,0
0,1,0,0,-3.6,0,GO:0051489,regulation of filopodium assembly,M010,1,0
1,0,0,-2.6,0,0,M233,PID EPO PATHWAY,M100,1,0
1,0,0,-3.3,0,0,R-HSA-194138,Signaling by VEGF,M100,1,0
0,1,0,0,-2.1,0,hsa04913,Ovarian steroidogenesis,M010,1,0
0,0,1,0,0,-2.5,GO:0043383,negative T cell selection,M001,1,0
0,1,0,0,-2.1,0,GO:0032272,negative regulation of protein polymerization,M010,1,0
0,1,0,0,-2.2,0,GO:0070672,response to interleukin-15,M010,1,0
0,1,0,0,-2.6,0,GO:0007613,memory,M010,1,0
0,0,1,0,0,-2.6,R-HSA-170660,Adenylate cyclase activating pathway,M001,1,0
0,1,0,0,-2.7,0,R-HSA-418555,G alpha (s) signalling events,M010,1,0
1,0,0,-2.1,0,0,GO:0061005,cell differentiation involved in kidney development,M100,1,0
1,0,0,-2.6,0,0,GO:0001914,regulation of T cell mediated cytotoxicity,M100,1,0
0,0,1,0,0,-2.6,GO:0034114,regulation of heterotypic cell-cell adhesion,M001,1,0
1,0,0,-2.3,0,0,GO:0019935,cyclic-nucleotide-mediated signaling,M100,1,0
1,0,0,-2.2,0,0,R-HSA-3656534,Loss of Function of TGFBR1 in Cancer,M100,1,0
1,0,0,-3.4,0,0,GO:0045687,positive regulation of glial cell differentiation,M100,1,0
0,1,0,0,-2.2,0,GO:0007494,midgut development,M010,1,0
1,0,0,-3.8,0,0,GO:0010631,epithelial cell migration,M100,1,0
0,0,1,0,0,-2.6,GO:0019082,viral protein processing,M001,1,0
0,1,0,0,-2.4,0,WP5395,Glycosaminoglycan synthesis in fibroblasts,M010,1,0
1,0,0,-2.7,0,0,WP408,Oxidative stress response,M100,1,0
0,0,1,0,0,-2.2,GO:0031589,cell-substrate adhesion,M001,1,0
1,0,0,-2.8,0,0,GO:0007249,canonical NF-kappaB signal transduction,M100,1,0
0,0,1,0,0,-2.1,R-HSA-75892,Platelet Adhesion to exposed collagen,M001,1,0
0,1,0,0,-2.5,0,R-HSA-525793,Myogenesis,M010,1,0
0,0,1,0,0,-2.3,R-HSA-422356,Regulation of insulin secretion,M001,1,0
1,0,0,-2,0,0,R-HSA-2173788,Downregulation of TGF-beta receptor signaling,M100,1,0
1,0,0,-2.3,0,0,GO:0032570,response to progesterone,M100,1,0
0,0,1,0,0,-2.1,GO:1903426,regulation of reactive oxygen species biosynthetic process,M001,1,0
0,1,0,0,-2,0,WP4313,Ferroptosis,M010,1,0
0,0,1,0,0,-2.3,R-HSA-3769402,Deactivation of the beta-catenin transactivating complex,M001,1,0
1,0,0,-2.2,0,0,GO:0046532,regulation of photoreceptor cell differentiation,M100,1,0
0,0,1,0,0,-2.2,GO:0071466,cellular response to xenobiotic stimulus,M001,1,0
0,1,0,0,-2.2,0,R-HSA-8983432,Interleukin-15 signaling,M010,1,0
0,0,1,0,0,-3.8,GO:0072102,glomerulus morphogenesis,M001,1,0
1,0,0,-2.8,0,0,hsa04657,IL-17 signaling pathway,M100,1,0
0,1,0,0,-4.3,0,GO:0070099,regulation of chemokine-mediated signaling pathway,M010,1,0
1,0,0,-2.9,0,0,GO:0060977,coronary vasculature morphogenesis,M100,1,0
0,0,1,0,0,-2.7,GO:0006869,lipid transport,M001,1,0
1,0,0,-4.4,0,0,GO:0032922,circadian regulation of gene expression,M100,1,0
0,0,1,0,0,-4.2,GO:0042060,wound healing,M001,1,0
1,0,0,-2.3,0,0,GO:0070169,positive regulation of biomineral tissue development,M100,1,0
0,0,1,0,0,-2.6,GO:0035771,interleukin-4-mediated signaling pathway,M001,1,0
1,0,0,-2,0,0,GO:0060113,inner ear receptor cell differentiation,M100,1,0
1,0,0,-3,0,0,GO:0019933,cAMP-mediated signaling,M100,1,0
1,0,0,-3.1,0,0,GO:0060993,kidney morphogenesis,M100,1,0
0,0,1,0,0,-2.2,GO:1903169,regulation of calcium ion transmembrane transport,M001,1,0
0,1,0,0,-2.1,0,GO:0046320,regulation of fatty acid oxidation,M010,1,0
0,1,0,0,-2.2,0,WP2637,Interleukin 1 IL 1 structural pathway,M010,1,0
1,0,0,-3.2,0,0,M48,PID MET PATHWAY,M100,1,0
0,0,1,0,0,-2.1,GO:0006874,intracellular calcium ion homeostasis,M001,1,0
0,1,0,0,-2.2,0,GO:0046640,regulation of alpha-beta T cell proliferation,M010,1,0
0,0,1,0,0,-2.7,GO:0042326,negative regulation of phosphorylation,M001,1,0
0,0,1,0,0,-2.6,GO:0051127,positive regulation of actin nucleation,M001,1,0
0,0,1,0,0,-2.4,R-HSA-3781865,Diseases of glycosylation,M001,1,0
1,0,0,-2.1,0,0,GO:0042789,mRNA transcription by RNA polymerase II,M100,1,0
1,0,0,-2.9,0,0,GO:0032495,response to muramyl dipeptide,M100,1,0
0,0,1,0,0,-2.5,GO:0071230,cellular response to amino acid stimulus,M001,1,0
0,0,1,0,0,-2.5,GO:1905809,negative regulation of synapse organization,M001,1,0
1,0,0,-3.5,0,0,GO:0003179,heart valve morphogenesis,M100,1,0
0,0,1,0,0,-2.2,R-HSA-5576891,Cardiac conduction,M001,1,0
1,0,0,-3.1,0,0,GO:0032930,positive regulation of superoxide anion generation,M100,1,0
0,1,0,0,-2.2,0,GO:0070228,regulation of lymphocyte apoptotic process,M010,1,0
1,0,0,-3.5,0,0,hsa04670,Leukocyte transendothelial migration,M100,1,0
0,0,1,0,0,-3.8,GO:0042391,regulation of membrane potential,M001,1,0
1,0,0,-3.3,0,0,GO:0021545,cranial nerve development,M100,1,0
0,0,1,0,0,-2.1,GO:0060216,definitive hemopoiesis,M001,1,0
0,1,0,0,-3.5,0,hsa04917,Prolactin signaling pathway,M010,1,0
0,0,1,0,0,-6.3,GO:0044057,regulation of system process,M001,1,0
0,0,1,0,0,-2.1,GO:0045063,T-helper 1 cell differentiation,M001,1,0
1,0,0,-2.6,0,0,WP5397,Vitamin A1 and A5 X pathways,M100,1,0
0,1,0,0,-4.9,0,GO:0032535,regulation of cellular component size,M010,1,0
0,0,1,0,0,-2.1,R-HSA-975576,N-glycan antennae elongation in the medial/trans-Golgi,M001,1,0
0,0,1,0,0,-3.2,R-HSA-1368082,RORA activates gene expression,M001,1,0
0,1,0,0,-3.8,0,GO:0016358,dendrite development,M010,1,0
0,1,0,0,-2.4,0,GO:0045059,positive thymic T cell selection,M010,1,0
0,0,1,0,0,-2.2,R-HSA-9013695,NOTCH4 Intracellular Domain Regulates Transcription,M001,1,0
0,1,0,0,-4.6,0,GO:0002504,antigen processing and presentation of peptide or polysaccharide antigen via MHC class II,M010,1,0
0,1,0,0,-2.2,0,GO:2000515,"negative regulation of CD4-positive, alpha-beta T cell activation",M010,1,0
0,1,0,0,-2.2,0,R-HSA-8941855,RUNX3 regulates CDKN1A transcription,M010,1,0
1,0,0,-4.1,0,0,GO:0009913,epidermal cell differentiation,M100,1,0
0,0,1,0,0,-3.6,GO:0032869,cellular response to insulin stimulus,M001,1,0
1,0,0,-2.5,0,0,WP1982,Sterol regulatory element binding proteins SREBP signaling,M100,1,0
0,1,0,0,-2.8,0,GO:0002891,positive regulation of immunoglobulin mediated immune response,M010,1,0
0,1,0,0,-2,0,WP2261,Glioblastoma signaling pathways,M010,1,0
0,1,0,0,-2.2,0,GO:1901724,positive regulation of cell proliferation involved in kidney development,M010,1,0
0,0,1,0,0,-2.1,GO:0043584,nose development,M001,1,0
0,1,0,0,-2.6,0,GO:0046660,female sex differentiation,M010,1,0
0,0,1,0,0,-6.1,GO:0051336,regulation of hydrolase activity,M001,1,0
0,0,1,0,0,-2.1,GO:0060259,regulation of feeding behavior,M001,1,0
1,0,0,-2.6,0,0,WP1433,Nucleotide binding oligomerization domain NOD pathway,M100,1,0
0,1,0,0,-2.9,0,M55,PID S1P S1P3 PATHWAY,M010,1,0
0,1,0,0,-2.6,0,GO:0036037,"CD8-positive, alpha-beta T cell activation",M010,1,0
0,0,1,0,0,-3.1,hsa04610,Complement and coagulation cascades,M001,1,0
0,0,1,0,0,-2.2,WP5420,ADHD and Autism ASD linked metabolic pathways and SNP,M001,1,0
1,0,0,-3,0,0,GO:0030858,positive regulation of epithelial cell differentiation,M100,1,0
1,0,0,-2.8,0,0,GO:0022404,molting cycle process,M100,1,0
0,0,1,0,0,-2.1,GO:2000311,regulation of AMPA receptor activity,M001,1,0
0,0,1,0,0,-2.9,WP61,Notch signaling pathway,M001,1,0
0,0,1,0,0,-2.5,GO:0043270,positive regulation of monoatomic ion transport,M001,1,0
0,1,0,0,-2.5,0,GO:0060586,multicellular organismal-level iron ion homeostasis,M010,1,0
1,0,0,-2.9,0,0,WP3850,Factors and pathways affecting insulin like growth factor IGF1 Akt signaling,M100,1,0
0,0,1,0,0,-2.2,GO:1902624,positive regulation of neutrophil migration,M001,1,0
0,1,0,0,-2.1,0,GO:0032355,response to estradiol,M010,1,0
1,0,0,-2.9,0,0,GO:0002440,production of molecular mediator of immune response,M100,1,0
1,0,0,-2.5,0,0,WP4565,Neural crest cell migration in cancer,M100,1,0
0,0,1,0,0,-2.6,GO:1904893,negative regulation of receptor signaling pathway via STAT,M001,1,0
0,0,1,0,0,-4.5,GO:0043408,regulation of MAPK cascade,M001,1,0
1,0,0,-3,0,0,GO:1901222,regulation of non-canonical NF-kappaB signal transduction,M100,1,0
1,0,0,-2.3,0,0,GO:0021610,facial nerve morphogenesis,M100,1,0
0,1,0,0,-2.1,0,GO:0002360,T cell lineage commitment,M010,1,0
1,0,0,-3.1,0,0,GO:0009649,entrainment of circadian clock,M100,1,0
0,1,0,0,-2.2,0,WP5063,FOXP3 in COVID 19,M010,1,0
0,0,1,0,0,-2.1,GO:0015908,fatty acid transport,M001,1,0
0,1,0,0,-2.1,0,GO:0043032,positive regulation of macrophage activation,M010,1,0
1,0,0,-2.9,0,0,R-HSA-9619665,EGR2 and SOX10-mediated initiation of Schwann cell myelination,M100,1,0
1,0,0,-2.6,0,0,GO:1990830,cellular response to leukemia inhibitory factor,M100,1,0
0,0,1,0,0,-2.4,GO:0031334,positive regulation of protein-containing complex assembly,M001,1,0
0,0,1,0,0,-2.2,GO:0006816,calcium ion transport,M001,1,0
1,0,0,-2,0,0,GO:2000756,regulation of peptidyl-lysine acetylation,M100,1,0
0,1,0,0,-2,0,WP5039,SARS CoV 2 innate immunity evasion and cell specific immune response,M010,1,0
1,0,0,-2.4,0,0,GO:0022011,myelination in peripheral nervous system,M100,1,0
0,1,0,0,-3.6,0,GO:0002673,regulation of acute inflammatory response,M010,1,0
0,0,1,0,0,-2.5,GO:0017121,plasma membrane phospholipid scrambling,M001,1,0
1,0,0,-3.1,0,0,WP2435,Quercetin and Nf kB AP 1 induced apoptosis,M100,1,0
0,1,0,0,-2.3,0,GO:0045931,positive regulation of mitotic cell cycle,M010,1,0
1,0,0,-6.9,0,0,GO:1903530,regulation of secretion by cell,M100,1,0
1,0,0,-2.3,0,0,GO:0042733,embryonic digit morphogenesis,M100,1,0
1,0,0,-2.8,0,0,hsa05214,Glioma,M100,1,0
0,0,1,0,0,-2.1,GO:1900407,regulation of cellular response to oxidative stress,M001,1,0
0,0,1,0,0,-2.6,GO:0002833,positive regulation of response to biotic stimulus,M001,1,0
1,0,0,-2.6,0,0,GO:0042551,neuron maturation,M100,1,0
0,1,0,0,-2.4,0,GO:0043413,macromolecule glycosylation,M010,1,0
0,1,0,0,-2.1,0,GO:0032736,positive regulation of interleukin-13 production,M010,1,0
0,1,0,0,-2.5,0,M241,PID RAC1 REG PATHWAY,M010,1,0
0,1,0,0,-3.8,0,GO:0044706,multi-multicellular organism process,M010,1,0
1,0,0,-2.8,0,0,GO:0032648,regulation of interferon-beta production,M100,1,0
1,0,0,-3.1,0,0,GO:2000516,"positive regulation of CD4-positive, alpha-beta T cell activation",M100,1,0
1,0,0,-2.5,0,0,GO:0033627,cell adhesion mediated by integrin,M100,1,0
1,0,0,-2.3,0,0,GO:0048512,circadian behavior,M100,1,0
0,0,1,0,0,-2.1,GO:0072109,glomerular mesangium development,M001,1,0
1,0,0,-2,0,0,GO:0046879,hormone secretion,M100,1,0
1,0,0,-2.7,0,0,GO:0048771,tissue remodeling,M100,1,0
1,0,0,-4.9,0,0,GO:0021675,nerve development,M100,1,0
1,0,0,-2.1,0,0,GO:0048745,smooth muscle tissue development,M100,1,0
0,1,0,0,-5.1,0,hsa05323,Rheumatoid arthritis,M010,1,0
1,0,0,-2,0,0,R-HSA-5218859,Regulated Necrosis,M100,1,0
0,1,0,0,-2.8,0,GO:0002526,acute inflammatory response,M010,1,0
1,0,0,-2.2,0,0,GO:0097191,extrinsic apoptotic signaling pathway,M100,1,0
0,0,1,0,0,-2.5,hsa04740,Olfactory transduction,M001,1,0
1,0,0,-3,0,0,GO:0006887,exocytosis,M100,1,0
1,0,0,-2.2,0,0,R-HSA-111931,PKA-mediated phosphorylation of CREB,M100,1,0
1,0,0,-2.1,0,0,hsa04910,Insulin signaling pathway,M100,1,0
0,1,0,0,-2.9,0,GO:0061377,mammary gland lobule development,M010,1,0
1,0,0,-2,0,0,GO:0035886,vascular associated smooth muscle cell differentiation,M100,1,0
0,1,0,0,-2.4,0,GO:0007512,adult heart development,M010,1,0
1,0,0,-2.3,0,0,GO:0032088,negative regulation of NF-kappaB transcription factor activity,M100,1,0
0,1,0,0,-2.5,0,WP3287,Overview of nanoparticle effects,M010,1,0
1,0,0,-3.1,0,0,R-HSA-448424,Interleukin-17 signaling,M100,1,0
1,0,0,-2.4,0,0,GO:0090207,regulation of triglyceride metabolic process,M100,1,0
0,0,1,0,0,-2.4,GO:0035249,"synaptic transmission, glutamatergic",M001,1,0
1,0,0,-2.9,0,0,GO:0045834,positive regulation of lipid metabolic process,M100,1,0
1,0,0,-3,0,0,GO:0034113,heterotypic cell-cell adhesion,M100,1,0
0,1,0,0,-2.7,0,WP2864,Apoptosis related network due to altered Notch3 in ovarian cancer,M010,1,0
1,0,0,-3.5,0,0,GO:0042752,regulation of circadian rhythm,M100,1,0
1,0,0,-2.1,0,0,GO:0045840,positive regulation of mitotic nuclear division,M100,1,0
0,0,1,0,0,-2.5,WP4146,Macrophage markers,M001,1,0
1,0,0,-2.5,0,0,GO:0045655,regulation of monocyte differentiation,M100,1,0
0,0,1,0,0,-2.1,M193,PID NEPHRIN NEPH1 PATHWAY,M001,1,0
1,0,0,-2.5,0,0,GO:0048857,neural nucleus development,M100,1,0
1,0,0,-3.5,0,0,M5193,SIG CHEMOTAXIS,M100,1,0
1,0,0,-3.5,0,0,GO:0001975,response to amphetamine,M100,1,0
0,0,1,0,0,-2.3,GO:0071356,cellular response to tumor necrosis factor,M001,1,0
0,1,0,0,-2.2,0,GO:0035024,negative regulation of Rho protein signal transduction,M010,1,0
1,0,0,-3.2,0,0,GO:0070328,triglyceride homeostasis,M100,1,0
1,0,0,-2.3,0,0,WP4008,NO cGMP PKG mediated neuroprotection,M100,1,0
0,1,0,0,-4,0,GO:1901137,carbohydrate derivative biosynthetic process,M010,1,0
0,1,0,0,-2.8,0,hsa04512,ECM-receptor interaction,M010,1,0
1,0,0,-2.1,0,0,GO:0010039,response to iron ion,M100,1,0
1,0,0,-2.6,0,0,GO:0007088,regulation of mitotic nuclear division,M100,1,0
1,0,0,-2.5,0,0,R-HSA-111996,Ca-dependent events,M100,1,0
0,1,0,0,-4.3,0,GO:0002503,peptide antigen assembly with MHC class II protein complex,M010,1,0
0,1,0,0,-2.6,0,R-HSA-3858494,Beta-catenin independent WNT signaling,M010,1,0
0,0,1,0,0,-4.6,GO:0043065,positive regulation of apoptotic process,M001,1,0
0,0,1,0,0,-2.6,GO:0060710,chorio-allantoic fusion,M001,1,0
1,0,0,-2.3,0,0,GO:0060675,ureteric bud morphogenesis,M100,1,0
1,0,0,-2.5,0,0,WP4564,Neural crest cell migration during development,M100,1,0
0,1,0,0,-2.1,0,GO:0035023,regulation of Rho protein signal transduction,M010,1,0
1,0,0,-2.6,0,0,M286,PID TGFBR PATHWAY,M100,1,0
0,0,1,0,0,-3.3,hsa04976,Bile secretion,M001,1,0
0,0,1,0,0,-2.6,GO:0071732,cellular response to nitric oxide,M001,1,0
0,1,0,0,-2.8,0,GO:0048813,dendrite morphogenesis,M010,1,0
0,1,0,0,-2.2,0,WP3941,Oxidative damage response,M010,1,0
1,0,0,-6.3,0,0,GO:0001667,ameboidal-type cell migration,M100,1,0
0,0,1,0,0,-2.6,GO:0099601,regulation of neurotransmitter receptor activity,M001,1,0
0,1,0,0,-3.6,0,GO:0050673,epithelial cell proliferation,M010,1,0
1,0,0,-2,0,0,GO:0050919,negative chemotaxis,M100,1,0
0,0,1,0,0,-3.2,GO:0097242,amyloid-beta clearance,M001,1,0
0,0,1,0,0,-2.2,GO:0003015,heart process,M001,1,0
1,0,0,-2.5,0,0,GO:0048713,regulation of oligodendrocyte differentiation,M100,1,0
0,0,1,0,0,-2.1,R-HSA-3906995,Diseases associated with O-glycosylation of proteins,M001,1,0
0,0,1,0,0,-3.2,R-HSA-9664422,FCGR3A-mediated phagocytosis,M001,1,0
1,0,0,-2.8,0,0,GO:0031032,actomyosin structure organization,M100,1,0
0,1,0,0,-3,0,GO:0046578,regulation of Ras protein signal transduction,M010,1,0
1,0,0,-2,0,0,GO:1901224,positive regulation of non-canonical NF-kappaB signal transduction,M100,1,0
1,0,0,-2.3,0,0,GO:0014037,Schwann cell differentiation,M100,1,0
0,1,0,0,-2.9,0,GO:1900016,negative regulation of cytokine production involved in inflammatory response,M010,1,0
0,0,1,0,0,-2.1,GO:1904753,negative regulation of vascular associated smooth muscle cell migration,M001,1,0
0,1,0,0,-2.8,0,hsa04672,Intestinal immune network for IgA production,M010,1,0
0,1,0,0,-2.2,0,GO:0097553,calcium ion transmembrane import into cytosol,M010,1,0
1,0,0,-2.1,0,0,GO:0030539,male genitalia development,M100,1,0
1,0,0,-2.6,0,0,GO:1902106,negative regulation of leukocyte differentiation,M100,1,0
0,1,0,0,-3.2,0,GO:0002685,regulation of leukocyte migration,M010,1,0
0,0,1,0,0,-2.6,GO:0043951,negative regulation of cAMP-mediated signaling,M001,1,0
0,1,0,0,-2,0,R-HSA-8939902,Regulation of RUNX2 expression and activity,M010,1,0
0,0,1,0,0,-2.6,R-HSA-170670,Adenylate cyclase inhibitory pathway,M001,1,0
0,0,1,0,0,-2.7,WP5422,IL 19 signaling pathway map,M001,1,0
1,0,0,-2,0,0,GO:0010656,negative regulation of muscle cell apoptotic process,M100,1,0
0,1,0,0,-3.1,0,hsa04012,ErbB signaling pathway,M010,1,0
1,0,0,-2.5,0,0,WP4932,7q11 23 copy number variation syndrome,M100,1,0
0,1,0,0,-2.5,0,R-HSA-381676,Glucagon-like Peptide-1 (GLP1) regulates insulin secretion,M010,1,0
0,1,0,0,-2.5,0,GO:0010935,regulation of macrophage cytokine production,M010,1,0
0,1,0,0,-2.8,0,GO:2000401,regulation of lymphocyte migration,M010,1,0
0,0,1,0,0,-2.6,GO:0042989,sequestering of actin monomers,M001,1,0
0,0,1,0,0,-4.3,GO:0040011,locomotion,M001,1,0
1,0,0,-2.3,0,0,GO:0016322,neuron remodeling,M100,1,0
0,1,0,0,-2.4,0,WP3,Transcriptional activation by NRF2 in response to phytochemicals,M010,1,0
0,1,0,0,-2.1,0,GO:0045773,positive regulation of axon extension,M010,1,0
1,0,0,-2.3,0,0,hsa04918,Thyroid hormone synthesis,M100,1,0
0,0,1,0,0,-2.6,GO:0072104,glomerular capillary formation,M001,1,0
1,0,0,-2.1,0,0,R-HSA-9759194,Nuclear events mediated by NFE2L2,M100,1,0
0,1,0,0,-2.4,0,GO:0002863,positive regulation of inflammatory response to antigenic stimulus,M010,1,0
0,1,0,0,-2.4,0,GO:0016339,calcium-dependent cell-cell adhesion via plasma membrane cell adhesion molecules,M010,1,0
1,0,0,-2.2,0,0,GO:0043353,enucleate erythrocyte differentiation,M100,1,0
0,1,0,0,-2.4,0,GO:0014033,neural crest cell differentiation,M010,1,0
0,0,1,0,0,-2.8,WP5224,2q37 copy number variation syndrome,M001,1,0
1,0,0,-2.5,0,0,WP712,Estrogen signaling pathway,M100,1,0
0,1,0,0,-2.2,0,R-HSA-9761174,Formation of intermediate mesoderm,M010,1,0
1,0,0,-3.6,0,0,GO:0010565,regulation of cellular ketone metabolic process,M100,1,0
1,0,0,-2.2,0,0,GO:0061309,cardiac neural crest cell development involved in outflow tract morphogenesis,M100,1,0
0,1,0,0,-2.5,0,R-HSA-2559585,Oncogene Induced Senescence,M010,1,0
0,0,1,0,0,-7.7,GO:0061061,muscle structure development,M001,1,0
1,0,0,-2.1,0,0,hsa04722,Neurotrophin signaling pathway,M100,1,0
1,0,0,-2.3,0,0,R-HSA-2173789,TGF-beta receptor signaling activates SMADs,M100,1,0
0,1,0,0,-2.9,0,GO:0036230,granulocyte activation,M010,1,0
0,0,1,0,0,-2.5,M190,PID TCR JNK PATHWAY,M001,1,0
1,0,0,-7.2,0,0,GO:1902532,negative regulation of intracellular signal transduction,M100,1,0
0,1,0,0,-2.5,0,GO:0015012,heparan sulfate proteoglycan biosynthetic process,M010,1,0
1,0,0,-3.1,0,0,GO:0009648,photoperiodism,M100,1,0
0,1,0,0,-2.4,0,R-HSA-1638091,Heparan sulfate/heparin (HS-GAG) metabolism,M010,1,0
1,0,0,-2.8,0,0,WP5180,DYRK1A involvement regarding cell proliferation in brain development,M100,1,0
0,0,1,0,0,-3,GO:0055006,cardiac cell development,M001,1,0
0,1,0,0,-3.6,0,GO:0044703,multi-organism reproductive process,M010,1,0
0,0,1,0,0,-3.5,GO:0060828,regulation of canonical Wnt signaling pathway,M001,1,0
1,0,0,-3.1,0,0,R-HSA-2151201,Transcriptional activation of mitochondrial biogenesis,M100,1,0
1,0,0,-3.1,0,0,GO:0045601,regulation of endothelial cell differentiation,M100,1,0
1,0,0,-3.9,0,0,GO:0120163,negative regulation of cold-induced thermogenesis,M100,1,0
0,0,1,0,0,-2.1,R-HSA-1839117,Signaling by cytosolic FGFR1 fusion mutants,M001,1,0
1,0,0,-2.6,0,0,GO:0051099,positive regulation of binding,M100,1,0
0,0,1,0,0,-3.2,GO:0021799,cerebral cortex radially oriented cell migration,M001,1,0
1,0,0,-2.6,0,0,GO:0009855,determination of bilateral symmetry,M100,1,0
1,0,0,-2.1,0,0,GO:0071425,hematopoietic stem cell proliferation,M100,1,0
1,0,0,-2,0,0,GO:0010544,negative regulation of platelet activation,M100,1,0
0,1,0,0,-2.4,0,GO:0042492,gamma-delta T cell differentiation,M010,1,0
1,0,0,-5.2,0,0,WP5381,Smith Magenis and Potocki Lupski syndrome copy number variation,M100,1,0
1,0,0,-2.1,0,0,WP734,Serotonin receptor 4 6 7 and NR3C signaling,M100,1,0
0,1,0,0,-2.4,0,GO:0006469,negative regulation of protein kinase activity,M010,1,0
0,1,0,0,-2.1,0,M45,PID CD40 PATHWAY,M010,1,0
1,0,0,-2,0,0,WP1539,Angiogenesis,M100,1,0
1,0,0,-2.3,0,0,GO:0021561,facial nerve development,M100,1,0
0,1,0,0,-2.8,0,M68,PID RHOA REG PATHWAY,M010,1,0
0,1,0,0,-2.6,0,GO:1990840,response to lectin,M010,1,0
0,0,1,0,0,-2.5,GO:0090077,foam cell differentiation,M001,1,0
0,0,1,0,0,-2.3,WP4971,Phosphoinositides metabolism,M001,1,0
1,0,0,-2.7,0,0,GO:0001946,lymphangiogenesis,M100,1,0
1,0,0,-3.3,0,0,hsa04217,Necroptosis,M100,1,0
0,1,0,0,-2.2,0,GO:0007216,G protein-coupled glutamate receptor signaling pathway,M010,1,0
1,0,0,-2.3,0,0,hsa04623,Cytosolic DNA-sensing pathway,M100,1,0
0,0,1,0,0,-4,WP4823,Genes controlling nephrogenesis,M001,1,0
1,0,0,-2.4,0,0,GO:0042303,molting cycle,M100,1,0
0,0,1,0,0,-2.3,GO:0045577,regulation of B cell differentiation,M001,1,0
1,0,0,-2.6,0,0,R-HSA-8943724,Regulation of PTEN gene transcription,M100,1,0
0,1,0,0,-3.5,0,WP4258,lncRNA in canonical Wnt signaling and colorectal cancer,M010,1,0
1,0,0,-2.3,0,0,GO:0010743,regulation of macrophage derived foam cell differentiation,M100,1,0
1,0,0,-2.4,0,0,R-HSA-170834,Signaling by TGF-beta Receptor Complex,M100,1,0
0,0,1,0,0,-2.6,GO:0071499,cellular response to laminar fluid shear stress,M001,1,0
0,0,1,0,0,-2.1,GO:0018210,peptidyl-threonine modification,M001,1,0
1,0,0,-2.6,0,0,GO:0072010,glomerular epithelium development,M100,1,0
1,0,0,-2.4,0,0,GO:1990928,response to amino acid starvation,M100,1,0
0,0,1,0,0,-2.8,GO:0019827,stem cell population maintenance,M001,1,0
0,1,0,0,-2.9,0,M41,PID ER NONGENOMIC PATHWAY,M010,1,0
0,0,1,0,0,-2.6,GO:0048341,paraxial mesoderm formation,M001,1,0
0,1,0,0,-3,0,GO:0045216,cell-cell junction organization,M010,1,0
0,0,1,0,0,-2.3,WP49,IL 2 signaling pathway,M001,1,0
0,1,0,0,-2.9,0,GO:0060749,mammary gland alveolus development,M010,1,0
0,0,1,0,0,-3.5,R-HSA-194315,Signaling by Rho GTPases,M001,1,0
0,1,0,0,-2.4,0,GO:0002864,regulation of acute inflammatory response to antigenic stimulus,M010,1,0
0,1,0,0,-2.8,0,GO:0007612,learning,M010,1,0
0,0,1,0,0,-2.2,hsa00510,N-Glycan biosynthesis,M001,1,0
1,0,0,-2.7,0,0,GO:0071404,cellular response to low-density lipoprotein particle stimulus,M100,1,0
0,0,1,0,0,-5.7,GO:0042327,positive regulation of phosphorylation,M001,1,0
1,0,0,-4.7,0,0,GO:0043588,skin development,M100,1,0
1,0,0,-2.1,0,0,GO:0034103,regulation of tissue remodeling,M100,1,0
1,0,0,-2.2,0,0,R-HSA-3656532,TGFBR1 KD Mutants in Cancer,M100,1,0
0,1,0,0,-2.7,0,GO:0048534,hematopoietic or lymphoid organ development,M010,1,0
0,0,1,0,0,-2.5,M69,PID REELIN PATHWAY,M001,1,0
1,0,0,-2.9,0,0,R-HSA-400206,Regulation of lipid metabolism by PPARalpha,M100,1,0
0,1,0,0,-2.5,0,GO:0043299,leukocyte degranulation,M010,1,0
0,1,0,0,-2.1,0,R-HSA-3232118,SUMOylation of transcription factors,M010,1,0
0,0,1,0,0,-2.1,R-HSA-9013404,RAC2 GTPase cycle,M001,1,0
0,0,1,0,0,-2.1,WP364,IL6 signaling pathway,M001,1,0
1,0,0,-2.3,0,0,GO:0002715,regulation of natural killer cell mediated immunity,M100,1,0
0,0,1,0,0,-2.6,GO:0055001,muscle cell development,M001,1,0
1,0,0,-2.8,0,0,GO:0019217,regulation of fatty acid metabolic process,M100,1,0
0,0,1,0,0,-3.2,GO:0090092,regulation of transmembrane receptor protein serine/threonine kinase signaling pathway,M001,1,0
1,0,0,-2.2,0,0,GO:0071901,negative regulation of protein serine/threonine kinase activity,M100,1,0
0,0,1,0,0,-2.5,R-HSA-9013508,NOTCH3 Intracellular Domain Regulates Transcription,M001,1,0
0,1,0,0,-2.3,0,GO:0006879,intracellular iron ion homeostasis,M010,1,0
0,1,0,0,-2.5,0,GO:0001909,leukocyte mediated cytotoxicity,M010,1,0
0,1,0,0,-4.4,0,GO:0008360,regulation of cell shape,M010,1,0
0,1,0,0,-2.1,0,WP4875,Disruption of postsynaptic signaling by CNV,M010,1,0
0,1,0,0,-2.8,0,GO:0003044,regulation of systemic arterial blood pressure mediated by a chemical signal,M010,1,0
1,0,0,-2.6,0,0,WP138,Androgen receptor signaling pathway,M100,1,0
0,1,0,0,-2.1,0,hsa04068,FoxO signaling pathway,M010,1,0
0,0,1,0,0,-4,GO:0045859,regulation of protein kinase activity,M001,1,0
0,1,0,0,-4.9,0,WP2431,Spinal cord injury,M010,1,0
0,0,1,0,0,-2.2,GO:0010876,lipid localization,M001,1,0
0,1,0,0,-2.2,0,hsa04071,Sphingolipid signaling pathway,M010,1,0
0,0,1,0,0,-2.1,GO:0031998,regulation of fatty acid beta-oxidation,M001,1,0
0,1,0,0,-2.4,0,R-HSA-8934593,Regulation of RUNX1 Expression and Activity,M010,1,0
0,0,1,0,0,-2.1,R-HSA-5621575,CD209 (DC-SIGN) signaling,M001,1,0
0,0,1,0,0,-2.7,GO:0099560,synaptic membrane adhesion,M001,1,0
0,1,0,0,-2.1,0,GO:0051491,positive regulation of filopodium assembly,M010,1,0
1,0,0,-2.1,0,0,GO:0043525,positive regulation of neuron apoptotic process,M100,1,0
0,1,0,0,-6.7,0,R-HSA-372790,Signaling by GPCR,M010,1,0
1,0,0,-3.3,0,0,GO:0043372,"positive regulation of CD4-positive, alpha-beta T cell differentiation",M100,1,0
1,0,0,-2.5,0,0,WP430,Statin inhibition of cholesterol production,M100,1,0
1,0,0,-3.2,0,0,GO:0043534,blood vessel endothelial cell migration,M100,1,0
1,0,0,-5.8,0,0,GO:0031668,cellular response to extracellular stimulus,M100,1,0
0,0,1,0,0,-2.5,GO:0032507,maintenance of protein location in cell,M001,1,0
1,0,0,-2.4,0,0,GO:1905330,regulation of morphogenesis of an epithelium,M100,1,0
0,1,0,0,-2.4,0,GO:0002866,positive regulation of acute inflammatory response to antigenic stimulus,M010,1,0
0,0,1,0,0,-2.6,GO:0001574,ganglioside biosynthetic process,M001,1,0
0,1,0,0,-2.5,0,WP3981,miRNA regulation of prostate cancer signaling pathways,M010,1,0
1,0,0,-2.6,0,0,GO:0001974,blood vessel remodeling,M100,1,0
1,0,0,-5.5,0,0,GO:0031669,cellular response to nutrient levels,M100,1,0
0,1,0,0,-3.5,0,GO:0031331,positive regulation of cellular catabolic process,M010,1,0
0,1,0,0,-4.2,0,GO:0019884,antigen processing and presentation of exogenous antigen,M010,1,0
0,1,0,0,-2.2,0,GO:0072124,regulation of glomerular mesangial cell proliferation,M010,1,0
0,0,1,0,0,-4.2,GO:0008015,blood circulation,M001,1,0
1,0,0,-3.2,0,0,GO:0035270,endocrine system development,M100,1,0
0,1,0,0,-2.1,0,GO:0010921,regulation of phosphatase activity,M010,1,0
1,0,0,-2.6,0,0,GO:0033625,positive regulation of integrin activation,M100,1,0
0,0,1,0,0,-2.1,WP313,Hepatocyte growth factor receptor signaling,M001,1,0
1,0,0,-2.3,0,0,GO:0014741,negative regulation of muscle hypertrophy,M100,1,0
1,0,0,-3.4,0,0,GO:0035987,endodermal cell differentiation,M100,1,0
1,0,0,-3,0,0,GO:0001711,endodermal cell fate commitment,M100,1,0
1,0,0,-2.7,0,0,GO:0016444,somatic cell DNA recombination,M100,1,0
1,0,0,-2.2,0,0,R-HSA-1852241,Organelle biogenesis and maintenance,M100,1,0
1,0,0,-2.6,0,0,GO:0016045,detection of bacterium,M100,1,0
0,0,1,0,0,-3.8,GO:0050852,T cell receptor signaling pathway,M001,1,0
0,1,0,0,-2.2,0,M5880,NABA ECM AFFILIATED,M010,1,0
0,1,0,0,-2.7,0,GO:0043467,regulation of generation of precursor metabolites and energy,M010,1,0
0,1,0,0,-2.4,0,GO:0097011,cellular response to granulocyte macrophage colony-stimulating factor stimulus,M010,1,0
0,1,0,0,-2.5,0,R-HSA-8941326,RUNX2 regulates bone development,M010,1,0
0,1,0,0,-2.5,0,GO:0032816,positive regulation of natural killer cell activation,M010,1,0
0,0,1,0,0,-2.6,WP3845,Canonical and non canonical Notch signaling,M001,1,0
0,1,0,0,-2.1,0,hsa04061,Viral protein interaction with cytokine and cytokine receptor,M010,1,0
1,0,0,-2.2,0,0,GO:0046016,positive regulation of transcription by glucose,M100,1,0
0,1,0,0,-2.5,0,hsa05310,Asthma,M010,1,0
1,0,0,-3.5,0,0,R-HSA-8866910,TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,M100,1,0
1,0,0,-3.6,0,0,GO:0090132,epithelium migration,M100,1,0
1,0,0,-2.5,0,0,WP4842,Mammalian disorder of sexual development,M100,1,0
1,0,0,-2.7,0,0,GO:0009712,catechol-containing compound metabolic process,M100,1,0
0,0,1,0,0,-2.2,GO:1902882,regulation of response to oxidative stress,M001,1,0
1,0,0,-3.9,0,0,WP3298,Melatonin metabolism and effects,M100,1,0
0,0,1,0,0,-2.6,GO:0044241,lipid digestion,M001,1,0
0,0,1,0,0,-3.5,GO:0032868,response to insulin,M001,1,0
1,0,0,-2.3,0,0,GO:0030239,myofibril assembly,M100,1,0
0,1,0,0,-2.6,0,GO:1990858,cellular response to lectin,M010,1,0
1,0,0,-2,0,0,hsa05031,Amphetamine addiction,M100,1,0
0,1,0,0,-2.6,0,GO:0070085,glycosylation,M010,1,0
0,1,0,0,-2.1,0,GO:0002069,columnar/cuboidal epithelial cell maturation,M010,1,0
0,1,0,0,-3.8,0,GO:0006979,response to oxidative stress,M010,1,0
1,0,0,-2.8,0,0,GO:0007422,peripheral nervous system development,M100,1,0
0,0,1,0,0,-3.2,GO:0045088,regulation of innate immune response,M001,1,0
0,1,0,0,-2.1,0,GO:0032814,regulation of natural killer cell activation,M010,1,0
0,1,0,0,-2.2,0,GO:0002221,pattern recognition receptor signaling pathway,M010,1,0
1,0,0,-2.5,0,0,GO:0032928,regulation of superoxide anion generation,M100,1,0
0,1,0,0,-2.9,0,GO:0030214,hyaluronan catabolic process,M010,1,0
0,0,1,0,0,-2.6,GO:0070374,positive regulation of ERK1 and ERK2 cascade,M001,1,0
1,0,0,-2.6,0,0,GO:0010919,regulation of inositol phosphate biosynthetic process,M100,1,0
1,0,0,-2.8,0,0,GO:2001056,positive regulation of cysteine-type endopeptidase activity,M100,1,0
0,0,1,0,0,-2.6,GO:0061009,common bile duct development,M001,1,0
0,0,1,0,0,-4,GO:0006935,chemotaxis,M001,1,0
1,0,0,-5,0,0,GO:0008544,epidermis development,M100,1,0
1,0,0,-2.9,0,0,R-HSA-2990846,SUMOylation,M100,1,0
0,1,0,0,-3.5,0,GO:1902414,protein localization to cell junction,M010,1,0
1,0,0,-6.5,0,0,GO:0071496,cellular response to external stimulus,M100,1,0
1,0,0,-2.5,0,0,GO:0001916,positive regulation of T cell mediated cytotoxicity,M100,1,0
0,0,1,0,0,-3.2,CORUM:725,P2X7 receptor signalling complex,M001,1,0
1,0,0,-2.2,0,0,GO:0043568,positive regulation of insulin-like growth factor receptor signaling pathway,M100,1,0
0,1,0,0,-2.8,0,GO:0031076,embryonic camera-type eye development,M010,1,0
0,1,0,0,-2.4,0,GO:0006930,"substrate-dependent cell migration, cell extension",M010,1,0
1,0,0,-2.4,0,0,GO:0048715,negative regulation of oligodendrocyte differentiation,M100,1,0
0,1,0,0,-2.6,0,GO:0035641,locomotory exploration behavior,M010,1,0
0,1,0,0,-2.5,0,GO:0002088,lens development in camera-type eye,M010,1,0
1,0,0,-4.2,0,0,GO:0001706,endoderm formation,M100,1,0
1,0,0,-2.3,0,0,GO:0002823,negative regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains,M100,1,0
1,0,0,-2.3,0,0,GO:0001958,endochondral ossification,M100,1,0
0,1,0,0,-2.4,0,GO:0019882,antigen processing and presentation,M010,1,0
1,0,0,-2,0,0,GO:0061333,renal tubule morphogenesis,M100,1,0
0,0,1,0,0,-2.1,GO:0095500,acetylcholine receptor signaling pathway,M001,1,0
1,0,0,-2.8,0,0,hsa05030,Cocaine addiction,M100,1,0
1,0,0,-2,0,0,GO:0010762,regulation of fibroblast migration,M100,1,0
1,0,0,-2.3,0,0,GO:0010574,regulation of vascular endothelial growth factor production,M100,1,0
1,0,0,-2.5,0,0,GO:0097205,renal filtration,M100,1,0
0,1,0,0,-2.5,0,GO:0002220,innate immune response activating cell surface receptor signaling pathway,M010,1,0
1,0,0,-2.1,0,0,GO:0006306,DNA methylation,M100,1,0
0,0,1,0,0,-2.1,WP22,IL 9 signaling pathway,M001,1,0
0,0,1,0,0,-2.1,GO:0035855,megakaryocyte development,M001,1,0
0,0,1,0,0,-2.1,GO:2000191,regulation of fatty acid transport,M001,1,0
0,1,0,0,-2.8,0,GO:0030534,adult behavior,M010,1,0
0,1,0,0,-2.5,0,GO:0048675,axon extension,M010,1,0
1,0,0,-2.3,0,0,GO:0050869,negative regulation of B cell activation,M100,1,0
0,0,1,0,0,-2.6,GO:0060074,synapse maturation,M001,1,0
0,0,1,0,0,-2.6,GO:0071104,response to interleukin-9,M001,1,0
0,1,0,0,-2.8,0,hsa05213,Endometrial cancer,M010,1,0
0,0,1,0,0,-5.4,R-HSA-1296072,Voltage gated Potassium channels,M001,1,0
1,0,0,-2.6,0,0,GO:0048617,embryonic foregut morphogenesis,M100,1,0
0,1,0,0,-5.2,0,GO:0002478,antigen processing and presentation of exogenous peptide antigen,M010,1,0
1,0,0,-2.7,0,0,R-HSA-1989781,PPARA activates gene expression,M100,1,0
0,0,1,0,0,-2.1,WP5074,Kallmann syndrome,M001,1,0
1,0,0,-4.3,0,0,WP5322,CKAP4 signaling pathway map,M100,1,0
0,1,0,0,-3.5,0,WP673,ErbB signaling pathway,M010,1,0
1,0,0,-2.2,0,0,GO:0070666,regulation of mast cell proliferation,M100,1,0
0,0,1,0,0,-3.1,GO:0051146,striated muscle cell differentiation,M001,1,0
1,0,0,-2.3,0,0,WP4963,p53 transcriptional gene network,M100,1,0
0,0,1,0,0,-6,GO:0031344,regulation of cell projection organization,M001,1,0
1,0,0,-2.8,0,0,hsa05410,Hypertrophic cardiomyopathy,M100,1,0
0,1,0,0,-2.4,0,GO:0021800,cerebral cortex tangential migration,M010,1,0
1,0,0,-2.8,0,0,WP4298,Acute viral myocarditis,M100,1,0
0,0,1,0,0,-2.8,GO:0001933,negative regulation of protein phosphorylation,M001,1,0
0,0,1,0,0,-2.4,GO:1904064,positive regulation of cation transmembrane transport,M001,1,0
0,1,0,0,-3.5,0,M18,PID INTEGRIN1 PATHWAY,M010,1,0
1,0,0,-2.3,0,0,GO:0055002,striated muscle cell development,M100,1,0
1,0,0,-6.2,0,0,GO:0062012,regulation of small molecule metabolic process,M100,1,0
0,1,0,0,-4.6,0,GO:0002495,antigen processing and presentation of peptide antigen via MHC class II,M010,1,0
1,0,0,-2.5,0,0,R-HSA-8986944,Transcriptional Regulation by MECP2,M100,1,0
0,0,1,0,0,-2.5,GO:0010742,macrophage derived foam cell differentiation,M001,1,0
0,0,1,0,0,-2.3,GO:0051495,positive regulation of cytoskeleton organization,M001,1,0
0,0,1,0,0,-3.5,hsa04360,Axon guidance,M001,1,0
0,0,1,0,0,-2.6,GO:0071355,cellular response to interleukin-9,M001,1,0
0,0,1,0,0,-2,GO:0042742,defense response to bacterium,M001,1,0
0,0,1,0,0,-2.1,R-HSA-5173105,O-linked glycosylation,M001,1,0
1,0,0,-2.6,0,0,GO:0060317,cardiac epithelial to mesenchymal transition,M100,1,0
1,0,0,-2.4,0,0,GO:0032292,peripheral nervous system axon ensheathment,M100,1,0
1,0,0,-2.3,0,0,WP4542,Leukocyte intrinsic Hippo pathway functions,M100,1,0
0,1,0,0,-3.2,0,GO:0030166,proteoglycan biosynthetic process,M010,1,0
1,0,0,-2.5,0,0,M236,PID DELTA NP63 PATHWAY,M100,1,0
0,0,1,0,0,-2.1,GO:0010883,regulation of lipid storage,M001,1,0
1,0,0,-2.8,0,0,hsa04922,Glucagon signaling pathway,M100,1,0
0,1,0,0,-2.4,0,GO:0034341,response to type II interferon,M010,1,0
1,0,0,-3.5,0,0,hsa05012,Parkinson disease,M100,1,0
1,0,0,-2.2,0,0,GO:0072028,nephron morphogenesis,M100,1,0
0,1,0,0,-2.9,0,R-HSA-9682385,FLT3 signaling in disease,M010,1,0
1,0,0,-2.4,0,0,GO:0043542,endothelial cell migration,M100,1,0
